СПОСОБ ПРОФИЛАКТИКИ ИММУНОДЕФИЦИТА У КОРОВ В СУХОСТОЙНЫЙ И ПОСЛЕРОДОВОЙ ПЕРИОДЫ

Изобретение относится к ветеринарной медицине. Для повышения эффективности профилактики иммунодефицита коровам давали в сухостойный период водно-спиртовую настойку эхинацеи с ионами серебра, а в послеродовой период - водно-спиртовую настойку эхинацеи, солодки, девясила с ионами серебра. Способ обеспечивает повышение активности Т-, В-лимфоцитов и способствует выработке эритроцитов, гемоглобина, общего белка и повышению других показателей крови организма животных. 1 з.п. ф-лы, 1 табл.

ФАРМАКОЛОГИЧЕСКАЯ КОМПОЗИЦИЯ ПРОТИВОТУБЕРКУЛЕЗНОГО ДЕЙСТВИЯ

Изобретение относится к химико-фармацевтической промышленности и медицине, в частности к композиции, обладающей бактериостатическим и бактерицидным действием и предназначенной для лечения туберкулезных заболеваний. Фармакологическая композиция противотуберкулезного действия содержит активные вещества - противотуберкулезные препараты (этамбутол, изониазид, рифампицин, пиразинамид), а в качестве потенцирующего агента синергетического действия, усиливающего воздействие химиопрепаратов, стабилизированные наночастицы серебра. Изобретение обладает свойствами подавлять лекарственно-устойчивые штаммы микробактерий туберкулеза. 1 табл.

СПОСОБ ПОЛУЧЕНИЯ БИОЦИДА

Изобретение относится к способу получения биоцида, который заключается в активации бентонита Na-формы ионами натрия путем его обработки водным раствором хлористого натрия с последующим удалением анионов хлора при промывке и фильтровании полученного полуфабриката. Затем полученный полуфабрикат интеркалируют ионами металлов бактерицидного действия обработкой в водных растворах неорганических солей: нитрата серебра, сульфата меди, сульфата или нитрата цинка, при этом соли натрия удаляют при промывке биоцидного продукта деионизованной водой, затем продукт фильтруют, сушат и измельчают до размера частиц 20-150 нм. Процессы активации и интеркалирования осуществляют при воздействии ультразвуком с частотой 20-50 кГц и интенсивностью 10-100 Вт/см2, а процесс очистки интеркалированного продукта от солей натрия осуществляют в два этапа: сначала продукт декантируют, а затем промывают в деионизованной воде, содержащей 30 - 100 ppm комплексообразователя ионов щелочных металлов на основе краун-эфиров ...

СПРЕЙ ДЛЯ ЛЕЧЕНИЯ ИНФИЦИРОВАННЫХ И НЕИНФИЦИРОВАННЫХ РАН ПРИ САХАРНОМ ДИАБЕТЕ I ТИПА

Изобретение относится к области медицины и фармацевтики и может быть использовано для лечения инфицированных и неинфицированных ран при сахарном диабете I типа. Для этого предложен спрей, содержащий в качестве активных ингредиентов 2-этил-6-метил-3-гидроксипиридиния N-ацетил-6-аминогексаноат, N-Ацетил-6-аминогексаноат серебра, ионол и наночастицы церия диоксида в количественном соотношении, масс. %: 5,0:0,1:1,0:0,1 или 0,2, соответственно. Изобретение обеспечивает ускорение заживления ран и уменьшение площади рубца у пациентов с сахарным диабетом I типа. 7 табл., 5 пр.

СПОСОБ ПОДДЕРЖАНИЯ ЖИЗНЕДЕЯТЕЛЬНОСТИ ОРГАНИЗМА БОЛЬНОГО, ОТЯГОЩЕННОГО ОНКОЛОГИЧЕСКИМ ПРОЦЕССОМ

Изобретение относится к медицине, в частности к реабилитации и лечению больных, отягощенных онкологическим процессом разной степени тяжести. Способ включает введение в организм электроактивированных водных растворов неорганических солей из группы, состоящей из AgNO3, NaCl, KCl, CaCl2 и MgSO4 - с отрицательным редокс-потенциалом (католит), либо с положительным редокс-потенциалом (анолит). Введение раствора католита или анолита осуществляют перорально, или ректально, или интравагинально, или в виде ингаляций, или путем наружных аппликаций, или путем локальных инъекций, или путем совмещения вариантов введения. Дополнительно в ходе лечения больным вводят раствора Рингера или плазму крови внутривенно капельным путем, которые перед введением активируют в растворе католита или анолита бесконтактным методом. При этом к лечебному раствору в ходе внутривенного введения добавляют препарат Essenciale N в объеме не менее 5 мл. Также дополнительно вводят «Баланс Нарине» четыре раза в день по 50 мл в ...

СРЕДСТВО ДЛЯ КОЖИ ПРОФИЛАКТИЧЕСКОЕ С ПРОТИВОТУБЕРКУЛЕЗНЫМ ЭФФЕКТОМ

Изобретение относится к профилактическому средству для кожи, обладающему противотуберкулезным эффектом, которое включает в качестве активных субстанций 0,50-0,75 мас.% стрептомицина и 7,0-10,0 мас.% стабилизированного золя наночастиц серебра, а также полиэтиленоксиды (ПЭО) марок 400 и 1500 в качестве основы. Изобретение обеспечивает синергетический эффект, который выражается в способности подавлять антибиотикоустойчивые штаммы микроорганизмов, в том числе микобактерии туберкулеза, и в усилении бактерицидных свойств заявленного средства. 1 табл.

СПОСОБ ПОЛУЧЕНИЯ АНТИСЕПТИЧЕСКОГО ПРЕПАРАТА

Изобретение относится к области санитарии и гигиены, в частности к способу получения антисептического препарата, в том числе дезинфицирующего средства для обеззараживания воды в плавательных бассейнах и иных искусственных водоемах, для санитарно-гигиенической обработки помещений, хозяйственного инвентаря, мебели, бытовой техники и промышленного оборудования, а также для обеззараживания промывных и сточных вод. Для получения наноразмерных частиц, включающих одновременно серебро и хлорид серебра, коллоидный раствор наноразмерных частиц хлорида серебра облучают электромагнитным излучением, способным осуществить фотохимическое разложение хлорида серебра, в присутствии окислителя. В качестве окислителя может быть использован пероксид водорода. Описанный фотохимический способ получения антисептического препарата является простым одностадийным. 4 з.п. ф-лы.

СПОСОБ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РЕЦИДИВОВ НЕОСЛОЖНЕННЫХ ФОРМ ЯЗВЕННОЙ БОЛЕЗНИ ЖЕЛУДКА И ДВЕНАДЦАТИПЕРСТНОЙ КИШКИ

Изобретение относится к медицине, в частности к гастроэнтерологии, и может быть использовано для лечения и профилактики рецидивов неосложненных форм эрозивно-язвенных деструкций желудка и двенадцатиперстной кишки. Способ включает энтеральный прием антибактериальных и антисекреторных препаратов. При этом в качестве антибактериального препарата принимают раствор гидратированного серебра в дистилляте в суточной дозе не более 70 мкг серебра в течение не более 20 дней. Дополнительно производят эндоскопическое орошение язвенного дефекта раствором гидратированного серебра в дистилляте концентрацией 2 мг/л в количестве 20 мл. Способ обеспечивает ускорение заживления язвенного дефекта за счет воздействия на патогенную микрофлору и улучшения микроциркуляции вокруг язвенного дефекта при минимальном токсическом воздействии серебра на организм. 1 з.п. ф-лы.

Способ лечения кандидозного глоссита

Изобретение относится к медицине, а именно к стоматологии, и может быть использовано для лечения кандидозного глоссита. Для этого на область поражения апплицируют лекарственное средство, содержащее пектин с нуль-валентным серебром, метилцеллюлозу и воду для инъекций. Средство наносят 6 раз в день при одновременном назначении нанобиокомпозита, содержащего экстрактивные вещества из ядровой части древесины лиственницы сибирской, 4 г которого растворяют в 100 мл воды без перемешивания, а затем выпивают в течение дня в 3 приема. При этом лекарственное средство выполнено в виде геля с содержанием серебра 0,17%. Способ позволяет быстро снять воспалительную реакцию, симптомы интоксикации, облегчить болевой синдром, увеличить ремиссию заболевания при повышении иммунного статуса организма. 1 з.п. ф-лы, 1 пр.

СПОСОБ ЛЕЧЕНИЯ ОСТРЫХ ГНОЙНЫХ ВЕРХНЕЧЕЛЮСТНЫХ СИНУСИТОВ

Изобретение относится к медицине, а именно к оториноларингологии, и касается лечения острых гнойных верхнечелюстных синуситов. Для этого либо накладывают медно-серебряные аппликаторы на области естественного соустья и «собачьей ямки» сроком на 8 часов, либо промывают верехнечелюстные пазухи физиологическим раствором с добавлением 100 мг/л лимонной кислоты, 24-25 мг/л ионов меди, 0,004-0,005 мг/л ионов серебра, либо используют сочетанное применение медно-серебряных аппликаторов и промывания верхнечелюстных пазух, как указано выше. Такое выполнение способа, исключающее применение внешнего электрического поля, обеспечивает эффективное лечение за счет антимикробных, антиоксидантных, иммуномодулирующих и противовоспалительных свойств меди, которые значительно усиливаются в присутствии ионов серебра. 2 н. и 1 з.п. ф-лы.

СПОСОБ ОБРАБОТКИ ПОВЕРХНОСТИ ПРЕПАРИРОВАННЫХ ЗУБОВ АНТИСЕПТИЧЕСКИМИ СРЕДСТВАМИ

Изобретение относится к медицине, в частности к стоматологии, и касается обработки поверхности препарированных зубов антисептическими средствами, причем для обработки применяют последовательно 3% раствор перекиси водорода, а затем 1% раствор азотнокислого серебра. Это обеспечивает достижение высокого антисептического эффекта в сочетании с минимальным окрашиванием зубов раствором азотнокислого серебра. 1 табл.

СПОСОБ ПРИГОТОВЛЕНИЯ ПРОТИВОТУБЕРКУЛЕЗНОГО ЛЕКАРСТВЕННОГО ПРЕПАРАТА

Изобретение относится способу приготовления противотуберкулезного лекарственного препарата, содержащего изониазид и наночастицы серебра. Заявленный способ заключается в том, что последовательно растворяется в дистиллированной воде 1-5% мас. хитозана и/или 6-10% мас. изониазида, раствор нагревается до 45-55°С, добавляется стабилизатор, выбранный из полиэтиленгликоля или желатина, в количестве 5-40% мас. и все перемешивается до полного их растворения. Затем добавляется цитрат аммония в количестве 1 г на 1 л раствора при перемешивании, проводится электрохимическое растворение серебряного анода в течение 10-30 мин из расчета выхода наночастиц серебра в водный раствор стабилизаторов 2-15 мг на 1 л и добавляется изониазид, если ранее он не был добавлен. Изобретение обеспечивает получение высокоэффективного препарата для лечения туберкулеза, в котором компоненты препарата проявляют синергетический эффект и снижают резистентность микобактерий туберкулеза к различным антибиотикам. 3 табл., 1 ил.

ЭМУЛЬСИОННАЯ КОМПОЗИЦИЯ ДИФЛЮПРЕДНАТА, СОДЕРЖАЩАЯ АНТИМИКРОБНЫЙ МЕТАЛЛ

Группа изобретений относится к химико-фармацевтической промышленности и представляет собой дифлюпреднат-содержащую эмульсионную композицию, содержащую по меньшей мере один антимикробный компонент, за исключением цинка, выбранный из группы, состоящей из серебра и меди, имеющий концентрацию иона серебра не менее 0,00005 масс./об.% и не более 0,6 масс./об.%, а концентрацию иона меди выше 0,0001 масс./об.% и не более 0,5 масс./об.%. Изобретение также представляет собой способ придания немедленной эффективности консервирующего действия данной эмульсионной композиции посредством заявленных антимикробных компонентов. Группа изобретений обеспечивает возможность получения эмульсии дифлюпредната при добавлении положительно заряженных ионов без коалесцирующего эффекта. 2 н. и 21 з.п. ф-лы, 10 табл., 3 пр.

Препарат для лечения отитов бактериальной и грибковой этиологии у собак

Изобретение относится к области ветеринарии и фармацевтики, а именно к препарату для лечения отитов бактериальной и грибковой этиологии у собак, содержащему наночастицы серебра, клотримазол, хлоргексидин, отличающемуся тем, что дополнительно содержит этиловый спирт и воду при соотношении компонентов, мас. %: наночастицы серебра 0,004-0,006; клотримазол 0,9-1,1; хлоргексидин 3,0-5,0; этиловый спирт 0,9-1,1; вода очищенная остальное. Технический результат заключается в антибактериальном и антигрибковом эффекте, снижении токсичности, повышении эффективности действия препарата для лечения отитов бактериальной и грибковой этиологии по изобретению. 3 табл., 6 пр.

СПОСОБ ПОЛУЧЕНИЯ ПОЛИСАХАРИДНЫХ МАТЕРИАЛОВ

Изобретение относится к способу получения полисахаридных волокон для изготовления материалов, а именно, для получения рассасывающихся в организме человека и млекопитающих хирургических шовных материалов, рассасывающихся и нерассасывающихся перевязочных материалов, рассасывающихся тканых матричных материалов. Способ характеризуется тем, что в 2,4-4,0 мас.% раствор полисахарида в диметилацетамиде, содержащем 4,56-10,00 мас.% хлорида лития, добавляют 1,0-5,0 мас.% поли-N-винилпирролидона с молекулярной массой 8-35 кДа или металлополимерный комплекс - высокодисперсное серебро, стабилизированное поли-N-винилпирролидоном в таком количестве, что содержание высокодисперсного серебра по отношению к растворенному полисахариду в прядильном растворе составляет от 0,07 до 0,87 мас.%, при этом массовое соотношение полисахарид: металлополимерный комплекс составляет 88,0-99,0:1,0-12 мас.%, смесь интенсивно перемешивают, выдерживают, фильтруют, дегазируют и полученный прядильный раствор при комнатной температуре ...

МУКОАДГЕЗИВНОЕ РАЗРУШИМОЕ УСТРОЙСТВО ДОСТАВКИ ЛЕКАРСТВ ДЛЯ КОНТРОЛИРУЕМОГО ВВЕДЕНИЯ ФАРМАЦЕВТИЧЕСКИХ ПРЕПАРАТОВ И ДРУГИХ АКТИВНЫХ СОЕДИНЕНИЙ

Настоящее изобретение относится к области лекарственных средств, в частности к водоразрушаемому устройству, способному прикрепляться к влажным поверхностям тканей тела, включающему первый водорастворимый адгезивный слой и второй водоразрушаемый неадгезивный защитный слой, регулирующий время пребывания водоразрушаемого устройства; причем первый слой включает водорастворимый пленкообразующий полимер в сочетании с мукоадгезивным полимером, а второй водоразрушимый неадгезивный защитный слой включает пленку, состоящую из одного компонента из числа гидроксипропилметилцеллюлозы, гидроксиэтилцеллюлозы, гидроксипропилцеллюлозы, поливинилпирролидона, поливинилового спирта, полиэтиленгликоля, полиэтиленоксида либо сополимеров этиленоксида и пропиленоксида и покрытую гидрофобным полимером и водорастворимым полимером при соотношении гидрофобный полимер(ы) и водорастворимый полимер(ы) 1:1-9:1 (по весу). Технический результат - хорошая липкость продукта, комфортность, желаемая продолжительность воздействия ...

ПРЕПАРАТЫ ДЛЯ ВВЕДЕНИЯ ПРОТИВОВОСПАЛИТЕЛЬНЫХ, ОСОБЕННО АНТИСЕПТИЧЕСКИХ, АГЕНТОВ И/ИЛИ АГЕНТОВ, СПОСОБСТВУЮЩИХ ЗАЖИВЛЕНИЮ РАН, В НИЖНИЕ ДЫХАТЕЛЬНЫЕ ПУТИ

Изобретение относится к области медицины. Антисептик может быть выбран из соединений, выделяющих кислород и галоген, соединений металлов, таких как соединения серебра и ртути, органических дезинфицирующих веществ, включающих в том числе соединения, выделяющие формальдегид, спирты, фенолы, включающие алкил- и арилфенолы, а также галоидированные фенолы, хинолины и акридины, гексагидропиримидины, четвертичные аммониевые соединения и соли иминия и гуанидины, антисептик выбран из группы, содержащей соединения металла, например, соединения ртути, производные фенолов, например, тимол, эвгенол и гексахлорофен, йод и комплексы йода. Антисептик может представлять собой повидон-йод. Противовоспалительный агент берут для получения фармацевтической композиции для лечения заболеваний нижних дыхательных путей, которые чувствительны к введению таких агентов. Изобретение обеспечивает значительное уменьшение образования нежелательных тканей в организме в процессе восстановления тканей и других процессов ...

ПРЕПАРАТЫ ДЛЯ ВВЕДЕНИЯ ПРОТИВОВОСПАЛИТЕЛЬНЫХ, ОСОБЕННО АНТИСЕПТИЧЕСКИХ ВЕЩЕСТВ И/ИЛИ ВЕЩЕСТВ, СПОСОБСТВУЮЩИХ ЗАЖИВЛЕНИЮ РАН, В ВЕРХНИЕ ДЫХАТЕЛЬНЫЕ ПУТИ И/ИЛИ В УХО

Изобретение относится к медицине и касается препарата для введения противовоспалительных, особенно антисептических веществ и/или веществ, способствующих заживлению ран, в верхние дыхательные пути и/или в ухо. Изобретение заключается в том, что фармацевтический препарат содержит, по меньшей мере, активное вещество и носитель в виде частиц, выбранных из группы, включающей липосомы, микросферы, наночастицы, а также в способе профилактики или лечения инфекционных болезней горла, носа и ушей человека или животного. Предлагают такие, как повидон-йод, для приготовления фармацевтической композиции для лечения заболеваний верхних дыхательных путей и/или уха, которые восприимчивы к введению таких веществ. Изобретение обеспечивает замедленное высвобождение лекарств и продолжительное локальное действие активного вещества в верхних дыхательных путях. 2 с. и 21 з.п.ф-лы, 1 табл.

СПОСОБ ПРИМЕНЕНИЯ КАТИОНОВ СЕРЕБРА ВНУТРИЖЕЛУДОЧНЫМ ЭЛЕКТРОФОРЕЗОМ КОЛЛОИДНОГО РАСТВОРА НА ФОНЕ АХЛОРГИДРИИ С ЦЕЛЬЮ ЭРАДИКАЦИИ ИНФЕКЦИИ HELICOBACTER PYLORI

Изобретение относится к медицине, в частности к гастроэнтерологии, и касается лечения язвенной болезни желудка и двенадцатиперстной кишки. Для этого дозированно во время каждого сеанса вводят в желудок человека коллоидный раствор серебра в объеме V, выбираемом из диапазона 50≤V≤600 мл, с его концентрацией С в пределах 3≤С≤40 мг/л в виде N доз, количество которых выбирают в диапазоне 1≤N≤25, составляющем цикл эрадикации, при взаимосвязанном неравенстве 1,04≤(Vi+V)/V≤2 соотношении объема Vi. Причем 1≤i≤n в каждой из вводимых доз раствора в выбранном их количестве N, и максимального V объема раствора, при соблюдении условия V1+V2…+Vi+…+Vn-1+Vn=V. Затем выполняют внутрижелудочный электрофорез на фоне ахлоргидрии, для чего до сеанса электрофореза перорально вводят: за 8-10 часов - препарат из группы Н2-блокаторов гистамина - ранитидин в дозе 300 мг или квамател в дозе 40 мг, а за 2-3 часа - препарат из группы блокаторов «протонной помпы» - омепрозол или париет в дозе 20 мг. Способ обеспечивает ...

ПЛАТФОРМА ДЛЯ ДОСТАВКИ ИОНОВ СЕРЕБРА

Изобретение относится к медицине, а именно к акушерству и гинекологии, и касается платформы для доставки высвобождающего ионы серебра соединения для лечения меноррагии. Платформа содержит физиологически инертную гибкую плоскую спираль, подходящую по размеру для введения в полость матки пациента женского пола, а также содержит некротизирующее ткань количество твердой, водорастворимой соли серебра. Ионы серебра доставляются в эндометрий и вызывают некроз ткани эндометрия. Ионы серебра, остающиеся внутри полости матки, можно нейтрализовывать раствором хлорида натрия, доставляемого в матку, например, посредством катетера, и удалять носитель из матки. Изобретение обеспечивает расширение арсенала средств, а также предоставляет улучшенное средство для лечения за счет более точной доставки нитрата серебра в полость матки. 21 з.п. ф-лы, 1 пр., 2 ил.

АНТИСЕПТИЧЕСКИЕ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЯ

Группа изобретений относится к антисептическим композициям и предназначена для дезинфекции поверхностей, таких как поверхности тела, и для лечения связанных с инфекцией состояний. Антисептическая композиция содержит в качестве действующих ингредиентов ментол и ионы серебра и фармацевтически приемлемый носитель. Концентрация указанных ионов серебра в композиции составляет от 0,25 мМ до 0,6 мМ и концентрация указанного ментола составляет от 0,64 мМ до 6,4 мМ. Также обеспечивается антисептический набор, содержащий вышеуказанную композицию и упаковочный материал. Другими воплощениями являются способ получения указанной антисептической композиции, способ снижения концентрации АОНов серебра в антисептической композиции и способ повышения антисептической активности указанной композиции. Использование группы изобретений обеспечивает получение антисептической композиции, что достигается за счет синергетического действия ментола и ионов серебра в используемых концентрациях в отношении различных бактерий ...

КОМБИНИРОВАННЫЙ ЛЕКАРСТВЕННЫЙ ПРЕПАРАТ ПРОТИВОТУБЕРКУЛЕЗНОГО ДЕЙСТВИЯ

Изобретение относится к медицине, а именно к химико-фармацевтической промышленности, и касается противотуберкулезного препарата, активного в отношении лекарственно-устойчивых штаммов микобактерий туберкулеза. Препарат синергетического действия содержит противотуберкулезный химиопрепарат - изониазид, а в качестве потенцирующего агента, усиливающего действие химиопрепарата, наночастицы серебра. Изобретение обладает свойствами подавлять лекарственно-устойчивые штаммы микобактерий туберкулеза и может быть использовано для создания новых лекарственных средств, для лечения лекарственно-устойчивого туберкулеза. 1 табл.

СПОСОБ ХИРУРГИЧЕСКОГО ЛЕЧЕНИЯ НЕСРОСШИХСЯ ПЕРЕЛОМОВ И ЛОЖНЫХ СУСТАВОВ ТРУБЧАТЫХ КОСТЕЙ ПРИ НАЛИЧИИ ДЕФИЦИТА МЯГКИХ ТКАНЕЙ В ПРОЕКЦИИ НЕСРОСШИХСЯ ПЕРЕЛОМОВ И ЛОЖНЫХ СУСТАВОВ

Изобретение относится к медицине, а именно к травматологии и ортопедии, и может быть использовано для хирургического лечения несросшихся переломов и ложных суставов трубчатых костей при наличии дефицита мягких тканей. Для этого за 5-6 дней до операции выполняют пункционную биопсию костных и мягкотканных фрагментов из очага поражения трубчатой кости и определяют наличие и характер облигатной внутриклеточной вирусной инфекции (ОВВИ). Также выполняют суперселективные ангиографические исследования микрососудистого русла до капиллярного звена. За 2-4 дня до операции пациенту вводят лекарственное средство валтрекс в дозе 500 мг 2 раза в день. Далее выполняют остеосинтез или реостеосинтез с резекцией концов отломков кости, вскрытие костно-мозговых каналов, костную стимуляцию и рыхлое заполнение пространства костного дефекта гелеобразным наноструктурированным композитным имплантатом. При наличии ОВВИ резекцию костных отломков выполняют в расширенном объеме до появления «кровяной росы», то есть ...

АНТИВИРУСНАЯ И БАКТЕРИЦИДНАЯ КОМПОЗИЦИЯ

Изобретение относится к области медицины и биологии. Антивирусная и бактерицидная композиция содержит тетрайод-гексаметилентетрамин общей формулы (СН2)6N4I4, (25-35 мас.%) и поливиниловый спирт и/или поливинилпирролидон (65-75 мас.%). Композиция обеспечивает хорошую растворимость в воде, малую токсичность и повышенную бактерицидную активность. 3 табл.

АНТИСЕПТИЧЕСКОЕ СРЕДСТВО И СПОСОБ ЕГО ПОЛУЧЕНИЯ

Группа изобретений относится к медицине, а именно к промышленному приготовлению антисептических средств медицинского назначения. Предложено антисептическое средство, включающее в себя наночастицы закаленного серебра в количестве от 0,01 до 0,05 мас %, основу, представленную вязкотекучим веществом и воду количеством не выше 5 мас. % от массы средства. Также предложен способ получения указанного антисептического средства в форме стабильного гидрозоля на основе дистиллированной воды. Группа изобретений обеспечивает изготовление и применение изделий медицинского назначения в форме антисептических гидрозоля и геле-мазевого препарата для обработки соответственно слизистой и кожной поверхностей тела человека. Полученное антисептическое средство, содержащее диспергированные наночастицы серебра, может быть использовано в офтальмологии, ЛОР, дерматологии, стоматологии, хирургии, урологии, акушерстве и гинекологии, комбустиологии. 2 н. и 3 з.п. ф-лы, 2 ил., 8 пр.

УСТРОЙСТВО ДЛЯ ПОЛУЧЕНИЯ СЕРЕБРЕНОЙ ВОДЫ ЗАДАННОЙ КОНЦЕНТРАЦИИ

Устройство для получения серебреной воды заданной концентрации относится к медицине, а именно к получению серебреной воды заданной концентрации и может быть использовано для профилактики различных заболеваний вирусной и микробной этиологии. Известно, что серебреная вода является сильнейшим антисептиком и ее бактерицидное действие превосходит хлорную известь, газообразный хлор. Авторы предлагают полезную модель, позволяющую получить серебреную воду заданной концентрации, не используя дорогостоящих материалов. Положительным результатом заявляемой полезной модели является повышение эффективности. Положительный результат достигается тем, что в заявляемой полезной модели в емкости используют кассету, заправленную импрегнированной серебреной тканью. Заявляемая полезная модель в отличие от известных позволяет насыщать воду ионами серебра естественным природным путем без разрушения структуры воды; проста, удобна и надежна в эксплуатации, электробезопасна, а так же позволяет получить серебреную ...

СПОСОБ ПОЛУЧЕНИЯ РАСТВОРА ИОННОГО СЕРЕБРА

Изобретение относится к области получения растворов, содержащих ионы серебра, и может быть использовано при производстве высокоэффективных препаратов для медицины и ветеринарии. Способ получения раствора ионного серебра заключается в использовании дистиллированной воды, имеющей сопротивление в интервале от 0,1 до 18 МОм, которую наливают в химически чистую посуду и нагревают на водяной бане до температуры выше 60°С в течение 30 минут, после чего в воду погружают кассету ионатора серебра, которую подключают в цепь постоянного тока. После появления электрической проводимости раствор перемешивают, причем циклы ионизации в покое и при перемешивании повторяют несколько раз до достижения необходимой концентрации раствора ионного серебра. Кассета ионатора серебра выполнена в виде электрохимической ячейки с серебряными электродами. Процесс получения и консервации раствора ионного серебра ведут в темноте и без доступа воздуха. Изобретение позволяет получить медицинские препараты высокой концентрации ...

СБОР ДЛЯ ЛЕЧЕНИЯ БРОНХИТОВ

Использование: изобретение относится к медицине и касается сбора для лечения бронхитов. Целью изобретения является повышение эффективности лечения. Сущность изобретения заключается в приготовлении сбора из следующих лекарственных растений: сабельник болотный (трава), ноготки лекарственные (цветки), тысячелистник обыкновенный (трава), пижма обыкновенная (цветки), девясил высокий (корни), шалфей лекарственный (листья), буквица лекарственная (трава), донник лекарственный (трава), лапчатка гусиная (трава), тимьян ползучий (трава), фиалка полевая (трава), фиалка трехцветная (трава), лопух большой (листья), чистотел большой (трава), коровяк скипетровидный (цветки, листья), коровяк метельчатый (цветки, листья), кипрей узколистный (листья), кипрей узколистный (цветки), хвощ полевой (трава), череда трехраздельная (трава), будра плющевидная (трава), аир обыкновенный (корни), богульник болотный (трава), вероника лекарственная (трава), береза бородавчатая (листья), душица обыкновенная (трава), марьянник ...

СПОСОБ СТИМУЛИРОВАНИЯ ДЕНТИНОБРАЗУЮЩЕЙ ФУНКЦИИ ПУЛЬПЫ ЗУБА

Изобретение относится к медицине, а именно к терапевтической стоматологии, и может быть использовано для стимулирования дентинобразующей функции пульпы зуба. Для этого местно наносят приготовленную ex tempora пасту, содержащую микрогранулированный хитозан и серебро на вскрытую или невскрытую пульпу зуба. Осуществляют изоляцию лекарственного вещества от постоянной или временной пломбы. Способ обеспечивает регенерацию дентина при отсутствии случаев некроза пульпы. 3 ил.

ПРОТИВООПУХОЛЕВАЯ, АНТИБАКТЕРИАЛЬНАЯ И АНТИВИРУСНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ЕЕ ВАРИАНТЫ)

Композиция по первому варианту содержит азотнокислое серебро, гексаметилентетрамин, тиосульфат натрия, альфа-аспарагиновую кислоту или аспарагин, никотиновую кислоту и воду в указанных в формуле изобретения количествах. Композиция по второму варианту содержит азотнокислое серебро, гексаметилентетрамин или имидазол, имидазолсодержащее соединение платины цис-[Pt(NH3)2Im2]Cl3 или цис-[Pt(NH2OH)2Im2]Cl2, альфа-аспарагиновую кислоту или аспарагин, никотиновую кислоту и воду в указанных в формуле изобретения количествах. Композиции по изобретению обладают повышенной противоопухолевой активностью с одновременным антибактериальным и антивирусным воздействием на организм. 2 н.п. ф-лы, 3 ил., 6 табл.

СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ЖЕЛУДОЧНО-КИШЕЧНЫХ ЗАБОЛЕВАНИЙ ЖИВОТНЫХ

Изобретение относится к области ветеринарии. В качестве средства для лечения желудочно-кишечных заболеваний животных применяют гидрозоль, состоящий из кластеров серебра и дистиллированной воды. При этом используют гидрозоль с концентрацией кластеров серебра 15 мг/л. Средство позволяет сократить сроки лечения животных.

Способ исследования борьбы с биопленками E. coli препаратом, содержащим наночастицы серебра

Изобретение относится к области медицины и ветеринарии и может быть использовано для исследования разрушения биопленок. Способ исследования борьбы с биопленками Е. coli препаратом, содержащим наночастицы серебра, заключается в том, что к 0,2 мл раствора препарата арговит с содержанием действующего вещества 13 мг/мл вносят 0,2 мл мясопептонного бульона и 0,2 мл 1,5×106 КОЕ/мл референтного штамма Е. coli АТСС 25922 или изолята Е. coli, выделенного от крупного рогатого скота с клиническим проявлением инфекционного заболевания, с последующим инкубированием в течение 24 ч при Т=37,5±0,5°С. Результат исследования борьбы с биопленками определяют по изменению интенсивности биопленкообразования, путем измерения оптической плотности на спектрофотометре при длине волны 492 нм. Изобретение позволяет оценить способность препаратов серебра препятствовать образованию биопленок Е. coli. 1 табл., 2 пр.

СПОСОБ ГЕМОСТАЗА РАНЕВОЙ ПОВЕРХНОСТИ И ПРОФИЛАКТИКИ ПОСТОПЕРАЦИОННОГО КРОВОТЕЧЕНИЯ ПОСЛЕ ТОНЗИЛЭКТОМИИ

Изобретение относится к медицине, а именно к оториноларингологии. После удаления небной миндалины в полость тонзиллярной ниши интраоперационно устанавливают гемостатическую коллагеновую губку. При этом после установки гемостатическую губку при помощи одноразового шприца 5,0 мл и иглы пропитывают 2 мл 1% водного раствора неполной серебряной соли полиакриловой кислоты, содержащей наночастицы серебра. Обеспечивают 5-ти минутную экспозицию. Способ позволяет улучшить результаты хирургического лечения хронического тонзиллита за счет ускорения гемостаза и уменьшения кровопотери путем оптимизации интраоперационной тампонады ниш небных миндалин, применяемой для остановки и профилактики интра- и послеоперационных кровотечений после тонзиллэктомии, сократить реабилитационный период. 4 ил., 1 пр.

Способ получения бактерицидного материала на основе органомодифицированной бентонитовой глины

Изобретение относится к области медицины и фармацевтики, а именно к способу получения бактерицидного материала на основе органомодифицированной бентонитовой глины. Способ получения бактерицидного материала на основе органомодифицированной бентонитовой глины: карьерная бентонитовая глина обрабатывается карбонатом натрия при комнатной температуре в следующем соотношении компонентов, мас.%: бентонит : карбонат натрия – 45-50:0,5-1,0, остальное – вода; полученный порошок глины после высушивания при температуре 110°С до постоянной массы смешивается с кристаллической 2-амино-5-гуанидинпентановой кислотой (аргинин) в следующем соотношении компонентов, мас.%: бентонит: аргинин – 45-50: 3,0-5,0, остальное – вода; выдерживается при комнатной температуре 24 часа, высушивается до постоянной массы при температуре 110°С; полученный порошок глины заливается водным раствором нитрата серебра с концентрацией 0,08-0,09 мас.% в следующем соотношении компонентов, мас.%: бентонит : раствор нитрата серебра – ...

Ранозаживляющая мазь и способ ее получения

Изобретение относится к медицине и может быть использовано для получения мази, обладающей ранозаживляющим, антимикробным, сорбционным и гемостатическим действием, и для лечения этой мазью мест поражения кожи. Требуемый технический результат, заключающийся в получении мази с составом, обеспечивающим более высокую эффективность применения при лечении поражений кожи и расширение на этой основе арсенала технических средств для получения мазей с более эффективным применением при лечении поражений кожи, достигается ранозаживляющей мазью, содержащей смесь полиэтиленоксида, полученного полимеризацией окиси этилена с консистенцией в фазе жидкости ПЭО-400 и в твердой фазе ПЭО-1500 и ПЭО-4000, а также водной суспензии комбинации сульфата цинка и сульфата меди. Способ получения мази заключается в том, что приготовленные навеску ПЭО-400 и растопленные при температуре 50-60°С навески ПЭО-1500 и ПЭО-4000, а также водную суспензию в выбранных концентрациях смешивают до полной гомогенизации, заливают в ...

СПОСОБ ЛЕЧЕНИЯ ЖЕНЩИН С ХРОНИЧЕСКОЙ ГОНОРЕЙНОЙ И ГОНОРЕЙНО-ТРИХОМОНАДНОЙ ИНФЕКЦИЕЙ

Изобретение относится к медицине, в частности к венерологии и гинекологии. Цель повышение эффективности лечения хронической гонорейной и гонорейно-трихомонадной инфекции у женщин. Для этого при проведении традиционной комплексной терапии в качестве дезинфицирующих средств в виде влагалищных ванночек используют растворы коллоидного серебра и перекиси водорода, которые вводят последовательно в виде 2 3%-ного раствора колларгола или протаргола в объеме 10 мл и 1 2%-ного раствора перекиси водорода или гидропирита в объеме 30 мл.

Способ получения коллоидного раствора наночастиц серебра

Изобретение относится к получению наночастиц, а именно к получению водного коллоидного раствора наночастиц серебра, и может быть использовано в медицине, фармакологии, биотехнологии, ветеринарии, косметологии, сельском хозяйстве, производстве бытовой химии, в лакокрасочной, текстильной и пищевой промышленности. Способ включает стадии получения слоя из серебряных волокон с удельной поверхностью по БЭТ 5 м2/г, активации поверхности серебряных волокон пропусканием через упомянутый слой последовательно уксусной кислоты, диметилсульфоксида, уксусной кислоты и дистиллированной воды, и пропускания через полученный слой активированных серебряных волокон дистиллированной воды. При этом получают водный коллоидный раствор наночастиц серебра с величиной рН от 5,5 до 7,5, содержащий серебряные частицы размером 3 нм в концентрации 938-2980 мкг/л. Обеспечивается повышение биологической активности частиц серебра в растворе, свободном от органических и неорганических примесей в виде тяжелых металлов, поверхностно-активных ...

ПРЕПАРАТ ДЛЯ ЛЕЧЕНИЯ КОЛИБАКТЕРИОЗА ТЕЛЯТ И СПОСОБ ЕГО ПРИМЕНЕНИЯ

Изобретение относится к ветеринарии, а именно к препарату, обладающему антибактериальными свойствами, и способу лечения колибактериоза телят с помощью этого препарата. Препарат для лечения колибактериоза телят включает нитрат серебра и стабилизирующее вещество - полимер медицинского назначения - поливинилпирролидон - в соотношении, % :нитрат серебра 7; стабилизирующее вещество остальное. Для лечения колибактериоза телят больным животным выпаивают водный раствор препарата для лечения колибактериоза в дозе 3-6 мг/кг действующего вещества или 1-2 мг/кг 0,3%-ного водного раствора два раза в день в течение 1-5 дней. Применение данного препарата и способа лечения колибактериоза позволяет сократить сроки лечения в 1,4 раза и повысить сохранность молодняка на 13-29,9%. 2 с. и 1 з.п. ф-лы.

СПОСОБ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ЖЕЛУДОЧНО-КИШЕЧНЫХ БОЛЕЗНЕЙ ТЕЛЯТ

Изобретение относится к ветеринарии, в частности к способам профилактики и лечения желудочно-кишечных болезней телят, вызванных условно-патогенной и патогенной микрофлорой. Технический результат - повышение эффективности профилактики и лечения желудочно-кишечных болезней телят. Способ осуществляется следующим образом. В качестве лекарственного препарата используют 0,01-0, 03%-ный раствор азотнокислого серебра, который вводят перорально в дозе 3-7 мг/гол. в течении 3-5 сут после рождения с профилактической целью и в дозе 8-15 мг/гол. в течении 2-3 дней со дня заболевания с лечебной целью. 3 табл.

МЕДЬСЕРЕБРОСОДЕРЖАЩЕЕ АНТИМИКРОБНОЕ СРЕДСТВО ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ОТИТА

Изобретение относится к фармацевтической промышленности и используется в качестве антибактериального средства для профилактики и лечения отита. Антимикробное средство, содержащее ацетат меди, нитрат серебра, полиэтиленгликоль, воду, взятые в определенном количестве. Средство обладает повышенным антимикробным действием и эффективно для профилактики и лечения отита. 1 табл.

ТУАЛЕТНАЯ БУМАГА С ЛЕЧЕБНО-ПРОФИЛАКТИЧЕСКИМИ СВОЙСТВАМИ

Изобретение относится к фармацевтической промышленности и представляет собой туалетную бумагу с лечебно-профилактическими свойствами, включающую бумажную основу с введенными в нее лекарственными препаратами в виде наночастиц равномерно в весь ее объем в соотношении их массы к массе бумаги от 1:50 до 1:1000, причем в качестве лекарственных препаратов, введенных в сухую бумажную основу, используются либо комплекс из Hamamelis Virginiana в виде настойки или в гомеопатических разведениях 3-6-С, Aesculus Hyppocastanum в виде настойки или в разведениях 3-6-С и Acidum Nitricum в разведениях 6-12-С, либо комплекс из Hamamelis Virginiana в виде настойки или в разведениях 3-6-С, Aesculus Hyppocastanum в виде настойки или в разведениях 3-6-С, Acidum Nitricum в разведениях 6-12-С и ромашки (Matricaria Chamomilla) в виде настойки или в разведениях 3-6-С. Изобретение обеспечивает улучшение профилактических и лечебных свойств изделия с одновременным упрощением и удешевлением процесса его изготовления.

СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ РАН И ОЖОГОВ

Изобретение относится к применению ультрадисперсных серебросодержащих систем в качестве противовоспалительных, антиэкссудативных и ранозаживляющих агентов. Ультрадисперсные серебросодержащие системы представляют собой нанокомпозиты нуль-валентного металлического серебра с размером частиц 10-25 нм, которые стабилизированы арабиногалактаном или его сульфатированным производным. Также изобретение относится к средству для лечения ран и ожогов, обладающему противовоспалительной, антиэкссудативной, противомикробной и ранозаживляющей активностью, которое включает указанные нанокомпозиты серебра в качестве фармакологически активного вещества и дополнительно содержит карбомер, триэтаноламин, глицерин или 1,2-пропиленгликоль и воду. Средство представлено в виде гидрофильного геля для наружного применения. Изобретение также относится к применению указанного средства для лечения ран и ожогов у нуждающегося субъекта. Заявленное изобретение обеспечивает создание гидрофильных гелей на основе нанокомпозитов ...

Способ повышения биоцидной и лечебной эффективности доксимага ионами серебра, глутаровым альдегидом и этонием

Изобретение относится к области медицины, а именно к фармакологии, микробиологии и битехнологии, и предназначено для повышения биоцидного и лечебного действия доксимага. Для повышения биоцидного и лечебного действия доксимага растворяют в 1 литре дистиллированной или кипяченой водопроводной воды 50 г доксимага, 0,1% глутарового альдегида, 1-2% этония и 3-5 мг ионов серебра. Расфасовывают полученный раствор во флаконы емкостью 100 мл и более, закрывают резиновыми пробками, обкатывают алюминиевыми колпачками и этикетируют. Использование изобретения позволяет снизить содержание с одновременным повышением биоцидного и лечебного действия доксимага. 2 табл., 4 пр.

МАЗЬ ДЛЯ ЛЕЧЕНИЯ ИНФИЦИРОВАННЫХ РАН

Изобретение относится к лекарственным средствам и может быть использовано для лечения гнойных ран, флегмон, пролежней и других патологий, вызываемых размножением в ранах штаммов микроорганизмов. Технический результат - создание нового бактерицидного препарата, ускоряющего заживление инфицированных ран. Заявлен состав мази, содержащий препараты серебра и основу, в которой в качестве препарата серебра она содержит коллоидное атомарное серебро, и 3-4% гель полиэтиленоксида, полученный методом радиационной сшивки, при соотношении компонентов, мас.%: коллоидное серебро - 0,07 - 0,48, поливинилпирролидон - 0,93 - 5,52, гель полиэтиленоксида -остальное.

СРЕДСТВО ДЛЯ АППЛИКАЦИИ ПОЛОСТИ РТА И НОСА И СПОСОБ ЕГО ПРИМЕНЕНИЯ В СОСТАВЕ КОМПЛЕКСНОЙ ТЕРАПИИ ИНФЕКЦИОННО-ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ НОСОВОЙ И РОТОВОЙ ПОЛОСТИ

Группа изобретений относится к антисептическим средствам для ухода за полостью рта и их применению для лечения или профилактики инфекционно-воспалительных заболеваний носовой и ротовой полости. Предлагаемое антисептическое средство для полости рта и носа характеризуется тем, что содержит хлоргексидин, глицерин или глицерол, масло или экстракт чайного дерева, воду очищенную и коллоидное серебро или ионы серебра Ag+ при следующем соотношении компонентов, мас.%: коллоидное серебро или ионы серебра Ag+ 0,04-0,06, хлоргексидина биглюконат раствор 20 % 0,04-0,12, глицерин или глицерол 13-17, масло чайного дерева или экстракт чайного дерева 0,02-0,04, вода очищенная - до 100. Предлагаемое средство обладает высокими органолептическими свойствами, эффективно для комплексного лечения или профилактики инфекционно-воспалительных заболеваний носовой и ротовой полости при орошении полости рта и носа, не вызывая аллергических реакций. Предлагается также применение указанного выше средства для лечения ...

СПОСОБ ПРОФИЛАКТИКИ ГНОЙНО-ВОСПАЛИТЕЛЬНЫХ ОСЛОЖНЕНИЙ РАН ПЕРЕДНЕЙ БРЮШНОЙ СТЕНКИ ПРИ УЩЕМЛЕННЫХ ВЕНТРАЛЬНЫХ ГРЫЖАХ

Изобретение относится к медицине, а именно к общей хирургии, и может быть использовано при профилактике гнойно-воспалительных осложнений ран передней брюшной стенки при ущемленных вентральных грыжах. Для этого интраоперационно, после устранения ущемления, в операционную рану вводят 10% раствор коллоидного наносеребра. При этом сначала обкалывают края грыжевых ворот по периметру из расчета 0,1 мл раствора на 1 смапоневроза. Затем после фиксации синтетического имплантата проводят обкалывание вдоль линии швов по периферии из расчета 0,1 мл на 1 см шва. После этого раствором коллоидного наносеребра инфильтрируют подкожно-жировую клетчатку из расчета 0,1 мл раствора на 1 смраны. Способ обеспечивает значительное снижение риска развития гнойно-воспалительных осложнений у пациентов с данной патологией, а также ускорение процессов репарации тканей за счет использования на все слои передней брюшной стенки и зону фиксации синтетического имплантата биологически активного коллоидного раствора наносеребра ...

Способ получения композиционного материала биотехнологического назначения

Предложен способ получения композиционного материала биотехнологического назначения, обладающего антимикробным действием, включающий синтез композиционного материала, состоящий из смешения наночастиц серебра с нулевой валентностью и стабилизатора наночастиц, поддержания температуры и воздействия ультразвуком, осаждение композиционного материала, фильтрование, промывку осадка и сушку. В качестве стабилизатора наночастиц используют оксид графена «Таунит» в виде водной суспензии, а синтез композиционного материала осуществляют смешением водной суспензии оксида графена «Таунит» с водной суспензией наночастиц серебра с нулевой валентностью, в качестве которой используют концентрат коллоидного серебра КНД-С-К 1% (10000 мг/дм), в количестве от 0,3 до 1,5 объемов на 1 объем водной суспензии оксида графена «Таунит» при температуре 20-40°С и воздействии ультразвуком в течение 30 мин. Технический результат – упрощение технологии, снижение затрат на изготовление композиционного материала и повышение ...

Применение серебряной соли N-{ 4-[(1,3-тиазол-2-ил)сульфамоил]фенил} -1-фенил-5-(4-этоксифенил)пиразол-3-карбоксамида в качестве противогрибкового средства в отношении штаммов грибов C. tropicalis, C. krusei и C. glabrata

Изобретение относится к применению серебряной соли N-{4-[(1,3-тиазол-2-ил)сульфамоил]фенил}-1-фенил-5-(4-этоксифенил)пиразол-3-карбоксамида формулы (I) в качестве противогрибкового средства в отношении штаммов грибов C. tropicalis, C. krusei и C. glabrata. Указанная соль обладает низкой токсичностью и может найти применение в медицине. 2 табл., 2 пр.

СПОСОБ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ РЕЦИДИВИРУЮЩИХ ЗАБОЛЕВАНИЙ, ВЫЗВАННЫХ ЛЕПТОТРИХИЯМИ

Изобретение относится к медицине, а именно к лечению инфекционных болезней, и может быть использовано для лечения заболеваний, вызванных лептотрихиями. Способ включает введение серебряной воды «Сильверия» с концентрацией ионов серебра 0,05 мг/л, размером коллоидных частиц серебра 0,01-0,005 мкм, полученную с серебряных электродов, имеющих степень чистоты металла 99,999% под язык для рассасывания, в виде питья, полосканий и орошений. Использование изобретения позволяет повысить эффективность лечения, уменьшить количество рецидивов за счет антисептического действия, предотвращения хронизации воспалительного процесса и иммуномодулирующего эффекта серебряной воды Сильверия. 4 з.п. ф-лы, 4 табл.

ПРОТИВОВОСПАЛИТЕЛЬНОЕ РАНОЗАЖИВЛЯЮЩЕЕ СРЕДСТВО

Изобретение относится к противовоспалительному ранозаживляющему средству, основой которого являются полиэтиленоксиды (ПЭО-400 и ПЭО-1500), содержащему активные субстанции - 0,5-0,75 мас.% хлорамфеникола и 3-4 мас.% метилурацила, а также потенцирующие агенты - стабилизированный золь наночастиц серебра в количестве 4-8 мас.% и стабилизированный золь наночастиц железа в количестве 4-6 мас.%. Указанное средство обладает повышенной эффективностью заживления ран, ожогов и язв с уменьшением вероятности возникновения аллергических реакций. Потенцирующие агенты, входящие в состав мази, расширяют спектр подавляемых разновидностей патогенных микроорганизмов. 1 табл.

РЕГУЛИРОВАНИЕ РОСТА КОСТИ С ИСПОЛЬЗОВАНИЕМ ЦЕОЛИТА В КОМБИНАЦИИ С ЗАМЕНИТЕЛЯМИ КОСТНОГО ТРАНСПЛАНТАТА

Изобретение относится к химико-фармацевтической промышленности и представляет собой заменитель костного трансплантата, содержащий остеогенный агент и цеолит, содержащий частицы, содержащие ионообменные катионы металлов, присутствующие в количестве, эффективном для стимуляции остеогенеза у нуждающегося в этом пациента, в котором вышеуказанные катионы металлов выбраны из группы, состоящей из ионов цинка, ионов серебра, ионов меди и их комбинаций. Изобретение обеспечивает оптимальную доставку катионов в участок повреждения с образованием в итоге здоровой костной ткани. 4 н. и 13 з.п. ф-лы.

СПОСОБ ПОЛОСТНОГО ЭЛЕКТРОФОРЕЗА

Способ полостного электорофореза ионов серебра через зонд, отличающийся тем, что при лечении инфекционно-зависимой бронхиальной астмы электрофорез осуществляют непосредственно в пищеводе на уровне бифуркации трахеи, причем проводят 10 процедур с комбинацией растворов серебра 0,5 мг/л, меди 0, 5 мг/л, цинка 0,5 мг/л.

СПОСОБ ЛЕЧЕНИЯ ХРОНИЧЕСКИХ НЕСПЕЦИФИЧЕСКИХ ЗАБОЛЕВАНИЙ ЛЕГКИХ С ПОМОЩЬЮ ИНГАЛЯЦИЙ СУХОГО АЭРОЗОЛЯ НАТРИЯ ХЛОРИДА, ИМПРЕГНИРОВАННОГО СЕРЕБРОМ

Способ лечения хронических неспецифических заболеваний легких с помощью ингаляций сухого аэрозоля натрия хлорида, импрегнированного серебром, заключающийся во введении в дыхательные пути сухого аэрозоля порошка натрия хлорида, дисперсностью 5-10 мкм, отличающийся тем, что в дыхательные пути ингаляционно вводится сухой аэрозоль порошка натрия хлорида, импрегнированного серебром, при этом дневная лечебная доза препарата содержит, по меньшей мере, 1 мг серебра и 10 мг натрия хлорида и используется за две ингаляции, а курс лечения составляет 180 дней.

СПОСОБ ПРОФИЛАКТИКИ ИММУНОДЕФИЦИТА У НОВОРОЖДЕННЫХ ТЕЛЯТ

Способ профилактики иммунодефицита у новорожденных телят, включающий использование водно-спиртовой настойки из травы эхинацеи и корневища солодки и водный раствор серебра, отличающийся тем, что с первого дня жизни телятам дают перорально в течение 10-14 дней один раз в день за 20-30 мин до кормления водно-спиртовую настойку из травы эхинацеи и корневища солодки в дозе 0,08-0,1 мл на 1 кг массы животного, а водный раствор серебра, в качестве которого используют антисептик «Катис» - антисептик «Катис» в дозе 5-7 мл (0,38-0,53 мг ионов серебра) разбавленного со 100-120 мл кипяченной воды на 30-40 кг массы животного.

СЕРЕБРОСОДЕРЖАЩИЙ СУХОЙ АЭРОЗОЛЬ ДЛЯ ЛЕЧЕНИЯ ХРОНИЧЕСКИХ НЕСПЕЦИФИЧЕСКИХ ЗАБОЛЕВАНИЙ ЛЕГКИХ

Серебросодержащий сухой аэрозоль для лечения хронических неспецифических заболеваний легких, содержащий водную суспензию металлического порошка серебра, отличающийся тем, что содержит сухую смесь двух компонентов: порошка металлического серебра дисперсностью 5-10 м2/м с удельной поверхностью по БЭТ 0,6-1,2 м2/г с массовым содержанием серебра 99% и порошка натрия хлорида дисперсностью 5-10 мкм в пропорции соответственно по меньшей мере 1:10.

СПОСОБ СТИМУЛИРОВАНИЯ АДАПТАЦИИ ОРГАНИЗМА К ЭКСТРЕМАЛЬНЫМ И СТРЕССОВЫМ ФАКТОРАМ

Использование: изобретение относится к способам повышения устойчивости организма к экстремальным воздействиям с использованием биологически активных веществ. Решение может быть использовано в медицине и ветеринарии в терапии острых гипоксических состояний, ишемии мозга, сердца, шока, стресса, а также в качестве анальгетического и антидепрессивного средства. Задача: создание физиологического способа стимулирования адаптации организма к воздействию неблагоприятных экстремальных факторов с использованием малотоксичных биологически активных веществ. Сущность изобретения: предложен способ защиты организма от экстремальных и стрессовых воздействий путем внутримышечного или внутрижелудочного введения в субтоксических дозах (1oC 300 мг/кг) водных растворов композиции, содержащей высокодисперсное металлическое серебро и поли-N-винилпирролидон (ПВП) с ММ (6oC 40) 103 при соотношении ингредиентов в мас. ч. ПВП - 1; серебро - 0,01 - 2,33. Положительный эффект: при внутрижелудочном введении указанных ...

СПОСОБ ЛЕЧЕНИЯ КАРИЕСА НИТРАТОМ СЕРЕБРА

Способ лечения кариеса нитратом серебра, включающий подготовку поверхности зуба, нанесение водного раствора нитрата серебра и восстановителя для осаждения нерастворимых солей серебра, отличающийся тем, что нитрат серебра используют в виде 30% водного раствора, а осаждение солей серебра производят путем облучения нитрата галогеновым излучением, например галогеновой лампой 12В, 75 Вт, со спектральным диапазоном 400...500 нм, оборудованной световодом для концентрации светового потока.

СПОСОБ ПРОФИЛАКТИКИ ПОСЛЕОПЕРАЦИОННЫХ СЕПТИЧЕСКИХ ОСЛОЖНЕНИЙ ПРИ КОРРЕКЦИИ ПРИОБРЕТЕННЫХ ПОРОКОВ СЕРДЦА НА ФОНЕ ПРОГРЕССИРУЮЩЕЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ

Способ профилактики послеоперационных септических осложнений при коррекции приобретенных пороков сердца на фоне прогрессирующей сердечной недостаточности, включающий механическую обработку, санацию антисептиками и ультразвуковом интракардиальных структур, отличающийся тем, что после механической внутрисердечной обработки в полость сердца заливают 50 - 70 мл 3% раствора повиаргола, опускают в раствор волновод и включают ультразвуковой генератор с интенсивностью 0,2 - 0,3 Вт/см3, выполняя обширную обработку в лабильном режиме в течение 3 - 4 мин, затем волновод извлекают, жидкость удаляют, после чего повторно обрабатывают внутрисердечные структуры ультразвуком интенсивностью 0,4 - 0,5 Вт/см2 в стабильном режиме в течение 1 - 2 мин, при этом волновод снабжен фетровой насадкой, пропитанной 5% раствором повиаргола.

АНТИБАКТЕРИАЛЬНЫЙ КОМПОЗИЦИОННЫЙ МАТЕРИАЛ И СПОСОБ ЕГО ПОЛУЧЕНИЯ

... 1. Антибактериальный композиционный материал, содержащий серебро, локализованное на поверхности носителя, отличающийся тем, что в качестве носителя используется порошок, поверхность которого носит основный характер, а толщина слоя нанесенного серебра не менее 5 нм. ! 2. Антибактериальный композиционный материал по п.1, отличающийся тем, что в качестве носителей используют высокодисперсные порошки оксида, гидроксида и оксикарбоната магния, природный каолин в косметических формах - белой, голубой и розовой глин. ! 3. Способ получения антибактериального композиционного материала, включающий восстановление серебра из водного раствора нитрата серебра с концентрацией серебра 0,1-3,0 мас.% раствором таннина с концентрацией 0,05-2,0 мас.% и нанесение восстановленного серебра на поверхность носителя, отличающийся тем, что процесс проводят при комнатной температуре на поверхности порошкового носителя, причем предварительно образец тестируют на наличие основного характера носителя, определяемого по ...

СПОСОБ ЛЕЧЕНИЯ ПАРОДОНТИТА И ПЕРИИМПЛАНТИТА

Изобретение относится к медицине, а именно к стоматологии, и может быть использовано при лечении пародонтита и периимплантита. Предлагаемый способ лечения пародонтита и периимплантита заключается в том, что в каждый пародонтальный и/или периимплантатный карман вводят рассасывающуюся нить, предварительно замоченную в течение 30 минут в составе, содержащем, в мас. %: раствор коллоидного серебра - 50, гидроксиапатит кальция - 15, энтеросорбент «Полисорб МП» - 15, гиалуроновую кислоту, 1 % - 10, йодоформ - 10. Использование способа обеспечивает эффективное лечение пародонтита и/или периимплантита за счет уменьшения количества пародонтопатогенных видов микроорганизмов в пародонтальном и/или периимплантатном кармане, снижение частоты рецидивов, сокращение сроков клинического лечения и повышение качества жизни больных с пародонтитом и/или периимплантитом. 2 пр.

ОЗОНИРОВАННЫЙ РАСТВОР КОЛЛОИДНОГО СЕРЕБРА ДЛЯ ЛЕЧЕНИЯ ПАРОДОНТИТА И ПЕРИИМПЛАНТИТА

Изобретение относится к медицине, а именно к стоматологии, и может быть использовано как при лечении пародонтита и периимплантита, так и для профилактики воспаления в полости рта. Предлагаемый озонированный раствор коллоидного серебра для пропитывания рассасывающейся нити, предназначенной для введения в пародонтальные и/или периимплантатные карманы при лечении пародонтита и периимплантита, характеризуется тем, что содержит β-трикальцийфосфат и полифосфат натрия и получен при использовании следующего соотношения компонентов, мас. %: раствор коллоидного серебра «Коллоидное серебро плюс» с концентрацией серебра 20 ppm, содержащий нульвалентное металлическое серебро в наноформе - 50, β-трикальцийфосфат - 30, полифосфат натрия - 10, озонированная вода - 10. Использование раствора указанного состава позволяет добиться уменьшения количества пародонтопатогенных видов микроорганизмов в пародонтальном и/или периимплантатном кармане, обеспечивает усиление остеогенеза костной ткани альвеолярной кости ...

СПОСОБ ЛЕЧЕНИЯ ХРОНИЧЕСКОГО РЕЦИДИВИРУЮЩЕГО АФТОЗНОГО СТОМАТИТА

Изобретение относится к медицине, в частности к терапевтической стоматологии. Способ заключается в том, что на участок воспалённой слизистой оболочки полости рта однократно проводят аппликацию 5% водного раствора химотрипсина в течение 30 минут, а затем проводят курс аппликаций повиаргола - металл-полимерной композиции, содержащей высокодисперсное металлическое серебро и полимерный стабилизатор (поливинилпирролидон), разведённой в стерильной дистиллированной воде до концентрации 6%, в течение 30 минут 8 раз в сутки до полного исчезновения проявлений заболевания. 4 ил.

Поликомпонентная наноразмерная система для диагностики и терапии новообразований

Изобретение может быть использовано в медицине. Поликомпонентная наноразмерная система для диагностики и терапии новообразований состоит из ядра, сформированного из диоксида кремния, диоксида титана, диоксида циркония или их композитов, внутреннего слоя, содержащего оксид меди, диоксид марганца, двойной оксид железа или их композитов, внешнего слоя, содержащего металлические наночастицы серебра, золота или их биметаллические частицы, и биологически активные молекулы - биомаркеры. Изобретение позволяет получить поликомпонентную наноразмерную систему, имеющую структуру «ядро-оболочка», содержащую сферические агрегативно устойчивые монодисперсные частицы, в качестве контрастного агента для магнитно-резонансной и компьютерной томографии и в качестве основы для препаратов адресной доставки лекарственных средств в противоопухолевой терапии. 6 ил., 3 пр.

СПОСОБ ЛЕЧЕНИЯ ПАРОДОНТИТА

Изобретение относится к медицине, а именно к стоматологии, и может быть использовано для местного лечения пародонтита различной степени тяжести. Для этого в течение одной или двух недель в зависимости от тяжести пародонтита проводят аппликации коллоидного раствора наносеребра в концентрации до 100 мг/л и диаметром наночастиц 10-15 нм с выдержкой в полости рта турунд от 15 до 20 мин за один сеанс на слизистые оболочки десны и пародонтальных карманов. Способ позволяется повысить эффективность комплексного лечения пародонтита, уменьшить количество осложнений.

СПОСОБ ВОЗДЕЙСТВИЯ НА МИКОБАКТЕРИИ ТУБЕРКУЛЕЗА В ЭКСПЕРИМЕНТЕ IN VITRO

Изобретение относится к медицине, а именно к фтизиатрии, и касается воздействия на микобактерии туберкулеза. Для этого в эксперименте in vitro используют полученную электрохимическим путем серебряную воду на негазированной минеральной воде «Красный ключ» с ионной концентрацией серебра 15%. С помощью этой воды проводят обработку чистой культуры микобактерий туберкулеза, выделенных из мокроты больных туберкулезом легких. При такой обработке рост микобактерий отмечается лишь в 5% случаев. 3 табл.

Способ лечения коров с послеродовым гнойно-катаральным эндометритом

Изобретение относится к области ветеринарии и представляет собой способ лечения коров с послеродовым гнойно-катаральным эндометритом, включающий введение бактерицидного препарата на основе активированной щелочной воды, обогащенной частицами коллоидного серебра, отличающийся тем, что насыщение ионами серебра ведут до концентрации ионов серебра 8-10 мг на 100 мл католита, который затем озонируют в течение 25-30 минут до концентрации озона 8-10 мг на 100 мл католита и вводят внутриматочно с помощью прибора для осеменения свиней - ПОС-5, по 100 мл через день до закрытия шейки матки, предварительно, перед введением, наружные половые органы животного промывают теплым водным раствором фурацилина в соотношении 5000:1 соответственно. Изобретение обеспечивает возможность повышение активности способа лечения гнойно-катарального эндометрита и снижение трудоемкости лечения. 1 табл., 1 пр.

СРЕДСТВО ДЛЯ КОЖИ ПРОФИЛАКТИЧЕСКОЕ С ПРОТИВОТУБЕРКУЛЕЗНЫМ ЭФФЕКТОМ

Средство для кожи профилактическое с противотуберкулезным эффектом, содержащее полиэтиленоксиды (ПЭО) марок 400 и 1500 в качестве основы и активные субстанции, отличающееся тем, что в качестве активных субстанций оно содержит стрептомицин и стабилизированный золь наночастиц серебра при следующем соотношении компонентов, мас.%: ! ПЭО-1500 5,0-15,0 Стабилизированный золь 7,0-10,0 наночастиц серебра Стрептомицин 0,50-0,75 ПЭО-400 до 100 ...

ПРОТИВОВИРУСНОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ СПИДА

Противовирусное лекарственное средство для лечения СПИДа состоит из пяти компонентов, в пропорциях, %: Барий - 20 Серебро - 20 Фосфор - 20 Дистиллированная вода - 20 Заряд + - 20 ...

СПОСОБ ЛЕЧЕНИЯ ХРОНИЧЕСКИХ РИНОСИНУСИТОВ В РАННЕМ ПОСЛЕОПЕРАЦИОННОМ ПЕРИОДЕ

Изобретение относится к оториноларингологии и представляет собой способ лечения хронических риносинуситов в раннем послеоперационном периоде, включает предварительную анемизацию слизистой оболочки полости носа раствором адреналина, удаление корок, отличается тем, что в полость носа после удаления корок вводят препарат «Аргогель» по 1,0 мл 2 раза в день на 10 минут в течение 2-х недель. Результатом осуществления изобретения является сокращение сроков лечения за счет быстрой ликвидации клинических проявлений воспаления, а также сохранение стойкой ремиссии, расширение спектра лекарственных препаратов, применяемых в оториноларингологии. 4 ил., 2 пр.

ВОДОРАСТВОРИМАЯ БАКТЕРИЦИДНАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ВЫСОКОДИСПЕРСНОЕ МЕТАЛЛИЧЕСКОЕ СЕРЕБРО, СПОСОБ ПОЛУЧЕНИЯ ЭТОЙ КОМПОЗИЦИИ

Изобретение относится к водорастворимым бактерицидным композициям, содержащим высокодисперсное металлическое серебро, стабилизированное защитным высокомолекулярным соединением, а также к способам получения этих композиций и может быть использовано при производстве высокоэффективных препаратов для медицины и ветеринарии. Задача: создание высокоэффективного бактерицидного средства, характеризующегося пониженной токсичностью и аллергенностью, а также воспроизводимостью физико-химических характеристик. Сущность изобретения: предложена композиция, содержащая следующие ингредиенты, мас.ч.: поли-N-винилпирролидон-2 с ММ 8•10 C1,63•101; высокодисперсное металлическое серебро 0,01-2,33. Предложен также способ получения таких композиций, который реализуется взаимодействием нитрата серебра с водно-спиртовым раствором поли-N-винилпирролидона-2 при следующих концентрациях ингредиентов, мас. %: поли-N-винилпирролидон-2 0,065-11,00; нитрат серебра 0,025-29,73; этиловый спирт 5,0-38,6; вода остальное до ...

Антибактериальная композиция для подавления роста патогенной микрофлоры, антибактериальная система и комплект на ее основе

КОМПОЗИЦИЯ МОЛОЧНОЙ СЫВОРОТКИ, ОБОГАЩЕННОЙ НАНОСЕРЕБРОМ, И СПОСОБ ЕЕ ПРОИЗВОДСТВА

... 1. Композиция молочной сыворотки, обогащенной наносеребром, содержащая сыворотку молочную подсырную или белково-сывороточный концентрат, отличающаяся тем, что, с целью получения продукта с улучшенными свойствами по обеспечению защиты кожи от воспалительных процессов и старения, регулирования и поддержке водно-жирового баланса кожи, она содержит ионы серебра.2. Композиция по п.1, отличающаяся тем, что мицеллярный раствор наночастиц серебра в виде водного раствора имеет концентрацию 500 мг/л - 0,01-0,5%.3. Способ производства композиции молочной сыворотки, обогащенной наносеребром, отличающийся тем, что во время всего процесса изготовления композиции температура смеси не превышает 55ºС, а в качестве дополнительного перемешивающего устройства, обеспечивающего рециркуляцию, используется кулачковый насос, позволяющий перемешивать продукт, не изменяя его структуры.

СПОСОБ И КОМПОЗИЦИЯ ДЛЯ ВНУТРИМАТОЧНОГО ХИМИЧЕСКОГО НЕКРОЗИРОВАНИЯ

... 1. Способ обработки слизистой оболочки матки, включающий стадии применение прижигающей композиции для указанной слизистой оболочки; пребывание указанной прижигающей композиции в контакте с указанной слизистой оболочкой в течение периода времени достаточного для осуществления химического некроза указанной слизистой оболочки; контактирование указанной прижигающей композиции с дезактивирующим агентом для дезактивации указанной прижигающей композиции и быстрого прекращения некроза; и удаление указанной дезактивированной прижигающей композиции и указанного дезактивирующего агента из указанной матки. 2. Способ обработки слизистой оболочки матки, включающий стадии применение композиции нитрата серебра для указанной слизистой оболочки указанной матки; пребывание указанной композиции нитрата серебра в контакте с указанной слизистой оболочкой в течение периода времени достаточного для осуществления химического некроза указанной слизистой оболочки; контактирование указанной композиции нитрата серебра ...

СПОСОБ ЛЕЧЕНИЯ ГНОЙНЫХ РАН

Изобретение относится к медицине - хирургии и травматологии, и предназначено для лечения и профилактики гнойных осложнений ран. Задача изобретения - профилактика госпитальной инфекции. Способ включает промывание ран раствором антисептика, обработанного ультразвуком. Новым в способе является использование низких концентраций детергента-повиаргола.

СПОСОБ ЛЕЧЕНИЯ ДИСПЕПСИИ У НОВОРОЖДЕННЫХ ТЕЛЯТ

Изобретение относится к ветеринарной медицине. Телятам до выпаивания молока или молозива 2-3 раза в сутки перорально вводят сброженный сок чистотела в дозе 0,008-0,012 мл/кг массы животного, растворенного в 50-150 мл раствора ионизированного серебра, взятого в количестве не менее 20-25 мг/л. Способ увеличивает процент выздоровлений и сокращает сроки лечения. 1 табл.

СПОСОБ ЛЕЧЕНИЯ ХРОНИЧЕСКОГО КАНДИДОЗНОГО ВУЛЬВОВАГИНИТА

Изобретение относится к медицине, а именно к гинекологии, и может быть использовано для лечения хронического кандидозного вульвовагинита у девочек-подростков. Изобретение решает задачу обеспечения лечения качества местного лечения кандидозного вульвовагинита на фоне стимуляции неспецифической резистентности организма. Поставленная задача решается тем, что в течение 3-5 дней утром производят спринцевание 3% раствором протаргола с последующим введением измельченной таблетки нистатина путем распыления ее на стенки влагалища, а вечером осуществляют спринцевание 5% раствором натрия гидрокарбоната.

СПОСОБ ОСТАНОВКИ ПАРЕНХИМАТОЗНЫХ И КАПИЛЛЯРНЫХ КРОВОТЕЧЕНИЙ ПРИ РАЗЛИЧНЫХ ХИРУРГИЧЕСКИХ ОПЕРАЦИЯХ У МЕЛКИХ ДОМАШНИХ ЖИВОТНЫХ

ЭКОЛОГИЧЕСКИ ПРИЕМЛЕМЫЕ СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ОБРАБОТКИ И ОБРАБОТАННЫЕ ИМИ МАТЕРИАЛЫ

... 1. Способ обработки пищевого материала или цветочных клубней или луковиц, включающий контактирование указанного пищевого материала, или цветочных клубней, или луковиц с раствором перекиси водорода и регулирование газового баланса диоксида углерода и кислорода на пищевом материале, или цветочных клубнях, или луковицах, при этом указанный раствор перекиси водорода содержит ионы металлов серебра и, по меньшей мере, одного из металлов, выбранного из меди и цинка, при этом указанные ионы металла присутствуют в количестве от 10 ч./млрд до 5%, и содержит, по меньшей мере, одну кислоту, выбранную из надуксусной, азотной, серной и фосфорной кислоты, и необязательно, по меньшей мере, одну кислоту, выбранную из салициловой, лимонной и фосфоновой кислоты, и необязательно глицерин, при этом указанный раствор наносят на указанный пищевой материал, или цветочные клубни, или луковицы в виде сухого тумана, окуривания или дыма, при этом указанный раствор содержит микрокапли, имеющие размер в диапазоне от ...

ВЕЩЕСТВО, ОБЛАДАЮЩЕЕ АНТИГИПОКСИЧЕСКОЙ АКТИВНОСТЬЮ

Использование: изобретение относится к применению известных ранее антимикробных коллоидных препаратов серебра протаргол и колларгол по новому назначению - в качестве антигипоксантов. Решение может быть использовано в медицине и ветеринарии при терапии острых гипоксических состояний, ишемии органов и тканей. Препараты протаргол и колларгол используются для защиты от гипоксии путем их внутримышечного или внутрижелудочного введения в организм в дозах 0,15 - 750 мг/кг массы тела в виде водных растворов. Положительный эффект: в условиях кислородного голодания достигается увеличение продолжительности жизни животных на 12,2 - 101,5 %, а в экстремальных условиях гемической тканевой гипоксии выживаемость животных возрастает в 2 - 10 раз.

СПОСОБ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ЖЕЛУДОЧНО-КИШЕЧНЫХ БОЛЕЗНЕЙ ТЕЛЯТ

Изобретение относится к ветеринарии, в частности к способам профилактики и лечения желудочно-кишечных болезней телят вызванных условно-патогенной и патогенной микрофлорой. Технический результат - повышение эффективности профилактики и лечения желудочно-кишечных болезней телят. Способ осуществляется следующим образом. В качестве лекарственного препарата используют 0,01 - 0,03%-ный раствор азотнокислого серебра, который вводят перорально в дозе 3 - 7 мг/гол. в течение 3 - 5 суток после рождения с профилактической целью и в дозе 8 - 15 мг/гол. в течение 2 - 3 дней со дня заболевания с лечебной целью.

СПОСОБ ПОЛУЧЕНИЯ ВОДНЫХ МЕДНО-СЕРЕБРЯНЫХ КОМПОЗИЦИЙ

... 1. Способ получения водных медно-серебряных композиций, заключающийся в использовании металлической меди и оксида серебра, отличающийся тем, что оксид серебра растворяют в дистиллированной воде с сопротивлением от 0,1 до 18,0 МОм, при температуре 20°С из расчета 13·10-3 г/л воды, полученный раствор ионного серебра отстаивают, фильтруют и частично используют для получения раствора ионов меди методом химического вытеснения серебра из раствора металлической медью с последующей фильтрацией медного раствора и соединением двух растворов в один в определенных пропорциях и дополнительной фильтрацией готовых композиций. ! 2. Способ по п.1, отличающийся тем, что раствор для перорального (внутреннего) употребления получают с концентрацией, не превышающей предельно допустимой концентрации меди для питьевой воды (1 мг/л).

Способ изготовления антивирусного водорастворимого соединения углерода

СПОСОБ ЛЕЧЕНИЯ ГНОЙНЫХ РАН

Изобретение относится к медицине - хирургии и травматологии, и предназначено для лечения и профилактики гнойных осложнений ран. Задача изобретения - профилактика госпитальной инфекции. Способ включает промывание ран раствором антисептика, обработанного ультразвуком. Новым в способе является использование низких концентраций детергента-повиаргола.

СПОСОБ СЕЛЕКТИВНОГО РАЗРУШЕНИЯ МАКРОФАГОВ В КЛЕТОЧНОЙ СУСПЕНЗИИ И ЦЕЛОСТНОМ ОРГАНИЗМЕ С ПОМОЩЬЮ ПРЕПАРАТОВ КОЛЛОИДНОГО СЕРЕБРА - ПРОТАРГОЛА И КОЛЛАРГОЛА

Изобретение относится к медицине, а именно к иммунологии и экспериментальной медицине, и может быть использовано для селективного разрушения макрофагов в клеточной суспензии или в организме. Способ включает добавление препарата либо непосредственно в питательную среду для культивирования живых клеток, либо введение внутривенно в организм мыши. В качестве селективного токсического агента для макрофагов используют препарат коллоидного серебра – либо протаргол, либо колларгол. При проведении экспериментов в условиях искусственного культивирования выделенных из организма мыши макрофагов диапазоне концентраций составляет от 10 до 20 мкг/мл, экспозиция 4 часа с каждым агентом по отдельности. В экспериментах, где препарат вводится непосредственно в организм мыши внутривенным способом, используют дозу из расчета 1мг/кг веса животного и времени экспозиции в 24 часа с каждым агентом по отдельности. Использование изобретения позволяет достичь селективного разрушения мышиных макрофагов при снижении ...

Sauerstoffverbindungen unterschiedlicher Art in Kombination mit Silberpartikeln zur Behandlung am Menschen

Sauerstoffverbindungen unterschiedlicher Art wie (z. B. Aluminiumoxid) die zum Zwecke der Schönheits- oder Problemhautbehandlung, bezogen auf die Methode der Abrasion (z. B. Microdermabrasion), eingesetzt werden. Diese Sauerstoffverbindungen werden mit Silberpartikeln unterschiedlicher Konzentration gemischt. Die Größe der Sauerstoffverbindungen, gemessen in um und die Größe der Silberpartikel, gemessen in nm sind variabel und nicht eindeutig definiert und somit unerheblich für diesen Schutzanspruch. Die Rohstoffe können je nach Verwendungszweck (Einsatz mit unterschiedlichen Gerätetypen) abweichend in Größe und Form sein. Ausdrücklicher Schutzanspruch bezieht sich auf die Zusammenführung, Kombination oder das Mischungsverhältnis in unterschiedlichen Konzentrationen von Sauerstoffverbindungen verschiedenster Art mit Silberpartikeln.

Topical Formulations Containing Silver (II) Oxide and Zinc Oxide

Formulation

Improvements in or relating to compositions containing silver halide

A composition comprising an insoluble silver halide, a silver-sodium or silver-potassium thiosulphate complex and silver thionate is prepared. The composition is prepared by mixing a silver halide with a solution of sodium or potassium thiosulphate to form a suspension which is then mixed with sodium or potassium sulphite. The mixture is then concentrated to yield the composition as above. At least the first two steps of the process are carried out in the dark or in red light. The composition generally contains a mixture of di-, tri-, tetra-, penta- and hexa-thionates depending on pH conditions. In an example silver chloride prepared from sodium chloride and silver nitrate, was mixed with sodium thiosulphate and then an acid solution of sodium sulphite was added. This mixture was concentrated at 70-80 DEG C. in vacuo, yielding the desired composition. The composition may be used in conjunction with cholesterol and ergosterol and used to promote growth of plants in which case an inert diluent ...

Plant extract compositions

A composition for topical application comprises a base, and dispersed within the base elemental silver as a colloidal suspension, and at least six plant extracts selected from the group consisting of: Equisetum arvense, Rumex crispus, Arctiurn lappa, Trifolium pratense, Chelidonium majus, Thuja occidentalis, Urtica dioica, Symphytum officinale, Mahonia aquifolium, Echinacea purpurea, Stellaria media, Galium aparine, Aloe vera, Matricaria recutita, Hypericum perforatum, Calendula officinalis, and Panax ginseng. Preferably the extractant is aqueous ethanol. The compositions may be used in the treatment of wounds, moles, and insect bites. Preferably, the base is water, and is present in an amount of from 80% to 99.9% v/v, the silver may be present at 1x10-5% to 1x10-2 % w/v, and the plant extract is present in an amount of from 0.1% to 10% w/v. A dressing or porous sheet may be impregnated with the composition.

Improvements in method of preparing colloidal silver iodide composition and the product

... 537,127. Antiseptics. BARNES CO., Ltd., A. C. Dec. 9, 1939, No. 31908. Convention date, Dec. 10, 1938. [Class 81 (i)] [Also in Group III] Colloidal silver iodide preparations for use as antiseptics &c. are stabilized against light and mould growth by the addition of a small proportion of colloidal zinc or zinc compound. The pH of the final preparation should be adjusted to about 7.0 to 9.0.

A novel formulation for rapid wound healing and control of infection

The present invention is a formulation of organic and non‐organic components for rapid wound healing and control of infection. The components of the present invention i.e. the formulation are an antimicrobial agent, an antioxidant, a cell proliferation inducing factor and an organic component responsible for matrix formation. Adding these four components in pre-determined proportions, formulations can be made for gels, liquid solution and biodegradable scaffolds which are safe and gives a synergistic effect.

Colloidal silver combined with plant extracts for use in treating wounds and other skin conditions

Disinfection composition based on h202 acids and metal ions

Supplement preparation.

Use of topical compositions for the control of microbial diseases of the nail.

A method of treating or preventing a microbial disease of a subject's nail, such as onychomycosis, the method comprising the step of topically administering to the nail an effective amount of copper silicate.

Disinfection composition based on h202 acids and metal ions

Disinfecting composition based on H2O2, acids and metal ions.

The invention concerns an oxidising aqueous composition useful in particular for disinfection, hygiene and depollution purposes, and for surface treatment (particularly a metal surface to be stripped and/or passivated), and said composition, containing water hydrogen peroxide, a RC02H/RC03H mixture (wherein R is a C1-C6 aliphatic radical with linear or branched hydrocarbon chain, saturated or unsaturated), a stabilising agent which is an acid and, as the case may be, Ag*ions. The invention is characterised in that it contains ions of at least one metal M which are ions of AgII, agIII, Vv, Nbv, Tav, Movi, Wvi, CoIII, InIII or T1III. Advantageously, said composition can be in gel form. The invention also concerns the method for preparing said composition.

Supplement preparation

Disinfection composition based on h202 acids and metal ions

Use of topical compositions for the control of microbial diseases of the nail.

Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds

According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a topical composition is provided, which can be formulated as a homogenous mixture, such as a spray, mist, aerosol, lotion, cream, solution, oil, gel, ointment, paste, emulsion or suspension or applied on a carrier material, such as a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold. Methods for producing such a topical composition and carrier material with the topical composition applied thereto are also disclosed.

Wound Dressings Containing Complexes of Transition Metals and Alginate for Elastase-Sequestering

Transition metal (e.g., silver and copper) derivatized phosphorylated polysaccharides (cellulose, starch, gauze) provide antimicrobial and elastase sequestration properties to wound dressings, and the wound dressing have enhanced water sorption and elastase sequestration when used with alginates. Wound dressings with alginates (e.g., silver alginate, crosslinked alginates, etc.) provide enhanced wound fluid absorption as well as elastase sequestration.

Method for Making an Antimicrobial Material from One-dimensional Nanometer Silver that Does Not Accumulate in a Human Body

Disclosed is a method for making an antimicrobial material from 1D nanometer silver that does not accumulate in a human body. At first, 1D nanometer silver is mixed in hydrophilic solution to produce 1D nanometer silver solution. Then, adhesive is blended in the 1D nanometer silver solution to produce the antimicrobial material. The antimicrobial material may be used in antimicrobial liquid, antimicrobial dressing or antimicrobial composite. Human skin can easily block the 1D nanometer silver. Therefore, the 1D nanometer silver does not enter or accumulate in the human body. Yet, the antimicrobial material exhibits a high bactericidal rate.

Novel synergistic pharmaceutical composition for topical applications

A synergistic pharmaceutical composition for the preparation of topical formulations for use in prophylaxis and treatment of wounds, burn wounds, skin grafts, pressure ulcers, diabetic foot ulcers and other skin diseases is provided. The composition may include one or more synergistically active ingredients and one or more inactive ingredients. The synergistically active ingredients may include Recombinant Human Epidermal Growth Factor (rh-EGF) (REGEN-D™ of Bharat Biotech International Limited) and/or Platelet Derived Growth Factor (rh-PDGF-BB), silver sulfadiazine (SSD) and chlorhexidine gluconate (CHG). One or more inactive ingredients may comprise carriers, preservatives, emulsifiers, skin emollients and soothers and one or more other constituents.

Metal-Containing Materials for Treatment of Bacterial Conditions

Metal-containing materials, as well as their preparation, formulations, and use are disclosed. 1. A method , comprising:contacting an area of a subject with a nanocrystalline silver-containing material, and killing bacterial spores in the area with the nanocrystalline silver-containing material.2Clostridium difficileClostridium perfringensClostridium tetaniClostridium botulinumBacillus cereusBacillus anthracis. The method of claim 1 , wherein the bacterial spores are selected from the group consisting of spores claim 1 , spores claim 1 , spores claim 1 , spores claim 1 , spores claim 1 , spores claim 1 , and combinations thereof.3. The method of claim 1 , wherein the area of the subject further comprises a sporulating bacterial infection.4Clostridium. The method of claim 3 , wherein the sporulating bacterial infection comprises a infection.5ClostridiumClostridium difficileClostridium perfringensClostridium tetaniClostridium botulinum. The method of claim 4 , wherein the infection is selected from the group consisting of infection claim 4 , infection claim 4 , infection claim 4 , and infection.6Clostridium difficile. The method of claim 3 , wherein the sporulating bacterial infection comprises a infection.7Bacillus. The method of claim 3 , wherein the sporulating bacterial infection comprises a infection.8BacillusBacillus cereusBacillus anthracis. The method of claim 7 , wherein the sporulating infection is selected from the group consisting of infection and infection.913-. (canceled)14. The method of claim 1 , further comprising contacting the area with a non-metal antibiotic medication.15. The method of claim 14 , wherein the non-metal antibiotic medication is selected from the group consisting of vancomycin claim 14 , metronidazole claim 14 , benzoxazinorifamycin claim 14 , rifaximin claim 14 , and combinations thereof.16. The method of claim 15 , wherein the non-metal antibiotic medication is vancomycin.17. The method of claim 15 , wherein the non-metal ...

DENTAL COMPOSITES COMPRISING NANOPARTICLES OF AMORPHOUS CALCIUM PHOSPHATE

Described herein are dental composites comprising amorphous calcium phosphate nanoparticles and methods of making and using the same. The dental composites display increased Ca and POrelease, improved mechanical properties, and improved antibacterial properties. Anti-bacterial agents, such as quaternary ammonium salts or silver-containing nanoparticles may be included in the composites. 1. A dental composite comprising nanoparticles of amorphous calcium phosphate (NACP) and a resin , wherein the NACP particles range in size from about 10 nm to about 500 nm , and where the NACP comprises about 5% to about 90% of the mass of the composite.2. The dental composite of claim 1 , wherein the composite further comprises a filler selected from the group consisting of a glass filler claim 1 , a ceramic filler claim 1 , and a polymer-based filler.3. The dental composite of claim 2 , wherein the filler is a glass filler selected from the group consisting of barium boroaluminosilicate claim 2 , strontium-alumino-fluoro-silicate glass claim 2 , silicon dioxide claim 2 , fluoroaluminosilicate glass claim 2 , a ytterbium tri-fluoride filler claim 2 , and a fiber glass filler.4. The dental composite of claim 3 , wherein the filler is barium boroaluminosilicate.5. The dental composite of claim 2 , wherein the filler is a ceramic filler selected from the group consisting of a porcelain filler claim 2 , a quartz filler claim 2 , and a zirconia filler.69-. (canceled)10. The dental composite of claim 1 , wherein the resin is one or more resins selected from the group consisting of bis-GMA (bisphenol glycidyl methacrylate) claim 1 , TEGDMA (triethylene glycol dimethacrylate) claim 1 , HEMA (2-hydroxyethyl methacrylate) claim 1 , UDMA (urethane dimethacrylate) claim 1 , PMGDM (pyromellitic acid glycerol dimethacrylate) claim 1 , ethoxylated bisphenol A dimethacrylate (EBPADMA) claim 1 , methacryloyloxyethyl phthalate (MEP) claim 1 , methacrylate-modified polyalkenoic acid claim 1 , a ...

SUBSTRATE HAVING AN ELECTRON DONATING SURFACE WITH METAL PARTICLES COMPRISING PALLADIUM ON SAID SURFACE

A substrate with an electron donating surface, characterized in having metal particles on said surface, said metal particles having palladium and at least one metal selected from gold, ruthenium, rhodium, osmium, iridium, or platinum, wherein the amount of said metal particles is from about 0.001 to about 8 μg/cm. Examples of coated objects include contact lenses, pacemakers, pacemaker electrodes, stents, dental implants, rupture nets, rupture mesh, blood centrifuge equipment, surgical instruments, gloves, blood bags, artificial heart valves, central venous catheters, peripheral venous catheters, vascular ports, haemodialysis equipment, peritoneal dialysis equipment, plasmapheresis devices, inhalation drug delivery devices, vascular grafts, arterial grafts, cardiac assist devices, wound dressings, intermittent catheters, ECG electrodes, peripheral stents, bone replacing implants, orthopaedic implants, orthopaedic devices, tissue replacing implants, intraocular lenses, sutures, needles, drug delivery devices, endotracheal tubes, shunts, drains, suction devices, hearing aid devices, urethral medical devices, and artificial blood vessels. 1. A device comprising an electron donating surface , wherein said electron donating surface comprises a metal selected from the group consisting of silver and zinc , wherein metal particles are deposited on said surface , said metal particles comprise palladium and at least one metal selected from the group consisting of gold , ruthenium , rhodium , osmium , iridium , and platinum and wherein the amount of said metal particles is from about 0.001 to about 8 μg/cm2.2. The device according to claim 1 , wherein said silver in said electron donating surface is present in an amount of about 0.05 to about 12 μg/cm2.3. The device according to claim 1 , wherein said substrate is a polymeric substrate.4. The device according to claim 3 , wherein said polymeric substrate is selected from the group consisting of latex claim 3 , vinyl claim 3 , ...

Immobilized metallic nanoparticles as unique materials for therapeutic and biosensor applications

The present invention relates to compositions and methods by which surface modification techniques can be used to modify wide range polymeric or metal substrates using metal nanoparticles.

TREATMENT OF BIOFILMS

The combination of a first species which is a polyanionic compound and a second species which is an antimicrobial agent is used for the treatment of microbial biofilms and for the topical treatment of wounds. The combination may be incorporated in a wound dressing. The polyanionic compound may be a polyphosphate, such as an alkali metal polyphosphate, e.g. sodium hexametaphosphate. Examples of antimicrobial agents include metallic silver, silver compounds, iodine, PHMB (polyhexamethylene biguanide), acetic acid, chlorhexidine, aminoglycosides (e.g. amikacin, gentamicin, streptomycin and tobramycin), ansamycins, carbacephem, cephalosporins, glycopeptides (e.g. vancomycin), macrolides (eg clarithromycin), monobactams and sulfonamides). 1. The combination of a first species which is a polyphosphate and a second species which is an antimicrobial agent for the treatment of microbial biofilms or for the topical treatment of wounds.24.-. (canceled)5. The combination of wherein the polyphosphate is an alkali metal polyphosphate.6. The combination as claimed in wherein the polyphosphate is sodium hexametaphosphate.79.-. (canceled)10. The combination according to wherein the antimicrobial agent is selected from metallic silver claim 1 , silver compounds claim 1 , iodine claim 1 , PHMB (polyhexamethylene biguanide) claim 1 , acetic acid claim 1 , chlorhexidine claim 1 , aminoglycosides (e.g. amikacin claim 1 , gentamicin claim 1 , streptomycin and tobramycin) claim 1 , ansamycins claim 1 , carbacephem claim 1 , cephalosporins claim 1 , glycopeptides (e.g. vancomycin) claim 1 , macrolides (eg clarithromycin) claim 1 , monobactams and sulfonamides).11. The combination according to wherein the antimicrobial agent is a silver compound.12. The combination as claimed in wherein the silver compound is selected from silver sulphate claim 11 , silver carbonate claim 11 , silver nitrate claim 11 , silver chloride claim 11 , silver oxide claim 11 , silver citrate claim 11 , silver ...

METHOD FOR CONTROLLING TOXICITY OF METALLIC PARTICLE AND LOW-TOXICITY COMPOSITE OF METALLIC NANOPARTICLE AND INORGANIC CLAY

The present invention provides a method for controlling toxicity of metallic particles and a low-toxicity composite of metallic nanoparticles and inorganic clay. The metallic nanoparticles are effective in preventing infection and in skinning over, and thus suitable for treating scalds/burns. In the composite, the weight ratio of metallic nanoparticles to inorganic clay preferably ranges 0.1/99.9 to 6.0/94.0 in a size of about 5 to 100 nm. Preferably, the metal is silver and the inorganic clay is nanosilicate platelets. 1. A method for producing a composite of metallic nanoparticles and inorganic clay , comprising a step of mixing and reacting metallic particles , layered inorganic clay and a reducing agent to generate the composite having a size of 5 to 100 nm , wherein the weight ratio of the metallic nanoparticles to the layered inorganic clay ranges from 0.1/99.9 to 6.0/94.0; the layered inorganic clay has an aspect ranging from 10 to 100 ,000 and serves as carriers of the metallic nanoparticles.2. The method of claim 1 , wherein the weight ratio of the metallic nanoparticles to the layered inorganic clay ranges from 0.5/99.5 to 3/97.3. The method of claim 1 , wherein the weight ratio of the metallic nanoparticles to the layered inorganic clay ranges from 0.5/99.5 to 2/98.4. The method of claim 1 , wherein the metallic particles are gold claim 1 , silver claim 1 , copper or iron.5. The method of claim 1 , wherein the layered inorganic clay is nanosilicate platelets claim 1 , montmorillonite (MMT) claim 1 , bentonite claim 1 , laponite claim 1 , synthetic mica claim 1 , kaolinite claim 1 , talc claim 1 , attapulgite clay claim 1 , vermiculite or layered double hydroxides (LDH).6. The method of claim 1 , wherein the reducing agent is methanol claim 1 , ethanol claim 1 , propanol claim 1 , butanol claim 1 , formaldehyde claim 1 , ethylene glycol claim 1 , or propylene glycol claim 1 , butanediol claim 1 , glycerine claim 1 , PVA (polyvinyl alcohol) claim 1 , PEG ( ...

METHOD OF PRODUCING PLEURODESIS

The present invention provides methods of producing pleurodesis in a mammalian subject, comprising administration of a low dosage of a sclerosing agent such as silver or a salt of silver. 1. A method of producing pleurodesis in a mammalian subject , comprising administering to the subject in need thereof silver or a salt of silver in a total dosage of about 5 to about 500 mg over a time period of administration.2. The method of claim 1 , wherein the total dosage is about 10 to about 450 mg.3. The method of claim 1 , wherein the total dosage is about 10 mg to about 300 mg.4. The method of claim 1 , wherein the time period of administration is about 2 to 30 days.5. The method of claim 1 , wherein the time period of administration is about 3 to 10 days.6. A method of producing pleurodesis in a mammalian subject claim 1 , comprising administering to a subject in need thereof silver or a salt of silver in an average daily dosage of about 0.005 mg/kg/day to about 2 mg/kg/day over a time period of administration.7. The method of claim 6 , wherein the average daily dosage is about 0.01 mg/kg/day to about 1 mg/kg/day.8. The method of claim 6 , wherein the average daily dosage is about 0.05 mg/kg/day to about 0.7 mg/kg/day.9. The method of claim 6 , wherein the time period of administration is about 2 to 30 days.10. The method of claim 6 , wherein the time period of administration is about 3 to 10 days.11. The method of claim 1 , wherein the mammalian subject is a human.12. The method of claim 1 , wherein the method is effective in treating or preventing pleural conditions selected from the group consisting of malignant pleural effusions claim 1 , benign pleural effusions claim 1 , and pneumothorax.13. A kit comprising: a device for removing fluid from the pleural space of a mammalian subject claim 1 , and instructions for use.14. The kit of claim 13 , wherein the device is selected from the group consisting of: catheter claim 13 , chest tube claim 13 , syringe claim 13 , and ...

Compositions with antibacterial and wound healing activity

The present invention relates to compositions based on silver and hyaluronic acid and their use in the management of cutaneous lesions of various origin (acute and chronic wounds, ulcerations, burns, etc.) mainly when characterized by the presence of exudate and hence at high risk of infection.

Method for treating cancer by using Fe-containing alloy particles

A method for treating a cancer is disclosed, which comprises: administering an effective amount of Fe-containing alloy particles to a subject in need, wherein a material of each Fe-containing alloy particle is an alloy comprising a first metal of Fe and a second metal. 1. A method for treating a cancer , comprising:administering an effective amount of Fe-containing alloy particles to a subject in need, wherein a material of each Fe-containing alloy particle is an alloy comprising a first metal of Fe and a second metal.2. The method as claimed in claim 1 , wherein the cancer is an oral cancer.3. The method as claimed in claim 1 , wherein the first metal of Fe is Fe with zero valences.4. The method as claimed in claim 1 , wherein the second metal is at least one selected from the group consisting of Ag claim 1 , Pt claim 1 , and Au.5. The method as claimed in claim 1 , wherein each Fe-containing alloy particles is respectively a FeAg particle claim 1 , a FePt particle claim 1 , or a FeAu particle.6. The method as claimed in claim 1 , wherein a size of each Fe-containing alloy particle is respectively in a range from 2 nm to 5 μm.7. The method as claimed in claim 6 , wherein the size of each Fe-containing alloy particle is respectively in a range from 2 nm to 1 μm.8. The method as claimed in claim 7 , wherein the size of each Fe-containing alloy particle is respectively in a range from 2 nm to 50 nm.9. The method as claimed in claim 1 , wherein a shape of each Fe-containing alloy particle is a rod claim 1 , a sphere claim 1 , a cubic or a dumbbell. This application claims the benefit of filing date of U.S. Provisional Application Ser. No. 61/609,430, entitled “Application of non-oxidized Fe containing alloy particles for tumor therapeutics” filed Mar. 12, 2012 under 35 USC §119(e)(1).1. Field of the InventionThe present invention relates to a method for treating a cancer and, more particularly, to a method for treating a cancer by using Fe-containing alloy particles.2. ...

MEDICAL DEVICES WITH GALVANIC PARTICULATES

Implantable medical devices having galvanic particulates are disclosed. The particulate may be coated onto at least part of a surface of the medical device. In addition, the galvanic particulates may be contained in the material used to manufacture the antimicrobial medical devices, or may be embedded into the surface of the medical devices. The present invention also provides novel coating methods and processing methods. The present invention further provides a combination of galvanic particulates with an aqueous gel, a method of making this combination, and a method of treatment using this combination. The devices and compositions may have advantageous characteristics and effects including anti-microbial, anti-inflammatory, tissue regeneration promoting, and pain reduction or elimination. 1. A composition comprising a galvanic particulate and an aqueous gel.2. The composition of claim 1 , wherein the galvanic particulate comprises a first conductive material and a second conductive material claim 1 , wherein both said first conductive material and said second conductive material have surfaces which are at least partially exposed claim 1 , wherein the particle size of said particulate is from about 10 nanometers to about 100 micrometers claim 1 , wherein the second conductive material comprises from about 0.01 percent to about 10 percent claim 1 , by weight claim 1 , of the total weight of said particulate claim 1 , and wherein the difference of the standard potentials of the first conductive material and the second conductive material is at least about 0.2 V.3. The composition of wherein the first conductive material is selected from the group consisting of zinc and magnesium claim 2 , and the second conductive material is selected from the group consisting of copper and silver.4. The composition of wherein the aqueous gel comprises a carboxylmethylcellulose.5. The composition of wherein the composition comprises 0.15 mg/ml to 2.5 mg/ml galvanic particulate/ ...

AQUEOUS ADDITIVE FOR POULTRY WATER

A method for increasing weight gain, water consumption, and rate of food consumption in poultry by administering an aqueous, acidic composition to the poultry drinking water is presented. 1. A method for increasing weight gain in poultry comprising providing an aqueous composition comprising an acid selected from the group consisting of sulfuric acid , phosphoric acid , fumaric acid , acetic acid , nitric acid and hydrochloric acid; at least one of an ammonium compound , sodium sulfate , potassium sulfate , and magnesium sulfate; and at least one metal ion selected from the group consisting of copper , silver , zinc , magnesium , manganese , nickel and iron , wherein the metal ion is provided as a metal sulfate; and administering the composition to the poultry , wherein consumption of the composition increases weight gain in the poultry.2. The method of claim 1 , wherein the ammonium compound of the composition is selected from the group consisting of anhydrous ammonia claim 1 , ammonium sulfate claim 1 , ammonium nitrate claim 1 , and urea ammonium nitrate.3. The method of claim 1 , wherein the at least one metal ion is present at a concentration of 0.5% to 30%.4. The method of claim 1 , wherein the aqueous composition is administered to the poultry in the poultry water supply.5. The method of claim 1 , wherein the aqueous composition added at a final concentration of 0.2 to 20 liquid ounces of the composition per gallon of water.6. The method of claim 1 , wherein the composition comprises sulfuric acid claim 1 , ammonium sulfate claim 1 , and at least one metal ion selected from copper and silver.7. The method of claim 1 , wherein providing the aqueous composition further comprises i) combining in a pressurized or non-pressurized vessel an acid of at least 89% purity, selected from the group consisting of sulfuric acid, phosphoric acid, fumaric acid, acetic acid, nitric acid and hydrochloric acid, with water and at least one of an ammonium compound, sodium sulfate ...

STABLE SILVER OXIDE FORMULATIONS

A topical formulation for application to exposed body tissue, the formulation containing: (a) a silver oxide, and (b) at least one inorganic whitener; selected from the group of inorganic whiteners consisting of an inorganic magnesium compound and an inorganic calcium compound, said silver oxide and said inorganic whitener compound intimately dispersed within a carrier medium, and wherein a ratio of said inorganic whitener compound, to said silver oxide, is at least 0.2:1, by weight. 1. A topical formulation for application to exposed body tissue , the formulation comprising:(a) a silver oxide, and(b) at least one inorganic whitener compoundselected from the group of inorganic whiteners consisting of an inorganic magnesium compound and an inorganic calcium compound,said silver oxide and said inorganic whitener compound intimately dispersed within a carrier medium,and wherein a ratio of said inorganic whitener compound, to said silver oxide, is at least 0.2:1, by weight, within the formulation.2. The topical formulation of claim 1 , the formulation containing at least 0.10% claim 1 , by weight claim 1 , of said silver oxide.3. The topical formulation of claim 2 , wherein a whiteness value of the formulation is claim 2 , initially claim 2 , at least 4 reflective units claim 2 , and wherein claim 2 , after constant exposure to said ultraviolet light for 3 days claim 2 , said value remains at least 3.5 reflective units.4. The topical formulation of claim 2 , wherein first whiteness value of the formulation is at least 4 reflective units claim 2 , and wherein claim 2 , after constant exposure to said ultraviolet light for 3 days claim 2 , a whiteness value of the formulation remains within 1.5 reflective units of said first whiteness value.5. The topical formulation of claim 1 , the formulation containing at least 0.05% claim 1 , by weight claim 1 , of said silver oxide.6. (canceled)7. The topical formulation of claim 1 , wherein said whitener compound is further ...

Touch Screen with Bacteria Inhibition Layer and Manufacturing Method Thereof

The present invention is to provide a touch screen having a bacteria inhibition layer for prohibiting bacteria from growing thereon and a method for manufacturing the same comprising uniformly dispersing particles of nano metal material in a solution to be applied to a surface treatment so that the solution can have a concentration of 20 ppm to 500 ppm; evenly spray coating the solution on a screen of the touch screen; and subjecting the solution coated on the screen of the touch screen to a heat treatment until solvent in the solution is completely evaporated so that the particles of the nano metal material are densely adhered to the screen of the touch screen to form a bacteria inhibition layer thereon.

Use of Silver-Containing Layers at Implant Surfaces

The disclosure relates to coatings that contain silver, either in the form of metallic silver, silver oxides, salts of silver, or combinations of these. The silver is present in a microparticulate or nanoparticulate form, which exerts antimicrobial activity when bacteria (e.g., in a body fluid) contact the coated surface. The coatings are applied through accumulation of silver-containing particles on the surface, such as by sputtering or electron beam vapor deposition. As a result, their thickness, particle size, and density can be controlled. Furthermore, the surface can also be coated with other substances, such as diamond-like carbon or alumina, either as a discrete layer or intermixed with the silver-containing particles. 1. An article that is implantable in an animal , the article comprising a microparticulate silver-containing antimicrobial layer stably adhered upon at least one surface of the article.2. The article of claim 1 , wherein the antimicrobial layer is stably adhered upon substantially the entire surface of the article.3. The article of claim 1 , wherein the antimicrobial layer is composed substantially entirely of microparticulate silver metal (Ag).4. The article of claim 1 , wherein the antimicrobial layer comprises at least two of Ag claim 1 , AgO claim 1 , AgO claim 1 , AgON claim 1 , and AgON.5. The article of claim 1 , wherein the antimicrobial layer comprises diamond-like carbon (DLC).6. The article of claim 5 , wherein the antimicrobial layer comprises a substantially uniform mixture of DLC and silver-containing microparticles.7. The article of claim 5 , wherein the antimicrobial layer comprises a proximal zone having a higher ratio of silver-containing microparticles to DLC than a distal zone.8. The article of claim 1 , wherein the antimicrobial layer is laminated between the surface of the article and an exterior layer comprising DLC.9. The article of claim 8 , wherein the exterior layer consists essentially of DLC and has a porosity ...

POLYMER COMPOSITIONS WITH BIOACTIVE AGENT, MEDICAL ARTICLES, AND METHODS

A polymer composition that includes a hydrophilic amine-containing polymer, an optional secondary organic polymer, an optional foaming agent, and a bioactive agent distributed therein, wherein the bioactive agent is selected from the group consisting of a silver compound, a copper compound, a zinc compound, and combinations thereof. 162.-. (canceled)63. A method of making a polymer composition , wherein the method comprises:combining an inverse emulsion comprising hydrophilic organic microparticles with water and a bioactive agent under conditions effective to distribute at least a portion of the bioactive agent in the hydrophilic organic microparticles, wherein the bioactive agent is selected from the group consisting of a silver compound, a copper compound, a zinc compound, and combinations thereof; wherein the silver compound has a solubility in water of at least 0.1 gram per liter in water.optionally adding a secondary organic polymer to the inverse emulsion comprising the microparticles and bioactive agent; andoptionally removing a substantial portion of the water.64. The method of further comprising subjecting the polymer composition to radiation.65. The method of further comprising extruding or molding the composition.66. The method of further comprising blending in a foaming agent.67. The method of wherein the foaming agent comprises thermally expandable microspheres.68. The method of further comprising processing the composition under conditions effective to expand the thermally expandable microspheres.69. The method of further comprising processing the composition under conditions that do not significantly expand the thermally expandable microspheres and subsequently exposing the extruded material to conditions effective to expand the thermally expandable microspheres.70. A method of making a polymer composition claim 67 , wherein the method comprises:combining monomers for a hydrophilic organic polymer with a bioactive agent under conditions effective to ...

TREATMENT OF SKIN DISEASE

The present invention is drawn to compositions, systems, and methods of treating skin disease. In one example, the composition includes a peroxygen, a transition metal or alloy thereof, and optionally, an alcohol and/or a drug. The composition can be packaged as part of a two-part system. 1. A composition suitable for treating skin disease , comprising:water,from 0.0001 wt % to 10.0 wt % of a peroxygen;from 0.0001 ppm to 50,000 ppm by weight of a transition metal or alloy thereof; anda drug suitable for treating the skin disease.2. The composition of claim 1 , wherein the drug includes a member selected from the group consisting of benzoyl peroxide claim 1 , salicylic acid claim 1 , sulfur claim 1 , resorcinol claim 1 , resorcinol monoacetate claim 1 , amorolfine claim 1 , butenafine claim 1 , naftifine claim 1 , terbinafine claim 1 , fluconazole claim 1 , itraconazole claim 1 , ketoconazole claim 1 , posaconazole claim 1 , ravuconazole claim 1 , voriconazole claim 1 , clotrimazole claim 1 , butoconazole claim 1 , econazole claim 1 , miconazole claim 1 , oxiconazole claim 1 , sulconazole claim 1 , terconazole claim 1 , tioconazole claim 1 , caspofungin claim 1 , micafungin claim 1 , anidulafingin claim 1 , amphotericin B claim 1 , AmB claim 1 , nystatin claim 1 , pimaricin claim 1 , griseofulvin claim 1 , ciclopirox olamine claim 1 , haloprogin claim 1 , tolnaftate claim 1 , undecylenate claim 1 , acyclovir claim 1 , penciclovir claim 1 , famciclovir claim 1 , valacyclovir claim 1 , trifluridine claim 1 , idoxuridine claim 1 , cidofovir claim 1 , gancyclovir claim 1 , podofilox claim 1 , podophyllotoxin claim 1 , ribavirin claim 1 , abacavir claim 1 , delavirdine claim 1 , didanosine claim 1 , efavirenz claim 1 , lamivudine claim 1 , nevirapine claim 1 , stavudine claim 1 , zalcitabine claim 1 , zidovudine claim 1 , amprenavir claim 1 , indinavir claim 1 , nelfinavir claim 1 , ritonavir claim 1 , saquinavir claim 1 , amantadine claim 1 , interferon claim 1 , ...

ALGINATE MICROPARTICLES AND METHODS OF USING THE SAME

By combining the anti-bacterial effects of silver sulfadiazine and silver nanoparticles with the absorption and slow-release capabilities of alginate, a product was created that can be used to heal and protect deep wounds. These microparticles can have a greater surface area to volume ratio. This, in turn, can permit the particles to have a larger area of exposure to bacterial colonies, thereby increasing antimicrobial activity. Additionally, engineered microparticles also may benefit from the ability to conform to the shape of the wound. 1. A composition comprising an alginate microparticle comprising silver , wherein said alginate microparticle has a mean diameter of less than 10 μm.2. The composition of wherein said alginate microparticle comprises an alginate lyase.3. The microparticle population of wherein said mean diameter is about 7 μm.4. The microparticle population of wherein said microparticle population is stable with regard to particle size and appearance after 2 weeks of storage at 4° C.5. A method of delivery of an antiseptic comprising providing a composition comprising a microparticle population; said microparticles comprising an alginate and silver; wherein said microparticle population has a mean diameter of less than 10 μm.6. The method of claim 5 , wherein said microparticles further comprise an antibiotic or bacteriostatic.7. The method of wherein said silver comprises silver sulfadiazine claim 5 , silver nano particles and/or colloidal silver.8. The method of wherein said composition provides sustained release of said silver from said alginate microparticle.9. The method of claim 6 , wherein said composition provides sustained release of said antibiotic.10. The method of wherein said sustained release continues for not less than 24 hours.11. The method of claim 5 , further comprising:contacting a wound or infection site of a subject in need thereof with said composition comprising the microparticle population.12. The method of claim 5 , ...

Biologically Efficacious Compositions, Articles of Manufacture and Processes for Producing and/or Using Same

Compositions, solid polymeric compositions, and/or articles of manufacture are provided that can include a polymer matrix having a plurality of ion-exchange particles distributed therein. Products by process are provided that can include prior to solidifying the polymeric precursors, blending the precursors with ion-exchange particles to form a mixture, and solidifying the mixture to form a solid polymeric composition product. Solid polymeric composition production methods are also provided that can include providing a plurality of ion-exchange particles, prior to solidifying the polymeric precursors, blending the precursors with the ion-exchange particles to form a mixture, and solidifying the mixture to form a solid polymeric composition. Article of manufacture production methods are provided that can include incorporating a solid polymeric composition into an article of manufacture, the solid polymeric composition including a polymer matrix and a plurality of ion-exchange particles distributed therein. 1. An article of manufacture comprising:a polymer matrix; anda plurality of antimicrobial particles distributed within the matrix, individual ones of the particles comprising at least one of a polymer of a polycarboxylated, polysulfonated, polyaminated, or polyphosphorylated material.2. The article of manufacture of claim 1 , wherein the polymer matrix is disposed upon a surface of the article of manufacture in a coating configuration.3. The article of manufacture of configured as a co-extrusion or over-molded component claim 1 , wherein the polymer matrix is disposed upon a surface of the article of manufacture.4. The article manufacture of configured as a medical device or medical device component.5. The article of manufacture of wherein the medical device comprises a catheter claim 4 , a tracheal tube claim 4 , a wound drainage device claim 4 , a wound dressing claim 4 , an implant claim 4 , an intravenous catheter claim 4 , a surgical repair mesh claim 4 , a ...

ANTIMICROBIAL GEL CONTAINING SILVER NANOPARTICLES

A gel comprising nano-sized particles of metallic silver (Ag), a polymer comprising carboxylate groups, carboxylate molecules comprising at least one group capable of binding to Ag, and metal ions, where the gel is useful as a topically applied antimicrobial agent. 2. A gel as claimed in claim 1 , wherein the polymer is a polysaccharide.3. A gel as claimed in claim 1 , wherein the polymer is selected from the group consisting of: alginic acid claim 1 , hyaluronic acid claim 1 , polyglutamic acid claim 1 , polygalacturonic acid claim 1 , and carboxymethyl cellulose.4. A gel as claimed in claim 1 , wherein the at least one group capable of binding to Ag is a thiol group or an amine group.5. A gel as claimed in claim 1 , wherein the carboxylate molecules are alkylcarboxylate molecules.6. A gel as claimed in claim 5 , wherein the alkylcarboxylate molecules are straight chain or branched claim 5 , cyclic or acyclic claim 5 , aromatic or non-aromatic C-Calkylcarboxylate molecules.7. A gel as claimed in claim 1 , wherein the carboxylate molecules are selected from the group consisting of: 6-mercaptohexanoic acid claim 1 , 8-mercaptooctanoic acid claim 1 , mercaptosuccinic acid claim 1 , 4-mercaptobenzoic acid claim 1 , 4-mercaptophenylacetic acid claim 1 , lipoic acid claim 1 , dihydrolipoic acid claim 1 , glutathione claim 1 , penicillamine claim 1 , 5-(4-amino-6-hydroxy-2-mercapto-5-pyrimidinyl)pentanoic acid claim 1 , and 2-mercapto-4-methyl-5-thiazoleacetic acid.8. A gel as claimed in claim 1 , wherein the metal ions are divalent metal ions.9. A gel as claimed in claim 8 , wherein the divalent metal ions are calcium claim 8 , zinc claim 8 , magnesium or strontium ions.10. A gel as claimed in claim 1 , having a Ag concentration in the range 230 to 1025 μg/mL.11. A method of preparing a gel as claimed in comprising the steps:(i) treating a Ag salt with a reducing agent to form nano-sized particles of Ag;(ii) treating the particles of Ag with a carboxylic acid to form a ...

ANTIMICROBIAL SILVER IODATE

The present invention is silver (I) periodate compounds and their use in preventing or reducing microbial contamination. The invention includes gels, coatings, and articles of manufacture having a surface contacted or coated with a gel comprising an antimicrobial silver (I) compound. Methods of treatment are also disclosed. 1. An article of manufacture comprising a polymer comprising an antimicrobial silver (I) periodate , wherein the silver (I) periodate is one or more compounds selected from the group consisting of pentasilver hexaoxoiodate (AgIO); AgHIO; AgHIO , where x+y=5; AgMIO , where the total cationic charge of x+y=5 and M is a cation; and combinations thereof.2. The article of manufacture of wherein the cation M is selected from the group consisting of K claim 1 , Na claim 1 , Mg claim 1 , Ca claim 1 , Au claim 1 , Pt claim 1 , Cu claim 1 , and Fe.3. The article of manufacture of wherein the polymer is one or more polymers selected from the group consisting of polyurethanes claim 1 , polyesters claim 1 , polyethylenes including high density polyethylene claim 1 , rayons claim 1 , polypropylenes claim 1 , polyvinyl chlorides claim 1 , silicones claim 1 , and rubber.4. The article of manufacture of wherein the article is a wound dressing claim 1 , a medical instrument claim 1 , a medical device claim 1 , a metallic article claim 1 , or a portion thereof.5. The article of manufacture of wherein the article is a catheter or a surface of a catheter.6. A method of making a surface antimicrobial claim 4 , comprising forming or coating the surface with a polymer comprising silver (I) periodate claim 4 , wherein the silver (I) periodate is one or more compounds selected from the group consisting of pentasilver hexaoxoiodate (AgIO); AgHIO; AgHIO claim 4 , where x+y=5; AgMIO claim 4 , where the total cationic charge of x+y=5 and M is a cation; and combinations thereof.7. The method of wherein the surface is a portion of a wound dressing claim 6 , a medical instrument ...

USE OF NANOPARTICLES FOR TREATING RESPIRATORY INFECTIONS ASSOCIATED WITH CYSTIC FIBROSIS

This disclosure relates to metal nanoparticle compositions and methods for treating respiratory infections associated with cystic fibrosis. An amount of nonionic, ground state metal nanoparticles are administered to a patient via inhalation. The metal nanoparticles have properties that enable effective transport through the viscous mucus layer to the epithelia and surrounding tissues, killing or deactivating infecting microbes at the targeted respiratory tissue and throughout the overlying mucus layer. 1. A method for treating a respiratory infection , the method comprising: nonionic, ground state, spherical metal nanoparticles, and', 'a carrier formulated for administration via inhalation; and, 'administering a treatment composition to a patient via inhalation, wherein the treatment composition comprises'}the treatment composition treating the respiratory infection.2. The method of claim 1 , wherein the respiratory infection is associated with cystic fibrosis.3. The method of claim 1 , wherein the treatment composition effectively penetrates mucus of the patient to kill or deactivate microbes within the mucus and to reach underlying respiratory tissue.4. The method of claim 1 , wherein the treatment composition is nebulized prior to administration to the patient.5Staphylococcus aureus, Escherichia coli, Listeria, Salmonella, PseudomonasAcinetobacter, Strenotrophomonas maltophilia, AchromobacterBurkholderia cepacia. The method of claim 1 , wherein the respiratory infection comprises an infection with one or more of claim 1 , nontuberculosis mycobacteria claim 1 , claim 1 , or complex.6Staphylococcus aureusPseudomonasPseudomonas aeruginosa, Strenotrophomonas maltophiliaBurkholderia cepacia. The method of claim 1 , wherein the respiratory infection comprises an infection with one or more of methicillin-resistant claim 1 , tobramycin-resistant claim 1 , multidrug-resistant claim 1 , or complex.7. The method of claim 1 , wherein the respiratory infection comprises an ...

SILVER TREATED BANDAGE

A bandage includes multiple portions with different concentrations of silver treatment upon the portions of the bandage. The bandage includes a cloth layer portion including a first silver treatment including a first silver concentration; and an adhesive layer upon a bottom surface of the cloth layer portion configured to adhere the bandage to skin of a wearer. The bandage further includes an absorbent pad portion comprising a second silver treatment including a second silver concentration lower than the first silver concentration. 1. A device comprising a bandage including multiple portions with different concentrations of silver treatment upon the portions of the bandage , comprising: a first silver treatment including a first silver concentration; and', 'an adhesive layer upon a bottom surface of the cloth layer portion configured to adhere the bandage to skin of a wearer;, 'a cloth layer portion comprisingan absorbent pad portion comprising a second silver treatment including a second silver concentration lower than the first silver concentration.2. The device of claim 1 , wherein the cloth layer portion comprising the first silver treatment comprises silver treated threads.3. The device of claim 1 , wherein the cloth layer portion comprising the first silver treatment comprises a layer of silver material upon a top surface of the cloth layer portion.4. The device of claim 3 , wherein the layer of silver material comprises one of an electroless plating layer claim 3 , a sputtering deposit layer claim 3 , a dip coating layer claim 3 , and a nano-coating layer.5. The device of claim 1 , wherein the first silver concentration comprises a silver concentration between 1% and 5% by weight.6. The device of claim 1 , wherein the first silver concentration comprises a silver concentration between 5% and 15% by weight.7. The device of claim 1 , wherein the first silver concentration comprises a silver concentration between 15% and 25% by weight.8. The device of claim 1 , ...

METHODS OF DEPOSITING SILVER NANOSTRUCTURES ON TO IMPLANT SURFACES

Methods of depositing nanoparticles onto a substrate (e.g., an implant) are provided, as are the resulting substrates (e.g., implants) formed by such deposition methods. The nanoparticles can be silver nanoparticles that provide antimicrobial or antibacterial properties to the substrate. 1. A dental implant comprising:a body including an external surface positioned to contact a jawbone of a patient when the dental implant is implanted, a majority of the external surface being coated with silver nanoparticles, wherein the silver nanoparticles are configured to provide antimicrobial properties to the dental implant.2. The dental implant of claim 1 , wherein the nanoparticles are between 0.1 nm and 100 nm in at least one dimension claim 1 , inclusive.3. The dental implant of claim 1 , wherein substantially all of the external surface is coated with the silver nanoparticles.4. The dental implant of claim 3 , wherein substantially all exposed surfaces of the dental implant are coated with the silver nanoparticles.5. The dental implant of claim 1 , wherein an amount by weight percentage of the silver nanoparticles is between 0.1 wt % and 25.0 wt % claim 1 , inclusive.6. The dental implant of claim 1 , wherein the silver nanoparticles have broad spectrum antimicrobial properties against Gram-negative and Gram-positive bacteria claim 1 , and a low microorganism resistance probability.7. A method of depositing nanoparticles on a dental implant comprising:{'sub': '3', 'preparing an electrolyte solution comprising an aqueous solution having silver nitrate (AgNO);'}positioning the dental implant within the electrolyte solution; andapplying an electric current to the electrolyte solution for a duration of time, thereby causing deposition of silver nanoparticles on a surface of the dental implant, the silver nanoparticles providing antimicrobial properties to the dental implant.8. The method of claim 7 , wherein the aqueous solution has a concentration of between about 0.01 mM to ...

Ultrastable Silver Nanoparticles

Ultrastable silver nanoparticles, methods of making the same, and methods of using the same, are disclosed. 1. A compound comprising the formula MAg(SR)wherein:M is a metal selected from the group consisting of Cs, Na, K, Li, Fr, and Rb; andSR is a mercaptophenyl ligand;and salts, isomers, stereoisomers, entantiomers, racemates, solvates, hydrates, polymorphs, and prodrugs thereof.2. The compound of claim 1 , wherein the mercaptophenyl ligand is selected from the group consisting of p-mercaptobenzoic acid claim 1 , p-mercaptophenyl alcohol claim 1 , and 4-mercaptophenol.3. (canceled)4. The compound of claim 1 , further comprising coordinating molecules selected from the group consisting of: deprotonated methanol ions claim 1 , deprotonated ethanol ions claim 1 , hydroxide ions claim 1 , citrate claim 1 , acetate claim 1 , DMSO claim 1 , DMF claim 1 , pyridine claim 1 , ammonia claim 1 , acetone claim 1 , acetonitrile claim 1 , ethers claim 1 , phosphines claim 1 , and combinations thereof.5. The compound of claim 4 , wherein the compound has a core comprising coordination sites claim 4 , and the coordinating molecules stabilize the compound by binding to the coordination sites.6. The compound of claim 5 , wherein one or more of the coordinating molecules is substituted by one or more of a pharmaceutical agent claim 5 , a fluorophore claim 5 , or a carbohydrate claim 5 , covalently bonded through a sulfur linkage at a coordination site.7. The compound of claim 1 , wherein the compound comprises a Agcore and a protecting layer of AgScapping structures.8. A silver cluster molecule comprising: a 32-silver-atom dodecahedral core consisting of a 12-silver-atom icosahedron encapsulated by a 20-silver-atom dodecahedron; and 30 coordinating ligands.9. The silver cluster molecule of claim 8 , wherein the coordinating ligands comprise p-MBA.10. The silver cluster molecule of claim 8 , wherein the dodecahedral core comprises icosahedral symmetry.11. The silver cluster molecule ...

Composition comprising antimicrobial metal ions and a quaternary cationic surfactant

The present invention relates to an antimicrobial composition suitable for use on skin and wounds comprising a source of an antimicrobial metal ion and a quaternary cationic surfactant.

A Composition for Use in the Prevention and/or Treatment of Epistaxis

A synergistic composition of naturally occurring active ingredients is described, which has proved particularly effective in the treatment and/or prevention of epistaxis, particularly in acute or chronic episodes of infectious and inflammatory epistaxis. The composition includes the synergistic combination of hyaluronic acid or a salt thereof, silver, vitamin B5 or pro-vitamin B5, and optionally vitamin E or an ester thereof. 1. A composition comprising hyaluronic acid or a salt thereof , silver , vitamin B5 or pro-vitamin B5 and optionally vitamin E or an ester thereof.2. The composition according to claim 2 , wherein silver is in the form of colloidal silver claim 2 , silver proteinate claim 2 , elementary silver claim 2 , micronized silver claim 2 , silver salts claim 2 , or silver complexed with other ingredients.3. The composition according to claim 1 , which is a pharmaceutical dosage form for topical application.4. The composition according to claim 3 , wherein the pharmaceutical dosage form comprises from 0.05 to 5 claim 3 ,500 mg of hyaluronic acid or a salt thereof claim 3 , from 0.0001 to 6 claim 3 ,000 mg of silver claim 3 , including one of ionic or salified or complexed silver claim 3 , from 0.1 to 7 claim 3 ,000 mg of vitamin B5 or pro-vitamin B5 claim 3 , and optionally from 0.01 to 10 claim 3 ,000 mg of vitamin E or an ester thereof.5. The composition according to claim 3 , wherein the pharmaceutical dosage form comprises from 0.01 to 50 wt % of hyaluronic acid or a salt thereof claim 3 , from 0.0001 to 20 wt % of silver including one of ionic or salified or complexed silver claim 3 , from 0.1 to 50 wt % of vitamin B5 or pro-vitamin B5 claim 3 , and optionally from 0.01% to 50 wt % of vitamin E or an ester thereof.6. The composition according to claim 3 , wherein the pharmaceutical dosage form for topical application is selected from the group consisting of nasal drops claim 3 , nasal cream claim 3 , nasal ointment claim 3 , nasal spray claim 3 , ...

BONE IMPLANT AND SYSTEMS THAT CONTROLLABLY RELEASES SILVER

Silver and/or zinc ion releasing implants, systems and method of operating, inserting and activating/inactivating them are described. In some variations the implant is configured as a bone implant that includes a bone-screw or intramedullary rod like body configured to receive a treatment cartridge having a plurality of ion-releasing members configured as an anode that can controllably engage with a catheter to turn galvanic release of ions on/off as desired. These devices may be configured to release silver ions (and/or zinc ions) above a predetermined level for a predetermined period of time and may maintain a concentration of ions over a relatively large volume of tissue. The ion-releasing members may be configured to reduce or prevent implant movement. 1. A method of controllably delivering silver , zinc , or silver and zinc ions from an implant to prevent or treat infection , the method comprising:engaging the implant with a removable silver, zinc or silver and zinc releasing treatment cartridge, wherein the treatment cartridge comprises a silver, zinc, or silver and zinc anode, and wherein the implant includes a cathode comprising a material having a higher half-cell potential than the anode, further wherein the cathode has a greater active surface area than the active surface area of the anode; andactivating a switchable control to initiate the galvanic release of silver, zinc or silver and zinc from the treatment cartridge by placing the cathode in electrical contact with the anode.2. The method of claim 1 , wherein engaging the implant comprises coupling the removable silver claim 1 , zinc or silver and zinc releasing treatment cartridge with the implant when the implant is already inserted into a patient.3. The method of claim 1 , further comprising placing at least a portion of the cathode in communication with a source of oxygen at a concentration of greater than 7×10mol/L.4. The method of claim 1 , further comprising inserting the implant into a patient ...

A NANOBIOCOMPOSITE FORMULATION FOR WOUND HEALING AND A PROCESS FOR THE PREPARATION THEREOF

The present invention involves the isolation of plant based CNCs from the leaves of . For the formation of NCs, a novel greener approach using LE as reducing agent for in situ impregnation of AgNPs as fillers into CNCs as matrix is reported. The silver nitrate solution in three different concentrations of 1 mM, 5 mM and 10 mM was used to form NCs where AgNPs have been incorporated into CNCs matrix. The CNCs and NCs were characterized using SEM, TEM, XRD, Zeta potential, FT-IR, and UV-Vis spectroscopy. NCs developed in the form of film and ointment showed strong antimicrobial activity against both gram negative and gram positive bacteria. NCs wound dressing is capable of regulating wound exudates and providing moisture to wound responsible for faster healing of acute wounds. The observations from histopathological and biochemical assays confirmed that NCs enhance healing because of lesser inflammation, rapid angiogenesis, early collagen formation and enhanced rate of reepithelization. 1Syzygium cumini. A nanobiocomposite formulation (NCs) in ointment form comprising silver nanoparticles (AgNPs) and cellulose nanocrystals (CNCs) wherein the ratio of AgNPs and CNCs is in the range of 0.067%-0.4% w/w AgNPs: 7-8% w/w CNCs , and wherein the cellulose is derived from leaves.2. A process for the preparation of the nanobiocomposite formulation in ointment form as claimed in claim 1 , the method comprising:{'i': 'Syzygium cumini', 'a) treating washed and dried leaves with bleaching agent at pH in the range of 3.0-4.0 for a time period ranging between 2-3 h at a temperature ranging between 70-100° C. to obtain a bleached fibrous material;'}b) filtering and washing the bleached fibrous material as obtained from (a) followed by treating with acidified bleaching agent solution at a temperature ranging between 22-30° C. for a time period ranging 16-18 h to obtain acidified fibrous material;c) washing the acidified fibrous material as obtained from (b) followed by keeping it into 2 ...

Treatment of skin disease

The present invention is drawn to compositions, systems, and methods of treating skin disease. The composition includes a peroxygen, a transition metal or alloy thereof, and optionally, an alcohol and/or a drug. The composition can be packaged as part of a two-part system, and in one example, the drug is acetylsalicylic acid.

SILVER NANOPLATE COMPOSITIONS AND METHODS

Embodiments of the present invention relate to methods for preparing high optical density solutions of nanoplates, such as silver nanoplates or silver platelet nanoparticles, and to nanoparticles, solutions and substrates prepared by said methods. The process can include the addition of stabilizing agents (e.g., chemical or biological agents bound or otherwise linked to the nanoparticle surface) that stabilize the nanoparticle before, during, and/or after concentration, thereby allowing for the production of a stable, high optical density solution of silver nanoplates. The process can also include increasing the concentration of silver nanoplates within the solution, and thus increasing the solution optical density. 1. (canceled)2. A process for increasing the optical density of a solution of stable , silver nanoplates , comprising:{'sup': '−1', 'providing a solution comprising silver nanoplates having a plate shape, an extinction spectra, and a first peak optical density between 0.1-10 cm;'}adding a concentration stabilizing chemical agent to the solution of silver nanoplates; and{'sup': '−1', 'increasing the concentration of silver nanoplates using tangential flow filtration, thereby increasing the optical density of the solution to a second peak optical density greater than 10 cm,'}{'sup': '−1', 'wherein the silver nanoplates retain the plate shape and the extinction spectra at the second peak optical density greater than 10 cm.'}3. The process of claim 2 , wherein the stabilizing agent comprises at least one of the group consisting of polyvinyl pyrollidone claim 2 , polyvinyl alcohol claim 2 , polyethylene glycol claim 2 , and dextran.4. The process of claim 2 , wherein the stabilizing agent comprises at least one of the group consisting of polysulphonates claim 2 , ethylene oxides claim 2 , phenols claim 2 , and carbohydrates.5. The process of claim 2 , wherein the concentration stabilizing chemical agent is a water soluble polymer.6. The process of claim 2 , ...

COLLAGEN MEMBRANE OR MATRIX WITH ANTIMICROBIAL PROPERTIES

The main purpose of this technology is developing a collagen matrix or membrane with antimicrobial properties, comprising collagen from fetal amniotic membranes and metallic nanoparticles. Additionally, its manufacturing procedure is described. 1. A collagen matrix or membrane with antimicrobial properties , characterized in that the collagen matrix or membrane comprises collagen from fetal amniotic membranes and metallic nanoparticles.2. The collagen matrix or membrane according to claim 1 , characterized in that the metallic nanoparticles are copper nanoparticles with a particle size of 25-60 nm claim 1 , and wherein the solution has a final copper concentration of 1 mg/mL.3. The collagen matrix or membrane according to claim 1 , characterized in that the metallic nanoparticles are a mixture of copper and silver claim 1 , wherein the copper nanoparticles have a particle size of 25-60 nm claim 1 , and the silver nanoparticles have a particle size of 100 nm or less.4. The collagen matrix or membrane according to claim 3 , characterized in that the solution has a final copper concentration of 1 mg/mL and a silver nanoparticle concentration of 2.5-5 ng/mL.5. The collagen matrix or membrane according to claim 1 , characterized in that the metallic nanoparticles are a mixture of cadmium quantumdots at a concentration of 0.1-10 nM.6. The collagen matrix or membrane according to claim 1 , characterized in that the metallic nanoparticles are a mixture of copper claim 1 , silver and gold claim 1 , wherein the copper nanoparticles have a particle size of 25-60 nm claim 1 , the silver nanoparticles have a particle size of 100 nm or less claim 1 , and the gold nanoparticles have a particle size of 5 nm.7. The collagen matrix or membrane according to claim 6 , characterized in that the solution has a final copper concentration of 1 mg/mL and a silver nanoparticle concentration of 2.5-5 ng/mL claim 6 , and a concentration of the gold nanoparticles in the final solution of 5.5E+ ...

Methods and Compositions for Treating Wounds and Reducing the Risk of Incisional Hernias

Provided are methods and compositions for treating a wound in a subject. The methods include applying a pharmaceutical composition that includes a first precursor material agent including fibrinogen, a second precursor material agent including thrombin, and silver particles to an abdominal incision site in an amount effective to treat the abdominal incision site. Also provided are pharmaceutical compositions and devices for use in the subject methods. 1. A method for treating a wound in a subject , the method comprising:applying a pharmaceutical composition comprising a first precursor material agent comprising fibrinogen, a second precursor material agent comprising thrombin, and silver particles to an abdominal incision site in an amount effective to treat the abdominal incision site.2. The method of claim 1 , wherein the first precursor material agent claim 1 , the second precursor material agent and the silver particles are adapted to be combined in situ.3. The method of claim 1 , wherein the applying comprises applying the first precursor material agent prior to applying the second precursor material agent.4. The method of claim 1 , wherein the applying comprises applying the second precursor material agent prior to applying the first precursor material agent.5. The method of claim 1 , wherein the silver particles are silver microparticles.6. The method of claim 5 , wherein the silver particles are spherical.7. The method of claim 5 , wherein the silver microparticles have an average diameter of 5 μm or more.8. The method of claim 7 , wherein the silver microparticles have an average diameter of 200 μm or more.9. The method of claim 1 , wherein the pharmaceutical composition comprises 25 mg/mL silver particles.10. The method of claim 1 , wherein the pharmaceutical composition comprises 250 mg/mL silver particles.11. A pharmaceutical composition for treating a wound in a subject claim 1 , the composition comprising:a fibrin glue and silver particles in an amount ...

SILVER OXIDE FORMULATIONS

Topical formulations for application to exposed body tissue. 1. A method comprising:{'sub': '50', '(a) providing a formulation including at least one silver oxide including a silver(II) oxide, said at least one silver oxide having an average particle size (D) within a range of from above 0.8 micrometers to below 8 micrometers, said silver(II) oxide having an irregular macrocrystal structure,'}said irregular macrocrystal structure characterized by a diffraction peak in a {111} diffraction plane, said diffraction peak having at least one of the following structural properties:(i) a measured full width half maximum (FWHM) of at least 0.30 degrees of 2θ and not more than 0.466 degrees of 2θ; and(ii) a net full width half maximum (net FWHM) of at least 0.20 degrees of 2θ and not more than 0.366 degrees of 2θ;the formulation being a topical formulation suitable for application to skin tissue, wherein said silver oxide predominantly includes said silver(II) oxide; and(b) applying said formulation to skin tissue.2. A method comprising:(a) providing a silver oxide raw material, said silver oxide raw material predominantly including a silver(II) oxide;(b) milling said silver oxide raw material in a vortex mill, to produce a silver oxide powder in which an average particle size is smaller by at least one micrometer an average particle size of silver oxide raw material;wherein said silver oxide powder contains a silver(I) oxide and said silver(II) oxide, and wherein a concentration of said silver(I) oxide in said silver oxide powder exceeds a concentration of said silver(I) oxide in said silver oxide raw material.3. The method of claim 2 , wherein said silver oxide powder has an average particle size (D) within a range of from above 0.8 micrometers to below 8 micrometers.4. The method of claim 3 , wherein said silver(II) oxide in said silver oxide powder has an irregular macrocrystal structure claim 3 ,said irregular macrocrystal structure characterized by a diffraction peak in ...

SKIN-REGENERATING MATERIAL COMPRISING SYNERGISTIC COMBINATION OF METAL OXIDES

Provided are materials including cell proliferation properties. The materials may include a polymer having incorporated therein a synergistic combination of at least two metal oxide powders, including a mixed oxidation state oxide of a first metal and a single oxidation state oxide of a second metal. The mixed oxidation state oxide may constitute from about 25% wt. to about 75% wt. of the total weight of the synergistic combination of the at least two metal oxide powders. The powders may be incorporated substantially uniformly within the polymer. The ions of the metal powders may be in ionic contact upon exposure of the material to moisture. Further provided are methods for the preparation of the materials and uses thereof, including in skin regeneration processes and cosmetic applications. 137.-. (canceled)38. A material having cell proliferation properties , said material comprising a polymer having incorporated therein a synergistic combination of at least two metal oxide powders , comprising a mixed oxidation state oxide of a first metal and a single oxidation state oxide of a second metal , wherein the mixed oxidation state oxide constitutes from about 25% wt. to about 75% wt. of the total weight of the synergistic combination of the at least two metal oxide powders , the powders are being incorporated substantially uniformly within said polymer , and the ions of the metal oxides are in ionic contact upon exposure of said material to moisture.39. The material according to claim 38 , wherein the mixed oxidation state oxide is selected from the group consisting of tetrasilver tetroxide (AgO) claim 38 , AgO claim 38 , AgO claim 38 , tetracopper tetroxide (CuO) claim 38 , Cu (I claim 38 ,III) oxide claim 38 , Cu (II claim 38 ,III) oxide and combinations thereof claim 38 , and the single oxidation state oxide is selected from the group consisting of copper oxide claim 38 , silver oxide claim 38 , zinc oxide and combinations thereof.40. The material according to ...

METHODS AND COMPOSITIONS FOR WOUND HEALING

The present invention relates to large scale manufacture of nanoscale microsheets for use in applications such as wound healing or modification of a biological or medical surface. 1. A process for manufacture of an article comprising:a) providing a flexible substrate comprising a low surface energy surface having a surface area of greater than 0.1 square meters;b) depositing a nanoscale polymer layer from about 0.5 nm to 10000 nm thick on the low surface energy surface; andc) introducing a bioactive agent into the nanoscale polymer layer to provide a bioactive nanoscale polymer layer.2. The process of claim 1 , wherein the depositing occurs via a roll to roll coating process.3. The process of claim 2 , wherein the roll to roll coating process comprises transferring the flexible substrate from a first roll to at least a second roll and coating the low surface energy surface of the flexible substrate with the nanoscale polymer layer while the flexible substrate is being transferred between the first roll and the second roll.4. The process of claim 1 , wherein the nanoscale polymer layer is deposited on the low surface energy surface of the flexible substrate by a coating or printing method selected from the group consisting of roll to roll coating claim 1 , spray coating claim 1 , dip coating claim 1 , immersion coating claim 1 , spin coating claim 1 , slot die coating claim 1 , inkjet coating claim 1 , anilox coating claim 1 , screen coating claim 1 , offset lithography printing claim 1 , flexographic coating claim 1 , gravure coating claim 1 , rotogravure coating claim 1 , reverse roll coating claim 1 , metering (Meyer) rod coating claim 1 , blade coating claim 1 , knife over roll coating claim 1 , air knife coating claim 1 , curtain coating claim 1 , melt extrusion coating claim 1 , solvent casting and any combinations thereof.5. The process of claim 1 , wherein the nanoscale polymer layer is formed by depositing alternating layers of at least one positively ...

Synthesis and Antimicrobial Uses of Dinuclear Silver(I) Pyrazolates

Novel dinuclear silver(I) pyrazolido complexes and methods of synthesizing them are provided. Advantageously, the novel silver(I) pyrazolido complexes have excellent antimicrobial activity and methods of using said complexes to treat bacterial, fungal, and viral infections are also provided. 2. The dinuclear silver(I) pyrazolido complex claim 1 , according to claim 1 ,{'sup': 1', '2', '3', '4', '5, 'wherein Rand Rare PTA; and R, R, and Rare each independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, alkyl, alkenyl, aryl, formyl, acetyl, hydroxyalkyl, halogen substituted alkyl, halogen substituted aryl, halogen substituted sulfuryl, imine-linked PTA, amine-linked PTA, imine-linked adamantane, amine-linked adamantane, imine-linked triphenylphosphine, and amine-linked triphenylphosphine.'}3. The dinuclear silver(I) pyrazolido complex claim 1 , according to claim 1 ,{'sup': 1', '2', '3', '4', '5, 'wherein Rand Rare phosphaadamantane; and R, R, and Rare each independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, alkyl, alkenyl, aryl, formyl, acetyl, halogen substituted alkyl, hydroxyalkyl, halogen substituted aryl, halogen substituted sulfuryl, imine-linked PTA, amine-linked PTA, imine-linked adamantane, amine-linked adamantine, imine-linked triphenylphosphine, and amine-linked triphenylphosphine.'}4. The dinuclear silver(I) pyrazolido complex claim 1 , according to claim 1 , wherein Rand Rare (4-sulfophenyl)diphenylphosphine; and R claim 1 , R claim 1 , and Rare each independently selected from the group consisting of hydrogen claim 1 , halogen claim 1 , hydroxyl claim 1 , nitro claim 1 , alkyl claim 1 , alkenyl claim 1 , aryl claim 1 , formyl claim 1 , acetyl claim 1 , hydroxyalkyl claim 1 , halogen substituted alkyl claim 1 , halogen substituted aryl claim 1 , halogen substituted sulfuryl claim 1 , imine-linked PTA claim 1 , amine-linked PTA claim 1 , imine-linked adamantane claim 1 , amine-linked ...

Method for Increasing and Sustaining Free Radical Levels in Tissue of Interest

A method of creating and sustaining an elevated level of free radicals in a volume of targeted tissue that utilizes targeted nanostructures ( 16 ) that include a metallic component ( 26 ) that acts to amplify the effects of a free radical-producing stimulus; a magnetic component; and a binding component ( 24 ) that acts to bind to cellular components present in the targeted tissue. To practice the method, the targeted nanostructures are introduced into the targeted tissue and a free radical-producing stimulus, which may be in the form of a particle beam ( 20 ) is provided at the targeted tissue volume.

A POLYMER NETWORK, METHOD FOR PRODUCTION, AND USES THEREOF

The present disclosure relates to a polymer network comprising a compound of Formula I cross-linked to a compound selected from the group consisting of a compound of Formula II; hyaluronate aldehyde, alginate aldehyde, dextran aldehyde, starch aldehyde, and chitosan aldehyde. It also relates to a process of preparing the polymer network. The present disclosure further relates to compositions comprising the polymer network and methods of preventing conditions and diseases that are caused by micro-organism. The present disclosure still further relates to a biocompatible antimicrobial hydrogel, a process for preparing the hydrogel, and methods of using the same, including a variety of tissue-related applications in which rapid adhesion to the tissue and gel formation is desired, as well as local delivery of pharmaceutical drugs to a site of application. 13. The polymer network as claimed in to , wherein A is selected from the group consisting of Cl , Br , I , OH , HCO , CO , RCOO , RSO , and RSO , wherein Ris selected from the group consisting of hydrogen , Calkyl , and Caryl , wherein Calkyl , and Caryl are optionally substituted with hydroxyl , nitro , halogen , alkyl , aryl , —COOR.14. The polymer network as claimed in to , wherein the compound of Formula II is cross linked to the compound of Formula I through aldehyde group of Formula II and the amine group of Formula I.15. The polymer network as claimed in claim 1 , wherein the compound of Formula I is N-(2-hydroxy)-propyl-3-trimethylammonium chitosan chloride.16. A process of the preparation of a polymer network as claimed in .17. The polymer network as claimed in any of the - for use in antimicrobial infections.18. The polymer network as claimed in for use as antimicrobial agents in the treatment of diseases caused by bacteria claim 17 , fungi claim 17 , and virus.19. The polymer network as claimed in any of the - for use as antibacterial agents in the treatment of diseases caused by Gram-positive claim 17 , ...

METASTABLE SILVER NANOPARTICLE COMPOSITES

Embodiments of the present invention relate to a metastable silver nanoparticle composite, a process for its manufacture, and its use as a source for silver ions. In various embodiments, the composite comprises, consists essentially of, or consists of metastable silver nanoparticles that change shape when exposed to moisture, a stability modulant that controls the rate of the shape change, and a substrate to support the silver nanoparticles and the modulant. 1. A composite comprising a metastable silver nanoparticle and a stability modulant where the silver nanoparticle undergoes a change in shape when the composite is exposed to moisture.2. The composite of further comprising a substrate.3. The composite of where the silver nanoparticles are nanoplates claim 1 , nanopyramids claim 1 , nanocubes claim 1 , nanorods claim 1 , or nanowires.4. The composite of where the silver nanoparticles are not spheres and undergo a reduction in aspect ratio when exposed to moisture.5. The composite in where the silver nanoparticles undergo a reduction in aspect ratio when exposed to water.6. The composite in where the nanoparticles are faceted and the vertices between their crystal faces undergo an increase in radius of curvature on exposure to moisture.7. The composite of where the stability modulant is a surface coating on the silver nanoparticles.8. The composite of where the surface coating is any one selected from the group consisting of an oxide claim 7 , a polymer claim 7 , organic ligand claim 7 , thiol claim 7 , stimulus responsive polymer claim 7 , polyvinylpyrollidone claim 7 , silica claim 7 , polystyrene claim 7 , tannic acid claim 7 , polyvinylalcohol claim 7 , polystyrene and polyacetylene.9. The composite of where the stability modulant is a chemical that is dried onto the substrate.10. The composite of where the chemical is an oxidant.11. The composite of where the chemical is any one selected from the group consisting of a borate salt claim 9 , a bicarbonate salt ...

Antimicrobial Amorphous Compositions

The present invention comprises compositions and methods for providing antimicrobial compositions. The antimicrobial compositions comprise gel delivery vehicles comprising stabilized silver, wherein ionic silver is provided to a site for antimicrobial purposes. Methods of making and using such compositions are taught, including application of the silver-containing gel compositions to wounds, burns, abrasions, cuts, surgical incision, sites where skin or organ integrity has been breached, and other sites to supply an antimicrobial environment. 127-. (canceled)28. An antimicrobial composition comprising an amorphous delivery vehicle and a stabilized silver salt comprising silver ions and halide anions , wherein the stabilized silver salt is stabilized by a molar excess of halide anions to silver ions , wherein the antimicrobial composition is spreadable and resistant to discoloration due to light exposure.29. The composition of claim 28 , wherein the halide anions comprise chloride anions.30. The composition of claim 28 , wherein the stabilized silver salt comprises silver chloride.31. The composition of claim 28 , wherein the stabilized silver salt is formed by combining silver nitrate and sodium chloride.32. The composition of claim 28 , wherein the ratio of the molar excess of halide anions to silver ions ranges from 1.1:1 to 200:1.33. The composition of claim 28 , further comprising glycerol.34. The composition of claim 28 , further comprising a polymer matrix powder.35. The composition of claim 34 , wherein the polymer matrix powder comprises polyacrylamide.36. The composition of claim 28 , further comprising water.37. The composition of claim 28 , further comprising an active agent.38. The composition of claim 37 , wherein the active agent is an antimicrobial agent claim 37 , an antifungal agent claim 37 , an antibacterial agent claim 37 , an antiviral agent claim 37 , an anti-parasitic agent claim 37 , a wound healing agent claim 37 , or a combination thereof. ...

METHODS OF USING WATER-SOLUBLE INORGANIC COMPOUNDS FOR IMPLANTS

A method for controlling generation of biologically desirable voids in a composition placed in proximity to bone or other tissue in a patient by selecting at least one water-soluble inorganic material having a desired particle size and solubility, and mixing the water-soluble inorganic material with at least one poorly-water-soluble or biodegradable matrix material. The matrix material, after it is mixed with the water-soluble inorganic material, is placed into the patient in proximity to tissue so that the water-soluble inorganic material dissolves at a predetermined rate to generate biologically desirable voids in the matrix material into which bone or other tissue can then grow. 1162-. (canceled)163. An implant suitable for placement in a patient , comprising:an implant component having an outer surface;a poorly-water-soluble matrix material having a physically continuous interconnected matrix as a porous structure disposed on at least a portion of the outer surface of the implant component and defining interstices within the porous structure; andwater-soluble inorganic material blended within and attached within at least some of the interstices of the porous structure such that, when the implant is placed in proximity of tissue, the water-soluble inorganic material dissolves at a predetermined rate to generate biological desirable voids within said interstices into which tissue can grow to assist fixation of the implant within the patient.164. The implant according to wherein the poorly-water-soluble implant material includes metallic claim 163 , ceramic claim 163 , or polymeric material.165. The implant according to wherein the implant is a fixation device selected from the group including an external fixator pin claim 163 , a bone screw claim 163 , an artificial joint or an interbody spinal fusion device.166. The implant according to wherein the ceramic material includes at least one of hydroxyapatite claim 164 , tricalcium phosphate or biphasic calcium ...

Oxygenated Antimicrobial Topical Composition

The present invention relates to an antimicrobial topical composition and process for making such composition. The composition comprises of ionic silver, silver nanoparticles, and oxygen, combined within a gel medium and applied topically. The composition optimizes the ionic silver and silver nanoparticle ratio providing for sufficient ionic silver to be delivered as an immediate antimicrobial agent, and sufficient nanoparticle silver to provide time release for conversion to silver ions for continuing antimicrobial effectiveness. 1. A antimicrobial composition comprising a total concentration of silver of between 15-200 parts per million with a percentage of silver nanoparticle between 10% to 100% , hydrogen peroxide and a gelling agent.2. The composition according to claim 1 , wherein the hydrogen peroxide concentration is between 3% wght/v to 10% wgt/v.3. The composition according to claim 1 , wherein the gelling agent comprises of sodium carbomer.4. An antimicrobial product made by the process comprising the steps:a. Obtaining a water-based solution of silver nanoparticles containing a high concentration of nanosilver particles that is more than 15% of the silver in a solution;b. Adding a gellating agent to the water-based solution of silver nanoparticles to create a gel;c. Mixing hydrogen peroxide into the gel and then isolating the gel compound; andd. Allowing ion silver particles to ionize in the presence of the hydrogen peroxide and thereby releasing oxygen gas into the gel compound for several hours to several days depending on the silver concentrations and ratios and on the concentration of hydrogen peroxide used.5. A method of making antimicrobial topical composition comprising of:a. Obtaining a water-based solution of silver nanoparticles containing a high concentration of nanosilver particles that is more than 15% of the silver in a solution;b. Adding a gellating agent to the water-based solution of silver nanoparticles to create a gel;c. Mixing ...

Co-encapsulation of antimicrobials and adjuvants in nanocarriers

Microbial infections have become increasingly difficult to treat due to the emergence of drug resistant microbes. Adjunctive therapies can be used to better treat resistant microbes, where multiple drugs are concurrently used to overcome resistant mechanisms and to synergistically treat infections. The practice of adjunctive therapies is limited by the ability to precisely control the pharmacokinetic profiles of the multiple actives. Composite particle-based approaches to enable and enhance adjunctive antimicrobial infections by simultaneous encapsulation and delivery of all components are described herein.

Therapeutic Medical Device and Methods of Use

A micro-emulsion compound, especially suited for topical applications, comprising a nanopolymer, an anesthetic agent such as lidocaine, and particles of biologically active silver, silver oxide complex, or another biologically active metal.

COMPOSITIONS COMPRISING SILVER NITRATE, HYALURONIC ACID AND ALLANTOIN AND METHODS FOR USE THEREOF

In one embodiment, a composition is provided, comprising: 0.0005 wt % to 0.05 wt % of silver nitrate, based on a total weight of the composition; 0.01 wt % to 1.0 wt % of hyaluronic acid, based on the total weight of the composition; and 0.05 wt % to 2.5 wt % of allantoin, based on the total weight of the composition. In one embodiment, a method of treating a skin wound is provided, comprising: topically applying a sufficient amount of a composition to the skin wound of a patient to cover the skin wound, the composition comprising: 0.0005 wt % to 0.05 wt % of silver nitrate, based on a total weight of the composition; 0.01 wt % to 0.1 wt % of hyaluronic acid, based on the total weight of the composition; and 0.05 wt % to 2.5 wt % of allantoin, based on the total weight of the composition. 1. A composition comprising:0.0005 wt % to 0.04 wt % of silver nitrate, based on a total weight of the composition;0.01 wt % to 1.0 wt % of hyaluronic acid, based on the total weight of the composition; and0.05 wt % to 2.5 wt % of allantoin, based on the total weight of the composition.2. The composition of claim 1 , wherein the composition comprises 0.002 wt % to 0.007 wt % of the silver nitrate claim 1 , based on the total weight of the composition.3. The composition of claim 1 , wherein the composition comprises 0.005 wt % of the silver nitrate claim 1 , based on the total weight of the composition.4. The composition of claim 1 , wherein the composition comprises 0.1 wt % to 0.3 wt % of the hyaluronic acid claim 1 , based on the total weight of the composition.5. The composition of claim 1 , wherein the composition comprises 0.2 wt % of the hyaluronic acid claim 1 , based on the total weight of the composition.6. The composition of claim 1 , wherein the composition comprises claim 1 , 0.3 wt % to 1 wt % of the allantoin claim 1 , based on the total weight of the composition.7. The composition of claim 1 , wherein the composition comprises 0.7 wt % of the allantoin claim 1 , ...

Continuous methods for treating liquids and manufacturing certain constituents (e.g., nanoparticles) in liquds, apparatuses and nanoparticles and nanoparticle/liquid solution(s) resulting therefrom

This invention relates generally to novel methods and novel devices for the continuous manufacture of nanoparticles, microparticles and nanoparticle/liquid solution(s). The nanoparticles (and/or micron-sized particles) comprise a variety of possible compositions, sizes and shapes. The particles (e.g., nanoparticles) are caused to be present (e.g., created and/or the liquid is predisposed to their presence (e.g., conditioned)) in a liquid (e.g., water) by, for example, preferably utilizing at least one adjustable plasma (e.g., created by at least one AC and/or DC power source), which plasma communicates with at least a portion of a surface of the liquid. At least one subsequent and/or substantially simultaneous adjustable electrochemical processing technique is also preferred. Multiple adjustable plasmas and/or adjustable electrochemical processing techniques are preferred. The continuous process causes at least one liquid to flow into, through and out of at least one trough member, such liquid being processed, conditioned and/or effected in said trough member(s). Results include constituents formed in the liquid including micron-sized particles and/or nanoparticles (e.g., metallic-based nanoparticles) of novel size, shape, composition, zeta potential and properties present in a liquid. 1. A method for treating a patient with a bacterial infection comprising administering to a patient in need thereof an effective amount of a composition comprising:water;silver constituents comprising silver ions and silver nanoparticles in said water, said silver constituents being present in an amount of 1 ppm to 20.6 ppm;zinc constituents comprising zinc ions in said water, said zinc constituents being present in an amount of 0.5 ppm to 20 ppm, wherein a ratio of the amount of said zinc constituents to said silver constituents varies from 8:1 to 0.5:1; andnitrogen oxides in said water.2. A method for treating a patient with a bacterial infection comprising administering to a ...

TOPICAL ANTIBIOTIC FORMULATIONS

There are disclosed topical silver(II) antibiotic formulations. Other embodiments are also disclosed. 1. A method of producing a silver(II) carboxylate or silver(II) carboxylate formulation , the method including the steps of: (a) mixing a carboxylic acid and silver(II) oxide to produce a reaction mixture; and (b) heating the reaction mixture to produce an aliphatic silver carboxylate , the silver of the aliphatic silver carboxylate having a nominal valence of 2.2. An antimicrobial formulation comprising:(a) at least one silver-containing compound, including an anti-microbial agent containing an aliphatic silver carboxylate, said silver of said aliphatic carboxylate having a nominal valence of 2, said at least one silver-containing compound having an average valence of at least 1.1; and(b) a carrier base;said at least one silver-containing compound being dispersed within said base.3. The formulation of claim 2 , the formulation having a form of a cream claim 2 , an emulsion claim 2 , or an ointment.4. The formulation of claim 2 , a total silver content of the formulation claim 2 , or a total silver content of said at least one silver-containing compound claim 2 , being within a range of 0.0005% to 20% claim 2 , 0.0005% to 12% claim 2 , 0.0005% to 7% claim 2 , 0.0005% to 3.5% claim 2 , 0.0005% to 3% claim 2 , 0.0005% to 2.5% claim 2 , 0.001% to 3.5% claim 2 , 0.005% to 3.5% claim 2 , 0.01% to 3.5% claim 2 , 0.03% to 3.5% claim 2 , 0.05% to 3.5% claim 2 , 0.10% to 3.5% claim 2 , 0.30% to 3.5% claim 2 , 0.5% to 3.5% claim 2 , 0.7% to 3.5% claim 2 , or 0.9% to 3.5% claim 2 , by weight.5. The formulation of claim 2 , a content of said aliphatic carboxylate being at least 0.1% claim 2 , on an AgOweight basis claim 2 , the formulation being white or at least off-white.6. The formulation of claim 2 , a content of said aliphatic carboxylate being within a range of 0.1% to 1.7% claim 2 , on an AgOweight basis claim 2 , the formulation having a standard whiteness value of at ...

DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS

A composition and method adapted for delivery of hydrophilic, biologically-active agents are disclosed. The composition can include a reverse microemulsion formed from at least one hydrophilic, biologically-active agent solubilized by a hydrophobic reverse emulsion surfactant in a non-stinging, volatile, hydrophobic solvent. The non-stinging, volatile, hydrophobic solvent is selected from the group consisting of volatile linear and cyclic siloxanes, volatile linear, branched, and cyclic alkanes, volatile fluorocarbons and chlorofluorocarbons, liquid carbon dioxide under pressure, and combinations thereof. The reverse microemulsion can be an optically clear solution. 1. A composition comprising:a reverse microemulsion comprising at least one hydrophilic, biologically-active agent solubilized by a hydrophobic reverse emulsion surfactant in a non-stinging, volatile, hydrophobic solvent,wherein said non-stinging, volatile, hydrophobic solvent is selected from the group consisting of volatile linear and cyclic siloxanes, volatile linear, branched and cyclic alkanes, volatile fluorocarbons and chlorofluorocarbons, liquid carbon dioxide under pressure, and combinations thereof.2. The composition according to claim 1 , wherein the reverse microemulsion is an optically clear solution.3. The composition according to claim 1 , wherein said reverse emulsion surfactant is selected from the group comprising sodium bis(2-ethylhexyl)sulfosuccinate claim 1 , sodium bis(tridecyl)sulfosuccinate claim 1 , bis(dialkyl)sulfosuccinate salts claim 1 , copolymers of polydimethylsiloxane and polyethylene/polypropylene-oxide claim 1 , polyoxypropylene (12) dimethicone claim 1 , cetyl PEG/PPG-10/1 dimethicone claim 1 , hexyl laurate and polyglyceryl-4-isostearate claim 1 , PEG-10 dimethicone claim 1 , sorbitan monolaurate claim 1 , sorbitan monooleate claim 1 , polyoxyethylenesorbitan trioleate claim 1 , polyoxyethylene octyl phenyl ether claim 1 , polyoxyethylene 20 cetyl ether claim 1 , ...

SYNTHESIS OF NANOPARTICLE IN LIQUID, SEMI-SOLID MEDIA AND IN CELLS AND TISSUES USING COLD PLASMA TECHNOLOGY

A method of forming metal nanoparticles includes applying a substance to an area of interest, applying cold plasma to the area of interest, and synthesizing nanoparticles from the substance using the cold plasma in the area of interest, wherein the substance is a solution that contains metal ions, and the nanoparticles synthesized are metallic in nature. 1. A method , comprising:applying a substance to an area of interest;applying cold plasma to the area of interest; andsynthesizing nanoparticles from the substance using the cold plasma in the area of interest.2. The method of claim 1 , wherein the substance is a solution that contains metal ions claim 1 , and the nanoparticles synthesized are metallic in nature.3. The method of claim 2 , wherein the metal ions comprise silver ions (Ag) claim 2 , gold ions (Au) claim 2 , copper ions (Cu and/or Cu) claim 2 , platinum ions (Pt) claim 2 , or a combination thereof.4. The method of claim 1 , wherein applying the substance to the area of interest comprises disposing the substance to a biofilm or a biological tissue.5. The method of claim 1 , wherein the substance comprises biological cells claim 1 , the area of interest comprises a metal-ion-containing medium claim 1 , and applying the substance to the area of interest comprises the disposing biological cells in the metal-ion-containing medium to allow diffusion of the metal ions into the biological cells and to form metal-ion-impregnated biological cells.6. The method of claim 5 , wherein synthesizing nanoparticles from the substance using the cold plasma comprises exposing the metal-ion-impregnated biological cells to the cold plasma to form metal-nanoparticle-impregnated biological cells.7. The method of claim 6 , comprising incorporating the metal-nanoparticle-impregnated biological cells into a targeted region.8. The method of claim 1 , comprising:applying additional cold plasma to the area of interest to heat the synthesized nanoparticles to provide local heating to ...

Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds

According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a topical composition is provided, which can be formulated as a homogenous mixture, such as a spray, mist, aerosol, lotion, cream, solution, oil, gel, ointment, paste, emulsion or suspension or applied on a carrier material, such as a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold. Methods for producing such a topical composition and carrier material with the topical composition applied thereto are also disclosed.

Continuous Methods for Treating Liquids and Manufacturing Certain Constituents (e.g., Nanoparticles) in Liquids, Apparatuses and Nanoparticles and Nanoparticle/Liquid Solution(s) Resulting Therefrom

This invention relates generally to novel methods and novel devices for the continuous manufacture of nanoparticles, microparticles and nanoparticle/liquid solution(s). The nanoparticles (and/or micron-sized particles) comprise a variety of possible compositions, sizes and shapes. The particles (e.g., nanoparticles) are caused to be present (e.g., created and/or the liquid is predisposed to their presence (e.g., conditioned)) in a liquid (e.g., water) by, for example, preferably utilizing at least one adjustable plasma (e.g., created by at least one AC and/or DC power source), which plasma communicates with at least a portion of a surface of the liquid. At least one subsequent and/or substantially simultaneous adjustable electrochemical processing technique is also preferred. Multiple adjustable plasmas and/or adjustable electrochemical processing techniques are preferred. The continuous process causes at least one liquid to flow into, through and out of at least one trough member, such liquid being processed, conditioned and/or effected in said trough member(s). Results include constituents formed in the liquid including micron-sized particles and/or nanoparticles (e.g., metallic-based nanoparticles) of novel size, shape, composition, zeta potential and properties present in a liquid.

ANHYDROUS HYDROGEL COMPOSITION

The present disclosure relates to anhydrous hydrogels useful as mucoadhesive (oral compositions) or as topical agents and may be used to deliver an active agent such as active pharmaceutical agents (API's), coagulants, fragrances, flavors, and other actives and excipients. 1. An active agent delivery system , comprising i. sodium carboxymethyl cellulose (NaCMC) in an amount of from 5% (w/w) to 30% (w/w), said sodium carboxymethyl cellulose including minimal residual water, and', 'ii. anhydrous glycerine in an amount of from 70% (w/w) to 95% (w/w);, 'a. a solid or semi-solid gel composition, the solid or semi-solid gel composition comprisingb. an active agent; andc. a rate controlling membrane.2. The active agent delivery system of claim 1 , wherein the active agent delivery system is a patch claim 1 , capsule claim 1 , lozenge or chew.3. The active agent delivery system of claim 1 , wherein the amount of active agent is from 0.1% (w/w) to 30% (w/w).4. The active agent delivery system of claim 1 , wherein the solid or semi-solid gel composition includes an interior claim 1 , a reservoir is within the interior and the reservoir includes the active agent.5. The active agent delivery system of claim 1 , wherein said active agent is cannabidiol (CBD).6. The active agent delivery system of claim 1 , wherein said active agent is selected from cannabidiol (CBD) oil and tetrahydrocannabinol (THC) oil.7. The active agent delivery system of claim 1 , wherein said active agent is a moisture sensitive active agent and said moisture sensitive active agent comprises pharmaceutical agents including biologicals claim 1 , enzymes claim 1 , proteins and fragments thereof claim 1 , Adderall claim 1 , alprazolam claim 1 , gemifloxacin claim 1 , hydromorphone and zolmitriptan.8. The active agent delivery system of claim 1 , wherein said active agent is a pharmaceutical agent selected from analgesics claim 1 , decongestants claim 1 , bronchodilators claim 1 , antiasthmatic agents claim 1 ...

USE OF GERANYLFLAVONE A IN PREPARATION OF DRUG FOR PROMOTING HEALING OF WOUNDS

The present invention belongs to the field of medicine, and relates to use of cannflavin A in preparation of a drug for promoting wound healing. Particularly, the present invention relates to use of cannflavin A in preparation of a drug for promoting wound healing of type II diabetes. Cannflavin A can effectively promote wound healing, and has the potential to prepare a drug for promoting wound healing, especially for preventing and treating diabetic feet. 1. Use of any one selected from the following (1)-(3) in preparation of a drug for promoting wound healing , treating or preventing diabetic feet , or promoting fibroblast proliferation:(1) cannflavin A or a pharmaceutically-acceptable salt or ester thereof;(2) a plant extract containing cannflavin A; and(3) a pharmaceutical composition comprising an effective amount of the item (1) or the item (2) and one or more pharmaceutically-acceptable adjuvants.2. The use according to claim 1 , wherein the wound is a non-ulcerative wound or an ulcerative wound.3. The use according to claim 1 , wherein the fibroblasts are mammalian fibroblasts claim 1 , such as human fibroblasts or NIH-3T3 cells.4. The use according to claim 1 , wherein in the item (2) claim 1 , the weight percentage content of cannflavin A in the plant extract is 0.1%-90% claim 1 , 1%-80% claim 1 , 5%-50% claim 1 , 0.1%-10% claim 1 , 0.1%-5% claim 1 , 1%-10% claim 1 , or 1%-5%.5. The use according to claim 1 , wherein in the item (3) claim 1 , the pharmaceutical composition further comprises an effective amount of one or more selected from the following components:a component having the effect of drawing out pus and toxin or eliminating necrotic tissues and promoting granulation, and a component for inhibiting bacteria or fungi.6. A pharmaceutical composition claim 1 , comprising an effective amount of cannflavin A or a pharmaceutically-acceptable salt or ester thereof claim 1 , and one or more pharmaceutically-acceptable adjuvants claim 1 , and further ...

COMPOSITIONS AND METHODS FOR REDUCING THE TRANSMISSIVITY OF ILLNESSES USING AN ORAL DELIVERY SYSTEM

Methods for prophylactic and anti-transmissivity uses of an anti-microbial composition are disclosed. The methods comprise the step of administering to a human an amount of a composition having a first ingredient being xylitol; a second ingredient comprised of a glycyrrhizin-protargin-quercetin complex, in addition to formula stabilizing ingredients of glycerol monolaurate, grapefruit seed extract; vitamin C (ascorbic acid), aloe emodin, curcumin, 1,8-cineole, zinc, quinine, flavoring, and an acceptable preservative for use in an oral application. When administered the composition is effective in reducing the incidence of contracting an illness or to prophylactically help prevent transmission of an illness into the or cavity and respiratory tract. 1. A pharmaceutically acceptable formulation comprising:xylitol;silver nanoparticles;glycyrrhizin; andquercetin.2. The pharmaceutically acceptable formulation according to claim 1 , further comprising: ascorbic acid; grapefruit seed extract; monolaurin; eucalyptol; emodin or aloe emodin; zinc citrate; and quinine.3. The pharmaceutically acceptable formulation according to claim 1 , wherein:the pharmaceutically acceptable formulation is an oral or intranasal liquid;the xylitol is present in an amount of at least 1 g/100 ml;the silver nanoparticles are present in an amount of at least 0.001 g/100 ml;the glycyrrhizin is present as glycyrrhizic acid in an amount of at least 0.1 g/100 ml; andthe quercetin is present in an amount of at least 0.1 g/100 ml.4. The pharmaceutically acceptable formulation according to claim 1 , wherein:the pharmaceutically acceptable formulation is an oral or intranasal liquid;the xylitol is present in an amount of between 1-10 g/100 ml;the silver nanoparticles are present in an amount of between 0.001-0.020 g/100 ml;the glycyrrhizin is present as glycyrrhizic acid in an amount of between 0.1-0.5 g/100 ml; andthe quercetin is present in an amount of between 0.1-5 g/100 ml.5. The pharmaceutically ...

ORAL AND DENTAL HYGIENE AND CLEANING AGENTS WITH IMPROVED ANTI-BACTERIAL ACTION

The anti-inflammatory and preventive action of antimicrobial substances can surprisingly be enhanced by the use of polylactic acid particles. Corresponding advantageous products are in particular oral and dental care and cleaning products that—based on the weight thereof—comprise 0.001 to 25 wt. % polylactic acid particles and 0.00001 to 5 wt. % of at least one antibacterial compound from the groups consisting of the benzoates and/or the parabens and/or the Cu salts and/or the Ag salts and/or triclosan and/or hexetidine. 1. An oral and dental care and cleaning product , comprising , based on the weight thereof ,a) 0.001 to 25 wt. % polylactic acid particles, and a. of the benzoates and/or', 'b. of the parabens and/or', 'c. of the Cu salts and/or', 'd. of the Ag salts and/or', 'e. triclosan and/or', 'f. hexetidine., 'b) 0.00001 to 5 wt. % of at least one antibacterial compound from the groups consisting'}2. The oral and dental care and cleaning product according to claim 1 , wherein the product comprises claim 1 , based on the weight thereof claim 1 , 0.002 to 20 wt. % of polylactic acid particles.3. The oral and dental care and cleaning product according to claim 1 , wherein the product comprises claim 1 , based on the weight thereof claim 1 , 0.004 to 15 wt. % polylactic acid particles.4. The oral and dental care and cleaning product according to claim 1 , wherein the product comprises claim 1 , based on the weight thereof claim 1 , 0.005 to 12.5 wt. % polylactic acid particles.5. The oral and dental care and cleaning product according to claim 1 , wherein the polylactic acid particles have particle sizes of 1 to 1000 μm.6. The oral and dental care and cleaning product according to claim 1 , wherein the polylactic acid particles have particle sizes of 2 to 750 μm.7. The oral and dental care and cleaning product according to claim 1 , wherein the polylactic acid particles have particle sizes of 10 to 500 μm.8. The oral and dental care and cleaning product according ...

SYNTHESIS AND ANTIMICROBIAL USES OF DINUCLEAR SILVER(I) PYRAZOLATES

Novel dinuclear silver(I) pyrazolido complexes and methods of synthesizing them are provided. Advantageously, the novel silver(I) pyrazolido complexes have excellent antimicrobial activity and methods of using said complexes to treat bacterial, fungal, and viral infections are also provided. 2. The dinuclear silver(I) pyrazolido complex claim 1 , according to claim 1 ,{'sup': 1', '2', '3', '4', '5, 'wherein Rand Rare PTA; and R, R, and Rare each independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, alkyl, alkenyl, aryl, formyl, acetyl, hydroxyalkyl, halogen substituted alkyl, halogen substituted aryl, halogen substituted sulfuryl, imine-linked PTA, amine-linked PTA, imine-linked adamantane, amine-linked adamantane, imine-linked triphenylphosphine, and amine-linked triphenylphosphine.'}3. The dinuclear silver(I) pyrazolido complex claim 1 , according to claim 1 ,{'sup': 1', '2', '3', '4', '5, 'wherein Rand Rare phosphaadamantane; and R, R, and Rare each independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, alkyl, alkenyl, aryl, formyl, acetyl, halogen substituted alkyl, hydroxyalkyl, halogen substituted aryl, halogen substituted sulfuryl, imine-linked PTA, amine-linked PTA, imine-linked adamantane, amine-linked adamantine, imine-linked triphenylphosphine, and amine-linked triphenylphosphine.'}4. The dinuclear silver(I) pyrazolido complex claim 1 , according to claim 1 , wherein Rand Rare (4-sulfophenyl)diphenylphosphine; and R claim 1 , R claim 1 , and Rare each independently selected from the group consisting of hydrogen claim 1 , halogen claim 1 , hydroxyl claim 1 , nitro claim 1 , alkyl claim 1 , alkenyl claim 1 , aryl claim 1 , formyl claim 1 , acetyl claim 1 , hydroxyalkyl claim 1 , halogen substituted alkyl claim 1 , halogen substituted aryl claim 1 , halogen substituted sulfuryl claim 1 , imine-linked PTA claim 1 , amine-linked PTA claim 1 , imine-linked adamantane claim 1 , amine-linked ...

TREATMENT WATER OF LIFESTYLE-RELATED DISEASES AND METHOD OF TREATING THE LIFESTYLE-RELATED DISEASES

To obtain a lifestyle-related disease therapeutic water which comprises a very small amount of anionized silver, nanosized gold, and 99.9% or more of water. A lifestyle-related disease therapeutic water comprising with respect to one liter of water (a), 3-15 mg in silver equivalent of thiosulfate silver ion (b), and 0.1-0.5 mg in gold equivalent of colloidal gold (c). 1. A lifestyle-related disease therapeutic water comprising the followings:(a) with respect to one liter of water,(b) 3-15 mg in silver equivalent of thiosulfate silver ion, and(c) 0.1-0.5 mg in gold equivalent of colloidal gold.2. The lifestyle-related disease therapeutic water according to claim 1 , wherein (a) the water is at least one kind selected from the group consisting of tap water claim 1 , mineral water claim 1 , purified water claim 1 , electrolyzed water and other drinking waters.3. The lifestyle-related disease therapeutic water according to claim 1 , wherein (b) the thiosulfate silver ion is represented by Formula [Ag(SO)]and/or Formula [Ag(SO)].4. The lifestyle-related disease therapeutic water according to claim 1 , wherein the lifestyle-related disease is at least one kind selected from the group consisting of cancer claim 1 , diabetes claim 1 , arteriosclerosis claim 1 , kidney disease claim 1 , liver disease claim 1 , lung disease claim 1 , heart disease claim 1 , and gastrointestinal disease.5. A method of treating lifestyle-related disease comprising administering 0.5 to 1.5 liters per day of the lifestyle-related disease therapeutic water according to per oral claim 1 , by drip or by catheter.6. The lifestyle-related disease therapeutic water according to claim 2 , wherein (b) the thiosulfate silver ion is represented by Formula [Ag(SO)]and/or Formula [Ag(SO)].7. The lifestyle-related disease therapeutic water according to claim 2 , wherein the lifestyle-related disease is at least one kind selected from the group consisting of cancer claim 2 , diabetes claim 2 , arteriosclerosis ...

AGENTS HAVING EFFICACY AGAINST VIRUSES, ALLERGENS, BACTERIA AND ODORANTS, MATERIALS INCLUDING SAID AGENTS, AND METHODS FOR PRODUCING SAID AGENTS

The present invention provides agents having efficacy against viruses, allergens, bacteria and odorants, materials including such agents, and methods for producing the agents. An agent according to an embodiment of the present invention includes titanium dioxide particles having low photocatalytic activity, and metal ions of at least one metal selected from gold, silver, platinum and copper that are adsorbed to the surface of the titanium dioxide particles. The agent may further include hydroxyapatite particles, and the metal ions may be adsorbed also to the surface of the hydroxyapatite. The metal ions may be at least partially present in the form of at least one of an oxide of the metal, a hydroxide of the metal, and the elemental metal. 1. An agent having efficacy against at least one of viruses , allergens , bacteria , fungi and odorants , the agent comprising:titanium dioxide particles having low photocatalytic activity, andmetal ions of at least one metal selected from gold, silver, platinum and copper that are adsorbed to the surface of the titanium dioxide particles.2. The agent according to claim 1 , further comprising hydroxyapatite particles claim 1 , the metal ions being adsorbed also to the surface of the hydroxyapatite.3. The agent according to claim 1 , wherein the metal ions are at least partially present in the form of at least one of an oxide of the metal claim 1 , a hydroxide of the metal claim 1 , and the elemental metal.4. A material comprising the agent of .5. The material according to claim 4 , applied to at least one substrate selected from:(a) at least one of fibers of any of woven fabrics, nonwoven fabrics and paper, wood, plastics, metals and ceramics,(b) compound materials formed of two or more of woven fabrics, nonwoven fabrics, paper, wood, plastics, metals and ceramics, and(c) at least one of paints, resin films, water, cleaning solutions, air filters and printing inks.6. The material according to claim 5 , whereinthe substrate is ...

Homeopathic Nasal Gel, Swab, and Spray Formulations

A homeopath nasal spray, swab or gel solution is provided. The composition includes a 1× to 6× (3C) dilution of argentum nitricum, 10× to 30× (5C to 15C), and any other higher or LM potencies, dilution of at least one of an additional argentum compound selected from the group consisting of argentum cyanatum, argentum iodatum, argentum metallicum, argentum muriaticum, argentum oxydatum and argentum phosphoricum; and, 10× to 30× (5C to 15C), and any other higher or LM potencies, dilution of at least one homeopathic compound for reducing various health conditions. 2. The homeopathic nasal spray solution according to claim 1 , further comprising one or more inactive oils selected from the group consisting of ginger essential oil claim 1 , eucalyptus oil and sweet birch oil.3. The nasal spray solution of claim 1 , further comprising a moisturizing agent selected from the group consisting of monosaccharides claim 1 , polysaccharides claim 1 , or sugar alcohols.4. A method of improving nasal airflow claim 1 , and improving claim 1 , preventing claim 1 , or correcting allergies or symptoms of the common cold claim 1 , flu claim 1 , immunization effects claim 1 , microbial or viral effects claim 1 , inflammation claim 1 , and/or congestion comprising administering the nasal spray solution of . The present application claims priority from U.S. Provisional Application No. 62/554,687 filed Sep. 6, 2017, the disclosure of which is incorporated herein by reference in its entirety.The present invention relates to homeopathic nasal gel and spray formulations, and in particular, a composition which contains a synergistic combination of silver (argentum) compounds, for relieving and reducing the symptoms of the common cold, flu, sinus, nasal allergies, and other upper respiratory problems.Homeopathic practitioners treat patients using diluted preparations and the pharmaceutical principle called “the law of similar” or “like cures like.” The process of preparing a homeopathic ...

PHARMACEUTICAL PREPARATION AND MEDICAL DEVICE

A problem to be solved by the present invention is to provide a pharmaceutical preparation to be administered to the intranasal mucosa, and in order to solve such a problem, the present invention provides a pharmaceutical preparation to be administered to the intranasal mucosa, in which the pharmaceutical preparation includes a composite particle containing one or more titanium oxide particles, one or more metal particles, and one or more calcium phosphate particles. 1. A pharmaceutical preparation to be administered to an intranasal mucosa , comprising a composite particle containing one or more titanium oxide particles , one or more metal particles , and one or more calcium phosphate particles.2. The pharmaceutical preparation according to claim 1 , for preventing or treating rhinitis.3. The pharmaceutical preparation according to claim 2 , wherein the rhinitis is allergic rhinitis.4. The pharmaceutical preparation according to claim 1 , wherein claim 1 , in the composite particle claim 1 , the one or more titanium oxide particles claim 1 , the one or more metal particles claim 1 , and the one or more calcium phosphate particles are arranged three-dimensionally and randomly.5. The pharmaceutical preparation according to claim 1 , wherein at least one metal particle of the one or more metal particles is fixedly attached to at least one titanium oxide particle of the one or more titanium oxide particles.6. The pharmaceutical preparation according to claim 1 , wherein the one or more metal particles are selected from the group consisting of a silver particle claim 1 , a gold particle claim 1 , a platinum particle claim 1 , and a copper particle.7. The pharmaceutical preparation according to claim 1 , wherein the one or more metal particles comprise a silver particle claim 1 , and the one or more calcium phosphate particles comprise a hydroxyapatite particle.8. A medical device for preventing or treating rhinitis claim 1 , the medical device comprising:a breathable ...

ANTIMICROBIAL PACKAING

An antimicrobial packaging polymer and its method of use, and more particularly to a contact antimicrobial such as metal or metal ions covalently bound to a polymeric material that may be suitable in a variety of applications such as film and container packaging of perishable items, medical equipment and devices, environmental, hygienic and sanitary applications, as well as other consumer and commercial use. 1. An antimicrobial polymeric film comprising a polymeric substrate having at least one surface having an antimicrobial compound , wherein said antimicrobial compound is between about 1% and 10% , by weight of the antimicrobial polymeric film.2. The antimicrobial polymeric film of claim 1 , wherein said antimicrobial compound is in particulate form.3. The antimicrobial polymeric film of claim 1 , wherein said antimicrobial compound is between about 1% and 5% claim 1 , by weight of the antimicrobial polymeric film.4. The antimicrobial polymeric film of claim 1 , wherein said antimicrobial compound is between about 2% and 4% claim 1 , by weight of the antimicrobial polymeric film.5. The antimicrobial polymeric film of claim 1 , wherein said antimicrobial compound further comprises an inorganic compound comprising a metal or metal ions selected from the group consisting of silver claim 1 , copper claim 1 , zinc claim 1 , tin claim 1 , mercury claim 1 , lead claim 1 , cobalt claim 1 , nickel claim 1 , manganese claim 1 , arsenic claim 1 , antimony claim 1 , bismuth claim 1 , barium claim 1 , cadmium claim 1 , chromium and combinations thereof.6. The antimicrobial polymeric film of claim 5 , wherein the inorganic compound comprises AgNO.7. The antimicrobial polymeric film of claim 5 , wherein said inorganic compound is between about 1% and 50% claim 5 , by weight of the antimicrobial compound.8. The antimicrobial polymeric film of claim 5 , wherein said inorganic compound is between about 1% and 30% claim 5 , by weight of the antimicrobial compound.9. The ...

COMPOSITION CONTAINING SPHERICAL AND CORAL-SHAPED NANOPARTICLES AND METHOD OF MAKING SAME

Nanoparticle compositions include a plurality of spherical-shaped nanoparticles and a plurality of coral-shaped metal nanoparticles, each coral-shaped metal nanoparticle having a non-uniform cross section and a globular structure formed by multiple, non-linear strands joined together without right angles. The nanoparticle compositions can be one-part or multi-part compositions. Nanoparticle compositions can have a mass ratio of spherical-shaped to coral-shaped nanoparticles of about 5:1-20:1, about 7.5:1-15:1, about 9:1-11:1, or about 10:1 and/or a number ratio of spherical-shaped to coral-shaped nanoparticles of about 50:1-200:1, about 75:1-150:1, about 90:1-110:1 or about 100:1. The nanoparticle compositions can be used for various purposes, including as an antimicrobial (e.g., anti-viral, anti-bacteria, or anti-fungal composition), fuel additive, or treating fabrics. 1. A nanoparticle composition comprising:a plurality of spherical-shaped nanoparticles; anda plurality of coral-shaped metal nanoparticles, each coral-shaped metal nanoparticle having a non-uniform cross section and a globular structure formed by multiple, non-linear strands joined together without right angles.2. A nanoparticle composition as in claim 1 , wherein the nanoparticle composition has a mass ratio of spherical-shaped nanoparticles to coral-shaped nanoparticles of about 5:1 to about 20:1.3. A nanoparticle composition as in claim 1 , wherein the nanoparticle composition has a particle number ratio of spherical-shaped nanoparticles to coral-shaped nanoparticles of about 50:1 to about 200:1.4. A nanoparticle composition as in claim 1 , wherein the spherical-shaped nanoparticles have a diameter of about 40 nm or less.5. A nanoparticle composition as in claim 1 , wherein the spherical-shaped nanoparticles have a mean diameter and wherein at least 99% of the spherical-shaped nanoparticles have a diameter within about 30% of the mean diameter.6. A nanoparticle composition as in claim 1 , wherein ...

VITALITY STICK SYSTEM AND METHOD

A device for affecting water. The device for affecting water includes a first-end, a second-end, a length from the first end to the second-end and an extruded member. Gemstones, which generate a pleasant subliminal functional aesthetic, and visible messages, which may have positive neurological and meta-physical effects, are included. The device for affecting water is useful for providing trace mineral elements to humans and animals and for producing positive changes to the overall physical health and emotional well-being of a user. 1. A device for affecting water , the device comprising:a first-end;a second-end;a length from the first end to the second-end; andan extruded member at least partially made of copper extending between the first-end and the second-end, the extruded member having a substantially constant cross-sectional perimeter perpendicular to the length between the first-end and the second-end, the substantially constant cross-sectional perimeter having an isosceles triangle shape, the isosceles triangle shape having a base and a height.2. The device of claim 1 , further comprising a mineral receptacle claim 1 , the mineral receptacle including an interlaced mesh structure configured to permit potable water to flow into and out of the mineral receptacle; andwherein the first-end, the second-end, and the interlaced mesh structure are integrated with the extruded member.3. The device of claim 2 , further comprising a mineral composition claim 2 , the mineral composition configured to leach mineral trace elements into the potable water when exposed to the potable water; andwherein the mineral receptacle is configured to be accessible by a user to removably-insert the mineral composition into the mineral receptacle.4. The device of claim 3 , wherein the mineral composition includes at least one of activated coconut carbon claim 3 , ionic silver nanoparticle balls claim 3 , tourmaline claim 3 , shungite claim 3 , silica-centered microclusters claim 3 , and ...

Antimicrobial Gels

The present invention pertains to antimicrobial compositions comprising inter alia at least one alkenyl- and/or alkynyl-substituted polysiloxane, at least one polysiloxane comprising silicon-bonded hydrogen atoms, and at least one hydrosilylation catalyst, as well as antimicrobial silicone gels, wound dressings, and methods of preparing the above. 1. An antimicrobial gel comprising at least two polysiloxanes , wherein the antimicrobial gel is formed by creating at least one covalent bond between at least one an alkenyl and/or alkynyl moiety of a first polysiloxane and at least one Si—H moiety of a second polysiloxane , the antimicrobial gel further comprises at least one hydrosilylation catalyst , at least one silver salt , and at least one hydrophilic component , wherein the at least one hydrophilic component makes the antimicrobial gel swell at least 5% (wt/wt) after 24 hours in a water solution containing 8.298 g/L of sodium chloride and 0.368 g/L of calcium chloride dehydrate , as measured by the free swell absorption method.2. The antimicrobial gel of claim 1 , wherein the at least one hydrophilic component comprises a mono-polysaccharide claim 1 , di-polysaccharide claim 1 , sugar alcohol claim 1 , polyol claim 1 , polyether claim 1 , polyester claim 1 , polyamide claim 1 , polymer comprising a pendant carboxylic acid group claim 1 , a polymer comprising a pendant sulphonate group claim 1 , or a mixture thereof.3. The antimicrobial gel of claim 1 , wherein the at least one hydrophilic component comprises a glucose claim 1 , xylitol claim 1 , sorbitol claim 1 , mannitol claim 1 , cyclodextrin claim 1 , cellulose claim 1 , hemicellulose claim 1 , carboxymethylated cellulose claim 1 , chitosan claim 1 , dextran claim 1 , chitin claim 1 , amylose claim 1 , amylopectin claim 1 , polyethylene glycol claim 1 , polypropylene glycol claim 1 , copolymer of polyethylene glycol and polypropylene glycol claim 1 , polyglycerol claim 1 , poly(acrylic acid) claim 1 , ...

USE OF AN ANTIMICROBIAL COMPOSITION

The invention concerns the use of an antimicrobial composition comprising metallic silver and metallic ruthenium as well as at least one vitamin or at least one vitamin derivative for the topical treatment or prevention of skin, skin adnexa or mucosa diseases which are caused by infection with at least one microorganism. The invention also concerns a bandaging material or patch comprising an antimicrobial composition which comprises metallic silver and metallic ruthenium as well as at least one vitamin or at least one vitamin derivative. The antimicrobial composition (“AgXX”) has a broad-spectrum effect against bacteria (a: ) and fungi (b: Pathogen is yeast and c: ). 1. Method for treating or avoiding skin , skin adnexa or mucosa diseases comprising:applying an antimicrobial composition comprising metallic silver and metallic ruthenium as well as at least one vitamin or at least one derivative of a vitamin topically to treat or avoid skin disease, skin adnexa or mucosa diseases which are caused by infection with at least one microorganism.2. The method according to claim 1 , wherein the microorganism is a virus claim 1 , a bacterium or a fungus.3. The method according to claim 1 , wherein the microorganism is a herpes simplex 1 virus.4. The method according to claim 1 , wherein the antimicrobial composition is applied onto at least one surface of a carrier material.5. The method according to claim 4 , wherein the carrier material is a tissue claim 4 , a foil claim 4 , a mesh claim 4 , a bandaging material claim 4 , a compress claim 4 , or a patch.6. The method according to claim 4 , wherein the carrier material is wettable and/or permeable to moisture.7. The method according to claim 4 , wherein the carrier material comprises a material for storing moisture.8. The method according to claim 4 , wherein the carrier material is permeable to gas and/or air.9. The method according to claim 1 , wherein the antimicrobial composition comprises at least one silver layer ...

SILVER NANOPLATE COMPOSITIONS AND METHODS

Embodiments of the present invention relate to methods for preparing high optical density solutions of nanoparticle, such as nanoplates, silver nanoplates or silver platelet nanoparticles, and to the solutions and substrates prepared by the methods. The process can include the addition of stabilizing agents (e.g., chemical or biological agents bound or otherwise linked to the nanoparticle surface) that stabilize the nanoparticle before, during, and/or after concentration, thereby allowing for the production of a stable, high optical density solution of silver nanoplates. The process can also include increasing the concentration of silver nanoplates within the solution, and thus increasing the solution optical density. 1adding a stabilizing agent to a pre-concentrated solution,wherein the pre-concentrated solution comprises silver nanoplates,wherein each of the silver nanoplates has a plate shape,wherein the pre-concentrated solution has a peak optical density at a first wavelength;wherein the stabilizing agent comprises a polyvinyl based polymer and a borate; andincreasing a concentration of the silver nanoplates in the pre-concentrated solution to generate a concentrated solution,wherein the concentrated solution has a peak optical density at a second wavelength,wherein the peak optical density of the concentrated solution is greater than the peak optical density of the pre-concentrated solution, andwherein at least a portion of the silver nanoplates in the pre-concentrated solution retain the plate shape in the concentrated solution.. A process for making concentrated silver nanoplates that preserve shape post-concentration while increasing optical density, the process comprising: This application is a continuation of U.S. application Ser. No. 14/947,508, filed Nov. 20, 2015 and issued as U.S. Pat. No. 9,526,745, which is a continuation of U.S. application Ser. No. 14/681,379, filed Apr. 8, 2015 and issued as U.S. Pat. No. 9,212,294, which is a continuation of ...

DEVICE POSITIONABLE IN THE UTERINE CAVITY AND METHOD OF TREATMENT THEREOF

A delivery vehicle for a silver ion source such as silver nitrate and the like, suitable for use in the treatment of menorrhagia, comprises a plurality of beads bearing a tissue cauterizing amount of a silver ion source. In some embodiments, the silver ion source is silver nitrate, in combination with a binder of hydroxy propyl cellulose and a diluent of potassium nitrate. In some embodiments, the plurality of beads is useful in treating menorrhagia of a mammalian uterus. Silver ions are delivered in a sufficient amount to the endometrium to cause necrosis of the endometrial tissue.

Collagen Membrane or Matrix with Antimicrobial Properties

The main purpose of this technology is developing a collagen matrix or membrane with antimicrobial properties, comprising collagen from fetal amniotic membranes and metallic nanoparticles. Additionally, its manufacturing procedure is described. 1. A manufacturing procedure for a cell- and protein-factor-free collagen matrix or membrane with antimicrobial properties , characterized in that the procedure comprises:i) forming collagen from fetal amniotic membranes;ii) adding and incorporating metallic nanoparticles to the thus formed collagen in order to form the collagen matrix or membrane with antimicrobial properties; and in that, for the collagen to be formed from the fetal amniotic membrane, chemically treating the fetal amniotic membrane in order to remove any remaining protein rest therein in a first treatment comprising dipping the fetal amniotic membrane in a 0.01% sodium dodecyl sulfate (SDS) solution for one hour at room temperature, in agitation by using an orbital shaker and inside a tightly closed container;', 'when the first treatment is finished, a second chemical treatment is performed in order to remove any remaining cell attached to the fetal amniotic membrane, for which the fetal amniotic membrane is dipped in a pH marker-free Trypsin-EDTA solution (colorless) for 1 hour at 37° C.; three washes are then performed with physiological saline for 15 minutes, each one to remove any cell that might have detached from the tissue during the trypsin wash process;', 'when the second treatment is finished, a new chemical treatment is performed with 0.01% SDS for one hour at room temperature, in agitation by using an orbital shaker and inside a closed container, for the collagen to finally form from the fetal amniotic membrane; and', 'in that, for metallic nanoparticles to be added and incorporated into the formed collagen, the collagen formed is embedded in an aqueous solution containing the metallic nanoparticles, and is placed in an electrophoresis chamber ...

SILVER NANOPLATE COMPOSITIONS AND METHODS

Embodiments of the present invention relate to methods for preparing high optical density solutions of nanoplates, such as silver nanoplates or silver platelet nanoparticles, and to nanoparticles, solutions and substrates prepared by said methods. The process can include the addition of stabilizing agents (e.g., chemical or biological agents bound or otherwise linked to the nanoparticle surface) that stabilize the nanoparticle before, during, and/or after concentration, thereby allowing for the production of a stable, high optical density solution of silver nanoplates. The process can also include increasing the concentration of silver nanoplates within the solution, and thus increasing the solution optical density. 1a. Adding a concentration stabilizing chemical agent to a solution of silver nanoplates or precursor reagents.b. Increasing the concentration of silver nanoplates to increase the optical density of the solution.. A process for generating a solution of silver nanoplates with extremely high optical density comprising the steps of: This application is a continuation of U.S. application Ser. No. 14/048,996 filed Oct. 8, 2013, which claims the benefit of priority from U.S. Provisional Application 61/795,149, filed on Oct. 11, 2012, each of which is incorporated by reference in its entirety. Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by reference under 37 CFR 1.57.1. Field of the InventionVarious embodiments of the invention relate to methods for preparing high optical density solutions of silver platelet nanoparticles (e.g., nanoplates) and to nanoparticles, solutions and substrates prepared by said methods.2. Description of the Related ArtNanoparticles, including nanospheres, nanorods, nanowires, nanocubes, nanoplates, as well as other shapes can be synthesized from a range of materials. Nanoparticles made from metals ...

Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds

According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a topical composition is provided, which can be formulated as a homogenous mixture, such as a spray, mist, aerosol, lotion, cream, solution, oil, gel, ointment, paste, emulsion or suspension or applied on a carrier material, such as a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold. Methods for producing such a topical composition and carrier material with the topical composition applied thereto are also disclosed.

BREAST CANCER POST TREATMENT SUPPORT GARMENT

A support garment for breast cancer patients who have undergone or are going through radiation therapy after lumpectomy, mastectomy, or breast reconstruction is provided. A garment for a wearer having breasts and an under bust located directly under the breasts can include a head opening, first and second arm openings, a band configured to fit at the under bust of the wearer, and a cup extending from the band. The cup may include an outer layer, an inner layer that is interior to the outer layer, and an attachment component configured to removably couple an insert to the inner layer. The garment may also include the insert removably coupled to the inner layer. When the garment is worn, at least a portion of the insert is exposed to skin of the wearer, and the insert provides topical therapy and cooling to the skin. 1. A garment for a wearer having breasts and an under bust located directly under the breasts , comprising:a head opening;first and second arm openings;a band configured to fit at the under bust of the wearer; an outer layer;', 'an inner layer that is interior to the outer layer; and', 'an attachment component configured to removably couple an insert to the inner layer; and', 'the insert removably coupled to the inner layer,, 'a cup extending from the band comprisingwherein, when the garment is worn, at least a portion of the insert is exposed to skin of the wearer, the insert providing topical therapy and cooling to the skin of the wearer.2. The garment of claim 1 , wherein the insert comprises a hydrogel claim 1 , the hydrogel comprising a silver salt and acemannan.3Aloe vera. The garment of claim 2 , wherein the acemannan is provided in gel.4. The garment of claim 2 , wherein the silver salt comprises silver nitrate claim 2 , silver dihydrogen citrate claim 2 , silver citrate claim 2 , silver chloride claim 2 , silver benzoate claim 2 , silver acetate claim 2 , silver galacturonate claim 2 , silver glucoronate claim 2 , or a combination thereof.5. The ...

Method of treating diabetic wounds using biosynthesized nanoparticles

The method of treating diabetic wounds using biosynthesized nanoparticles includes administering an effective amount of silver and gold nanoparticles to a patient in need thereof. The silver and gold nanocomposite is prepared by ‘biosynthesis”, i.e., by providing a first aqueous solution of a noble metal salt or a noble metal oxide; providing a second solution of an aqueous plant extract, and combining the first solution and the second solution to produce a solution including nanoparticles of the noble metal. The second solution includes a plant extract obtained from Solenostemma argel, Trigonella foenum - graecum and Cinnamomum cassia . The metal salt can include silver nitrate (AgNO 3 ) and chloroauric acid (HAuCl 4 ). Nanoparticles of gold and nanoparticles of silver are prepared separately, and then mixed to obtain a composition containing a gold and silver nanocomposite.

ANTIMICROBIAL POLYNUCLEOTIDE-TEMPLATED METAL NANOCLUSTER

There is provided a polynucleotide-templated metal nanocluster for use in therapy. There is also provided use of a polynucleotide-templated metal nanocluster in the manufacture of a medicament for prophylactically or therapeutically treating a microbial infection as well as a method of prophylactically or therapeutically treating a microbial infection comprising administering to a subject a polynucleotide-templated metal nanocluster. There is also provided an antimicrobial agent comprising a polynucleotide-templated metal nanocluster. 1. A method for inhibiting the growth of or killing microorganism that is present on a surface comprising the step of administering a polynucleotide-templated metal nanocluster to said surface.2. The method of claim 1 , wherein said microorganism is a bacteria selected from the group consisting of a Gram positive bacteria and a Gram negative bacteria.3Pseudomonas aeruginosaBurkholdera cenocepacia.. The method of claim 2 , wherein said Gram negative bacteria is or4. The method of claim 1 , wherein said polynucleotide is a DNA claim 1 , RNA or mixtures thereof.5. The method of claim 4 , wherein said DNA is single-stranded DNA or double-stranded DNA.6. The method of claim 5 , wherein said DNA is selected from the group consisting of homocytosine single-stranded DNA sequence claim 5 , homoadenine single-stranded DNA sequence claim 5 , homothymine single-stranded DNA sequence claim 5 , homoguanine single-stranded DNA sequence claim 5 , 5′-AGGTCGCCGCCC-3′(SEQ ID NO:1) claim 5 , 5′-AATTCCCCCCCCCCCCAATT-3′ (SEQ ID NO:2) claim 5 , i-motif (dTAC)(SEQ ID NO:3) claim 5 , i-motif (dCA)C(SEQ ID NO:4) claim 5 , 5′-CCCTTTAACCCC-3′ (SEQ ID NO:5) claim 5 , 5′-CCCTCTTAACCC-3′(SEQ ID NO:6) claim 5 , 5′-CCCTTAATCCCC-3′ (SEQ ID NO:7) claim 5 , 5′-CCTCCTTCCTCC-3′(SEQ ID NO:8) claim 5 , 5′-CCCTAACTCCCC-3′(SEQ ID NO:9) claim 5 , 5′-CCCACCCACCCTCCCA-3′(SEQ ID NO:10) claim 5 , dTCT(SEQ ID NO:11) claim 5 , dsDNA with a Cloop and mixtures thereof.7. The method of ...

METHOD FOR PREPARING NOBLE METAL NANOPARTICLES FROM MYRRH

The method for preparing metal nanoparticles includes preparing an extract of myrrh and mixing the extract with an aqueous solution including a metal salt. The mixture changes in color from light yellow to dark brown upon formation of nanoparticles. The extract of myrrh can be a water extract prepared by, for example, soaking a quantity of myrrh in water, filtering the soaked myrrh to obtain a filtered product, and then centrifuging the filtered product. The metal salt can be, for example, silver nitrate (AgNO). The metal nanoparticles can be spherical, spheroidal, elongated spherical, rod, and/or faceted. The metal nanoparticles can be used to treat Leishmaniasis (lesions) caused by 15- (canceled)6. A method of treating epidermal lesions caused by leishmaniasis comprising:{'sub': '3', 'topically applying an effective amount of silver nanoparticles having a mean diameter in the range of from about 5 nm to about 100 nm to the lesions, the silver nanoparticles being prepared by mixing an extract of myrrh with an aqueous solution of silver nitrate (AgNO).'}7Leishmania major.. The method of treating epidermal lesions caused by leishmaniasis according to claim 6 , wherein the leishmaniasis is caused by8. The method of treating epidermal lesions caused by leishmaniasis according to claim 6 , wherein the lesions are subcutaneous epidermal lesions.9. The method of treating epidermal lesions caused by leishmaniasis according to claim 6 , wherein the silver nanoparticles are spherical claim 6 , spheroidal claim 6 , elongated spherical claim 6 , rod-shaped claim 6 , and/or faceted. 1. Field of the InventionThe present invention relates to bio-nanotechnology and particularly to a method of preparing nanoparticles synthesized from plant gum extract, which can be used for the treatment of Leishmaniasis.2. Description of the Related ArtNanoparticles exhibit completely new or improved properties compared to their corresponding bulk materials. Because of their size, catalytic ...

PHARMACEUTICAL COMPOSITIONS COMPRISING COLLAGEN AND SODIUM HYALURONATE

The present invention relates to pharmaceutical compositions comprising collagen and hyaluronic acid, and optionally containing silver. 19-. (canceled)10. Pharmaceutical compositions in the form of hydrogel , pad or dry spray comprising equine origin type I collagen and hyaluronic acid in the form of sodium salt , wherein the hyaluronic acid has a mean molecular weight ranging from 130 to 500 kDa and a concentration ranging from 0.1 to 4% w/w , and the collagen in the pharmaceutical compositions in pad form is present in quantities of not less than 90% w/w for use in the treatment of skin lesions , wherein the skin lesions are selected from the group consisting of pressure ulcers , arterial vascular ulcers , venous vascular ulcers , vasculitic vascular ulcers , diabetic foot ulcers , surgical and traumatic wounds , first- and second-degree burns.11. Pharmaceutical compositions for use according to claim 10 , wherein the pad is free from crosslinking agents.12. Pharmaceutical compositions for use according to claim 10 , wherein the hyaluronic acid has a molecular weight ranging from 160 to 230 kDa (mean MW 200 kDa).13. Pharmaceutical compositions for use according to claim 10 , wherein the sodium hyaluronate has a concentration ranging from 2 to 3% w/w.14. Pharmaceutical compositions for use according to claim 13 , wherein the sodium hyaluronate has a concentration of 2.5% w/w.15. Pharmaceutical compositions for use according to claim 10 , further comprising silver in a quantity ranging from 0.001 to 5% w/w.16. Pharmaceutical compositions according to claim 15 , wherein silver is present in a quantity ranging from 1 to 2% w/w.17. Process for the preparation of pharmaceutical compositions according to in the pad form claim 10 , comprising the following steps:a) homogenising collagen of equine origin in a 1% w/w gel preferably at pH≈3.5, in the presence of an organic acid, preferably acetic acid,b) preparing an aqueous solution of sodium hyaluronate, preferably at a ...

METHOD FOR PRODUCING POLYMER LATEX PARTICLE COATED WITH SILVER NANOPARTICLES

This invention is related to a method for producing polymer latex particle coated with silver nanoparticles. First, a polymer latex particle suspension is mixed with a silver nitrate solution in a weight ratio of 10:1 to 1:10 at 50° C. to 90° C. for 10 to 120 minutes to form a mixed solution. After the temperature of the mix solution is cooled to 50° C. to 85° C., a sodium citrate solution is added to react with the mixed solution for 10 to 240 minutes to form a polymer latex particle coated with silver nanoparticles, which has antibacterial activity. 1. A method for producing polymer latex particle coated with silver nanoparticles , comprising the step of:{'sub': '3', 'mixing a polymer latex particle suspension with a silver nitrate (AgNO) solution in a weight ratio of 10:1 to 1:10 at 50° C. to 90° C. for 10 to 120 minutes to form a mixed solution; and'}cooling the temperature of the mixed solution to 50° C. to 85° C. and then adding a sodium citrate solution to react with the mixed solution for 10 to 240 minutes to form a polymer latex particle coated with silver nanoparticles, wherein the polymer latex particle has a diameter greater than 50 nm, and the silver nanoparticle has a diameter of 1 to 500 nm.2. The method for producing polymer latex particle coated with silver nanoparticles as claim 1 , wherein the polymer latex particle suspension contains 3.85 wt % polymer latex particles in water.3. The method for producing polymer latex particle coated with silver nanoparticles as claim 1 , wherein the polymer latex particle is polystyrene latex particle claim 1 , poly(methyl methacrylate) latex particle claim 1 , poly(butyl acrylate) latex particle claim 1 , poly(styrene-methyl methacrylate) copolymer latex particle claim 1 , poly(styrene-butyl acrylate) copolymer latex particle claim 1 , or poly(methyl methacrylate-butyl acrylate) copolymer latex particle.4. The method for producing polymer latex particle coated with silver nanoparticles as claim 3 , wherein the ...

DEVICES FOR APPLYING A TOPICAL TREATMENT

A device comprising a housing having a handle end and a treatment end. The treatment end is configured to provide an antimicrobial treatment and a heat treatment. The treatment end comprises an applicator having an applicator surface for providing at least the heat treatment. The device includes a heat generation unit configured to heat the applicator surface in use, a source of antimicrobial agent, and a control unit operatively connected to at least the heat generation unit for controlling the heat generation unit. The device can be a hand-held device and used to apply topical treatment to a treatment area of a subject. 1. A device comprising:a housing having a handle end and a treatment end;the treatment end being configured to provide an antimicrobial treatment and a heat treatment, the treatment end comprising an applicator having an applicator surface for providing at least the heat treatment;a heat generation unit configured to heat the applicator surface in use;a source of antimicrobial agent; anda control unit operatively connected to at least the heat generation unit for controlling the heat generation unit.2. The device of claim 1 , wherein the applicator surface comprises a heat conductive material.3. The device of claim 1 , wherein the source of antimicrobial agent is a coating on the applicator or the applicator surface and/or is incorporated in the applicator or the applicator surface.4. The device of claim 1 , wherein the antimicrobial agent comprises ions or particles of silver claim 1 , copper claim 1 , zinc claim 1 , nickel claim 1 , or boron.5. The device of claim 1 , wherein the applicator surface comprises a silver coating.6. The device of claim 1 , wherein the applicator body comprises a metal material which is different from the applicator surface.7. The device of claim 1 , wherein the applicator has an opening formed therethrough and extending through the applicator surface.8. The device of claim 1 , further comprising a light source ...

ANTIBACTERIAL SHEET MATERIAL THAT CAN BE USED AS A WOUND DRESSING AND METHOD FOR PRODUCING SAME

A sheet material that can be used as a wound dressing and contains elemental metal particles. 1. A method for producing a sheet material useable as a wound dressing , comprising:providing a liquid collagen-containing starting material;adding a suspension containing elemental metal particles; anddrying the liquid collagen-containing starting material so that a sheet material is produced.2. The method for producing a sheet material useable as a wound dressing as claimed in claim 1 , wherein the drying of the liquid collagen-containing starting material is performed at a temperature above a freezing point of the liquid collagen-containing starting material.3. The method for producing a sheet material useable as a wound dressing as claimed in claim 1 , wherein the suspension containing elemental metal particles includes silver particles.4. The method for producing a collagen-containing sheet material as claimed in claim 1 , wherein the elemental metal particles have an average particle size between 10 nm and 10 μm.5. A sheet material useable as a wound dressing that is produced by the method according to .6. A sheet material useable as a wound dressing as claimed in claim 5 , wherein the sheet material has a closed porosity of less than 50%.7. A sheet material useable as a wound dressing as claimed in claim 5 , wherein the sheet material comprises more than 70%.8. A sheet material useable as a wound dressing as claimed in claim 5 , wherein the sheet material has a thickness between 0.05 and 2 mm.9. The method for producing a sheet material useable as a wound dressing as claimed in claim 1 , wherein the liquid collagen-containing starting material is a collagen-containing suspension.10. The method for producing a sheet material useable as a wound dressing as claimed in claim 1 , wherein the liquid collagen-containing starting material is a collagen-containing solution.11. The method for producing a collagen-containing sheet material as claimed in claim 4 , wherein the ...

ANTIBACTERIAL POWDERS BASED ON ANIONIC SILICON OR TITANIUM DIOXIDE ADSORBED WITH PHARMACEUTICALLY ACTIVE CATIONS

The present invention relates to a dioxide silicon or titanium derivative of formula (I): (MO)(A), as active ingredient for the preparation of a composition having antibacterial properties useful, e.g. for topical administration. 1. A derivative of formula (I):{'br': None, 'sub': 2', 'y, 'sup': −', 'm+, '(MO)(A)\u2003\u2003(I)'}wherein:M is a Si or Ti atom;{'sub': '2', 'sup': '−', '(MO) represents an anionic dioxide particle comprising tetrahedral Silicon or octahedral Titanium atoms interconnected through bridging oxygen atoms,'}{'sup': 'm+', 'A represents at least one positively charged active species, linked to the anionic dioxide particle by elecrostatic interaction, wherein m represent the charge of said active species, and is comprised from 1 to 20, preferably from 1 to 10,'}{'sup': 'm+', 'Y represents the number of different active species A co-adsorbed to the same anionic silicon or titanium dioxide particle, and it is comprised from 1 to 4.'}2. The derivative of formula (I) according to claim 1 , wherein M=Si.3. The derivative of formula (I) according to claim 1 , characterized by the fact that the anionic silicon or titanium dioxide particles have an average diameter of at least 200 nm.4. The derivative of formula (I) according to claim 1 , wherein A is an antibacterial claim 1 , antimycotic claim 1 , antiviral and/or sporicidal agent.5. The derivative of formula (I) according to claim 4 , wherein A is at least one compound selected from the group consisting of: chlorexidine cations claim 4 , poliexamethylene biguanide hydrochloride cation claim 4 , quaternary ammonium cations claim 4 , a cationic silver complex of general formula Ag-L wherein L is optionally substituted 8-mercapto-quinoline hydrochloride or 2-mercapto-4-(C-CAlk)pyrimidine hydrochloride claim 4 , and mixtures thereof.6. The derivative of formula (I) according to claim 5 , wherein A is chlorexidine digluconate or acetate.7. The derivative of formula (I) according to claim 5 , wherein A is ...

ANTICANCER NANO-SILVER COMPOSITION FOR TREATMENT OF LUNG CANCER, AND PREPARATION METHOD AND USE THEREOF

The present invention provided an anticancer nano-silver composition for the treatment of lung cancer. The composition contains spherical nano-silver powder 12-200 mg/kg, pharmaceutically acceptable dispersing agent carbomer 700-800 mg/kg, triethanolamine 700-800 mg/kg, glucose 2.8-3.2 g/kg, and purified water as the diluent; of the spherical nano-silver powder, the purity of silver is ≧99.99% and the particle size is 1-5 nm. Experiments demonstrated that the anticancer nano-silver composition can be used to inhibit proliferation of the human non-small cell lung cancer A549, and cause all cells death. The nano-silver composition of the present invention can be used in the manufacture of medicaments and for the treatment of lung cancer. 1. An anticancer nano-silver composition for treatment of lung cancer , the composition , on a basis of per kilogram of total weight , comprising:nano-silver powder 12-200 mg;carbomer 700-800 mg;triethanolamine 700-800 mg;glucose 2.8-3.2 g;water as remaining;wherein, purity of silver of the nano-silver powder is ≧99.99%, and particles of the nano-silver powder are 1-5 nm in size and spherical in shape;wherein, the anticancer nano-silver composition is prepared by a method which comprises:(1) preparing the nano-silver powder, carbomer, triethanolamine, glucose and water in a defined ratio;(2) adding the carbomer into ½ to ⅔ of total amount of the water with mixing to obtain a mixture, which is then dispersed in a ultrasonic disperser for 2-5 min;(3) adding the nano-silver powder and the triethanolamine into the mixture dispersed in step (2) to obtain a mixture, which is then dispersed in a ultrasonic disperser for 2-5 min;(4) adding the glucose and remaining water into the mixture dispersed in step (3) to obtain a mixture, which is then dispersed in a ultrasonic disperser for 1-3 min;(5) cooling the mixture dispersed in step (4) to 2-12° C. to obtain a mixture, which is dispersed in an ultrasonic atomizer into a mist, which is ...

Laser Assisted Wound Healing Protocol and System

A method of treating diseased tissue while healing the wound using a diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400 nm-700 nm) at a laser power of 0.001 to 12 watts, used with intermittent stops to control tissue temperature and biostimulate epithelial regeneration when used with or without substrates. A method of treating diseased tissue using a laser light in the green wavelength range (520-570 nm) at a laser power of 0.001 W to 5 W. A method of treating diseased tissue using a laser light in the IR wavelength range (700-1400 nm) at a laser power of 0.001 W to 5 W. 1. A method of treating damage to a tissue in the form of a wound , comprising:(a) providing an instrument comprising a hand piece, further comprising at least one opening through which a diode laser is positioned, the diode laser generating a beam of light having a wavelength from about 400 nm to about 700 nm, wherein the beam of light exits the instrument through the at least one opening;(b) providing a power source to operate the instrument; and(c) positioning the at least one opening from the hand piece of the instrument directly or in close proximity to the damage to the tissue of an individual.2. The method of claim 1 , wherein the beam of light has a wavelength from about 520 nm to about 570 nm and the power source transmits a range of power from about 0.5 W to about 1.2 W to the instrument.3. The method of claim 2 , wherein the tissue that is damaged is gum tissue.4. The method of claim 1 , wherein the beam of light has a wavelength selected from the group consisting of from about 520 nm to about 570 nm claim 1 , from about 620 nm to about 750 nm and from about 570 am to about 590 nm claim 1 , further wherein the power source transmits a range of power from about 0.0001 W to about 5 W to the instrument.5. The method of claim 4 , wherein the power source transmits a range of power selected from the group consisting of ...

NANOSCALE PARTICLE FORMULATIONS AND METHODS

Provided herein in some embodiments is a formulation comprising (a) one or more nanoscale particle; and (b) a film-forming polymer. In some instances, the formulation is an immediate and sustained released formulation suitable for topical administration or administration to surfaces. Also provided here in certain embodiments is a method of reducing the population of pathogenic microorganisms on skin or surfaces, the method comprising applying to the skin or surface a composition, the composition comprising (a) one or more nanoscale particle; and (b) a film-forming polymer. 1. A formulation comprising: (a) one or more nanoscale particle having a particle size of about 5 nm to about 200 nm; and (b) a film-forming polymer.2. The formulation of claim 1 , wherein the film-forming polymer comprises polyolprepolymer-2 (PPG-12/SMDI) claim 1 , poly(styrene-co-maleic anhydride) copolymers (SMA) claim 1 , acrylate copolymers claim 1 , cellulosic polymers claim 1 , ethylene/acrylic acid copolymer claim 1 , polyacrylic acid claim 1 , C-Calkyl galactomannan claim 1 , isododecane/ethylene mixed copolymer claim 1 , adipic acid/diethylene glycol/glycerin crosspolymer claim 1 , trimethylpentanediol adipic acid copolymer claim 1 , trimethylpentanediol/adipic acid/isononanoic acid claim 1 , PVP/hexadecene copolymer claim 1 , PVP/eicosene copolymer claim 1 , alpha olefin/isopropyl maleate/MA polymer claim 1 , cycloalkyl methacrylate copolymer/isododecane trimethyl polysiloxane claim 1 , octadecene/MA copolymer claim 1 , acrylates C-Calkyl acrylate crosspolymer claim 1 , cetyl hydroxyethylcellulose claim 1 , dimethiconol claim 1 , dimethicone claim 1 , diglycol/cyclohexane-dimethanol/isophthalates/sulfoisophthalate copolymer claim 1 , polyethylene claim 1 , waxes claim 1 , polyurethane claim 1 , polyurethane resins claim 1 , natural gums claim 1 , or a combination thereof.3. The formulation of claim 1 , wherein the film-forming polymer is polyolprepolymer-2 (PPG-12/SMDI) claim 1 , poly( ...

COMPOSITE FIBER

The present invention provides a composite fiber which comprises an alginate fiber, a polymer material, an antibacterial agent, and a plasmid encoding growth factor-gene. The present invention also provides a wound dressing, wherein the wound dressing comprises a composite fiber as described above. The composite fibers prepared according to the present invention are capable of releasing the antibacterial agent and the growth factor gene, not only to reduce microorganism growth, but also to secrete growth factors in a wound site through transfection, thereby promoting wound healing. 1. A composite fiber , wherein the composite fiber comprises an alginate fiber , a polymer material , an antibacterial agent and at least one plasmid encoding growth factor-gene.2. The composite fiber of claim 1 , wherein the antimicrobial agent is a metal ion claim 1 , nanoparticle claim 1 , or an oxide thereof claim 1 , an antibiotic claim 1 , graphene or carbon nanotubes or a combination thereof.3. The composite fiber of claim 1 , wherein the polymer material comprises polyester claim 1 , polyamide claim 1 , polycarbonate claim 1 , polyurethane claim 1 , or a combination thereof.4. The composite fiber of claim 1 , wherein the growth factor-gene is a gene encodes a platelet-derived growth factor claim 1 , an epidermal growth factor claim 1 , a keratinocyte growth factor claim 1 , a fibroblast growth factor claim 1 , a transforming growth factor-β1 claim 1 , a vascular endothelial growth factor claim 1 , an insulin-like growth factor growth factor or a combination thereof.5. The composite fiber of claim 1 , wherein the weight ratio of the alginate fiber and the polymer material ranges from 1:9 to 9:1.6. The composite fiber of claim 5 , wherein the weight ratio of the alginate fiber and the polymer material is 8:2.7. The composite fiber of claim 2 , wherein the antibacterial agent is nano-silver.8. The composite fiber of claim 1 , wherein the alginate fiber crosslink by using a calcium ...

COMPOSITIONS AND METHODS FOR TREATING WOUNDS

The present invention provides compositions and methods that promote wound healing. The invention provides a composition comprising an effective amount of a biopolymer, an antiseptic, an anti-inflammatory agent, and other agents. 1. A composition comprising an effective amount of a biopolymer , an antiseptic , and an anti-inflammatory agent.2. The composition of claim 1 , further comprising an acid selected from the group consisting of acetic claim 1 , propionic claim 1 , citric claim 1 , lactic claim 1 , hypochlorous claim 1 , and phosphoric acid; wherein the biopolymer is selected from the group consisting of chitosan claim 1 , chitin claim 1 , collagen claim 1 , alginate claim 1 , dextran claim 1 , and combinations thereof3. (canceled)4. The composition of claim 1 , further comprising a natural healing agent and/or a bittering agent in an amount sufficient to prevent licking or ingestion of the composition.5. The composition of claim 4 , wherein the natural healing agent is honey.6. A composition comprising an effective amount of a biopolymer selected from the group consisting of chitosan claim 4 , collagen claim 4 , cellulose claim 4 , alginate claim 4 , and dextran; an antiseptic selected from the group consisting of chlorhexidine gluconate claim 4 , povidone iodine claim 4 , alcohol claim 4 , benzalkonium chloride claim 4 , benzethonium chloride claim 4 , and parachlorometaxylenol (PCMX); and an acid that is acetic acid or citric acid.7. A composition comprising an effective amount of chitosan claim 4 , acetic acid claim 4 , and chlorhexidine digluconate in an excipient for topical administration.8. The composition of claim 1 , further comprising silver nanoparticles.910-. (canceled)11. An ointment claim 1 , spray claim 1 , gel claim 1 , or hydrogel composition comprising an effective amount of chitosan claim 1 , acetic acid claim 1 , and chlorhexidine digluconate in an excipient for topical administration.12. The composition of claim 1 , further comprising ...

ANTIMICROBIAL COMPOSITIONS COMPRISING HYPOCHLOROUS ACID AND SILVER

The present invention relates to methods and compositions for treating a surface characterized by microbial infection or colonization. Particularly, the methods of the present invention involve applying a hypohalous acid (e.g., hypochlorous acid) composition and a silver additive. The present invention is useful, for example, in disinfecting or cleaning a mammalian tissue, such as a wound or burn, or disinfecting or cleaning a hard surface, such as a medical device. 1. A method for treating a surface characterized by microbial infection or colonization , comprising applying a hypochlorous acid (HOCl) composition and a silver additive to the surface , thereby reducing the microbial infection or colonization.2. The method of claim 1 , wherein the surface is a hard surface.3. The method of claim 2 , wherein the surface is a tubing claim 2 , contact lens claim 2 , dental prosthesis claim 2 , orthodontic device claim 2 , surgical instrument claim 2 , dental instrument claim 2 , medical examination surface claim 2 , bathroom surface claim 2 , dental water line claim 2 , fabric claim 2 , or bandage or tissue dressing.4. The method of claim 1 , wherein the surface is a medical device.5. The method of claim 4 , wherein the medical device is a urinary catheter claim 4 , mucous extraction catheter claim 4 , suction catheter claim 4 , umbilical cannula claim 4 , intrauterine device claim 4 , intravaginal device claim 4 , intraintestinal device claim 4 , endotracheal tube claim 4 , bronchoscope claim 4 , endoscope claim 4 , electrodes claim 4 , or external prosthesis.6. The method of claim 1 , wherein the surface is a human or animal tissue or organ.7. The method of claim 6 , wherein the surface is a wound or burn.8. The method of any one of to claim 6 , wherein the surface is characterized by bacterial biofilm formation.9. The method of any one of to claim 6 , wherein the HOCl and silver additive are applied in a single composition.10. The method of any one of to claim 6 , ...

METHODS AND COMPOSITIONS FOR WOUND HEALING

The present invention relates to large scale manufacture of nanoscale microsheets for use in applications such as wound healing or modification of a biological or medical surface. In some embodiments, the present invention provides devices for application to a wound comprising: a first polymer layer comprising a first bioactive agent; a second polymer layer comprising a second bioactive agent; and a third polymer layer positioned in between the first and second polymer layer so that the three polymer layers are stacked in a sandwich-type structure. 1. A device for application to a wound comprising:a first polymer layer comprising a first bioactive agent;a second polymer layer comprising a second bioactive agent; anda third polymer layer positioned in between the first and second polymer layer so that the three polymer layers are stacked in a sandwich-type structure.2. The device of claim 1 , wherein the first polymer layer is a nanoscale polymer multilayer.3. The device of claim 1 , wherein the nanoscale polymer multilayer comprises alternating layers of at least one positively charged polyelectrolyte and at least one negatively charged polyelectrolyte.4. The device of claim 3 , wherein the at least one positively charged polyelectrolyte is selected form the group consisting of poly(allylamine hydrochloride) (PAH) claim 3 , polyl-lysine (PLL) claim 3 , poly(ethylene imine) (PEI) claim 3 , poly(histidine) claim 3 , poly(N claim 3 ,N-dimethyl aminoacrylate) claim 3 , poly(N claim 3 ,N claim 3 ,N-trimethylaminoacrylate chloride) claim 3 , poly(methyacrylamidopropyltrimethyl ammonium chloride) claim 3 , and natural or synthetic polysaccharides such as chitosan.5. The article of claim 3 , wherein said at least one negatively charged polyelectrolyte is selected from the group consisting of poly(acrylic acid) (PAA) claim 3 , poly(styrenesulfonate) (PSS) claim 3 , alginate claim 3 , hyaluronic acid claim 3 , heparin claim 3 , heparan sulfate claim 3 , chondroitin sulfate ...

NOBLE METAL NANOPARTICLES, METHOD FOR PREPARING THE SAME AND THEIR APPLICATION

The present invention discloses a method for preparing noble metal nanoparticles, comprising the following steps: a) preparing an fruit extract; b) preparing an extract; c) mixing the fruit extract and the extract for preparing a mixed extract; d) providing an aqueous solution containing a noble metal compound dissolved therein; e) mixing the mixed extract obtained in step c) and the aqueous solution of step d) to form noble metal nanoparticles; noble metal nanoparticles obtained thereby and their use. 1. Method for preparing noble metal nanoparticles , comprising the following steps:{'i': 'Olea Europaea', 'a) preparing an fruit extract'}{'i': 'Acacia Nilotica', 'b) preparing an extract'}{'i': Olea Europaea', 'Acacia Nilotica, 'c) mixing the fruit extract and the extract for preparing a mixed extract'}d) providing an aqueous solution containing a noble metal compound dissolved thereine) mixing the mixed extract obtained in step c) and the aqueous solution of step d) to form noble metal nanoparticles.2. Method according to claim 1 , wherein the mixed extract obtained in step c) contains flavonoids claim 1 , phenols and/or pentacyclic triterpenoids.3Olea EuropaeaOlea Europaea. Method according to claim 1 , wherein the preparation of the fruit extract is performed by adding deionized or distilled water to fruit.4Acacia NiloticaAcacia Nilotica.. Method according to claim 1 , wherein the preparation of the extract is performed by adding deionized or distilled water to5Olea EuropaeaAcacia Nilotica. Method according to claim 1 , wherein the fruit extract and the extract are mixed in a range of mixing ratios from 5:1 to 1:5.6. Method according to claim 1 , wherein the mixing of step e) is at room temperature.7. Method according to claim 1 , wherein the noble metal is Au or Ag.8. Method according to claim 7 , wherein the noble metal compound is chloroauric acid.9. Method according to claim 1 , wherein the aqueous solution provided in step d) also comprises a surfactant.10. ...

In Situ Film-Forming Bioactive Solutions of Absorbable Multiblock Copolymers

An in situ film-forming methyl acetate-based solution of at least one absorbable, segmented block copolymer with amorphous and semi-crystalline segments contains at least one bioactive agent which exhibits antimicrobial, anti-inflammatory, antiviral, anesthetic, hemostatic, and/or antineoplastic activity. The absorbable polymers can be a polyaxial copolyester, polyether-ester and polyether-ester urethane. The solution can be applied (e.g., sprayed or swabbed) onto animal and human skin or accessible body cavities to prevent or treat one or more disorders preventable or treatable by the bioactive agent therein. 1. An in situ film-forming solution comprising at least one absorbable , segmented block copolymer with amorphous and semi-crystalline segments in a methyl acetate solvent , the solution further comprising at least one bioactive agent selected from the group consisting of antimicrobial agents , anesthetic agents , antiviral agents , anti-inflammatory agents , hemostatic agents , and antineoplastic agents.2. The in situ film-forming solution as in wherein the solvent consists essentially of methyl acetate.3. The in situ film-forming solution as in wherein said solution can be sprayed or applied on animal or human skin and accessible body cavities to form an adherent claim 2 , flexible claim 2 , conformable claim 2 , stretchable claim 2 , dimensionally stable film having a tack-free outer surface claim 2 , the film exhibiting an elongation of 100 to 600 percent claim 2 , a tensile strength of 3-10 MPa and a tensile modulus of 5-20 MPa.4. The in situ film-forming solution as in wherein the segmented copolymer comprises from about 0.1 to about 20 weight/volume percent of the solution.5. The in situ film-forming solution as in wherein the at least one absorbable claim 2 , segmented block copolymer with amorphous and semi-crystalline segments is selected from the group consisting of polyaxial copolyesters claim 2 , polyether-esters and polyether-ester-urethanes and ...

CONJUGATED ANTI-MICROBIAL COMPOUNDS AND CONJUGATED ANTI-CANCER COMPOUNDS AND USES THEREOF

Disclosed herein are synthesis methods for generation of conjugated anti-microbial compounds and conjugated anti-cancer compounds. Several embodiments, related to the uses of such compounds in the treatment of infections, in particular those caused by drug-resistant bacteria. Some embodiments relate to targeting cancer based on the metabolic signature of tumor cells. 1. An anti-bacterial conjugate , comprising:a targeting antibiotic; andan anti-bacterial agent, wherein the anti-bacterial agent has generalized anti-bacterial activity, wherein the anti-bacterial agent is an agent to which bacteria do not develop resistance.235.-. (canceled) This application claims the benefit of U.S. Provisional Application Nos. 61/742,443 and 61/742,444, both filed on Aug. 9, 2012 the entire disclosure of each of which is incorporated by reference herein.1. FieldSeveral embodiments of the invention relate generally to processes for synthesizing antimicrobial agents that are effective against targets such as gram-negative and gram-positive bacteria, gram-variable, and gram-indeterminate bacteria, including multidrug resistant strains, viruses, fungi, and other microorganisms. Additionally, several embodiments relate generally to processes for synthesizing and using novel compounds as anti-cancer agents. Methods for using the resultant compounds to treat or prevent microbial infections and/or cancer are also disclosed herein.2. Description of Related ArtPathogenic microbial agents include viruses, bacteria, fungi, parasites, and prions, among others and may be primary or opportunistic pathogens. Primary pathogens cause infection as a direct result of their virulence, while opportunistic pathogens typically require a compromised host defense system to produce an infection. While modern medicine has reduced the prevalence of many infections due to pathogenic microorganisms, such microorganisms continue to account for a large degree of morbidity and mortality.Given the increasing ...

Silver Oxide Formulations

Topical formulations for application to exposed body tissue. 1. A topical formulation for application to exposed body tissue , the formulation comprising a silver(II) oxide and zinc oxide , said silver(II) oxide and said zinc oxide intimately dispersed within a carrier medium ,a ratio of said zinc oxide to said silver(II) oxide being at least 0.5:1, by weight.2. The topical formulation of claim 1 , wherein the formulation contains at least 0.05% claim 1 , by weight claim 1 , of said silver(II) oxide claim 1 , and at least 0.05% claim 1 , by weight claim 1 , of said zinc oxide.4. The topical formulation of claim 3 , wherein an initial whiteness value of the formulation is at least 4 reflective units.5. The topical formulation of claim 3 , wherein a whiteness value of the formulation is claim 3 , initially claim 3 , at least 4 reflective units claim 3 , at least 4.5 reflective units claim 3 , at least 5 reflective units claim 3 , at least 5.5 reflective units claim 3 , or at least 6 reflective units claim 3 , and wherein claim 3 , after constant exposure to said ultraviolet light for 3 days claim 3 , said value remains at least 3.5 reflective units claim 3 , at least 3.75 reflective units claim 3 , at least 4 reflective units claim 3 , at least 4.5 reflective units claim 3 , at least 5 reflective units claim 3 , or at least 5.5 reflective units.6. The topical formulation of claim 3 , wherein said silver oxide includes claim 3 , largely includes claim 3 , mainly includes claim 3 , predominantly includes claim 3 , or consists essentially of a silver(II) oxide.7. A solid biocompatible formulation suitable for insertion within chronic and acute wounds of humans and animals claim 3 , the formulation comprising a topical antibiotic claim 3 , a biocompatible humectant claim 3 , a biocompatible viscosity-building agent claim 3 , and at least 5% water claim 3 , by weight claim 3 , said humectant and said viscosity-building agent intimately mixed within the formulation claim 3 ...

POLYSACCHARIDE FIBRES FOR WOUND DRESSINGS

A polysaccharide fibre useful in biomedical applications such as wound management is made as a bicomponent fibre with alginate and psyllium polymers. An antimicrobial silver salt may be incorporated. The fibre may be made by extruding an aqueous mixture of alkaline-solubilised psyllium and sodium alginate into a calcium chloride bath. 1. A polysaccharide fibre having , as components of the same fibre , alginate and psyllium polymers.2. A fibre according to wherein the alginate and psyllium polymers are bonded to each other.3. A fibre according to which is produced by extrusion or spinning of a mixture of the alginate and psyllium polymers.4. A fibre according to which is a bicomponent fibre containing the psyllium and alginate polymers as the only structural components.5. A fibre according to further including an antimicrobial substance.6. A fibre according to wherein the antimicrobial substance is a silver substance.7. An antimicrobial fibre containing alginate claim 5 , psyllium and a silver substance.8. (canceled)9. A fibre according to wherein the silver substance is silver nitrate or silver carbonate.10. A method of making a polysaccharide fibre comprising spinning or extruding an aqueous mixture of soluble psyllium and alginate polymers into a bath containing a substance which coagulates the aqueous mixture to form a fibre.11. A method according to wherein the coagulating substance comprises a calcium salt which forms insoluble calcium alginate with the soluble alginate polymer of the aqueous mixture.12. A method according to wherein the bath contains 1-2% by weight calcium chloride.13. A method according to wherein the soluble psyllium polymer is solubilised in alkaline solution.14. A method according to wherein the soluble alginate polymer comprises sodium alginate.15. A method according to claim 10 , further including washing the formed fibre with aqueous acetone.16. A method according to wherein the aqueous mixture contains psyllium and alginate polymers ...

ANTIMICROBIAL NASAL INSERT AND METHOD OF MANUFACTURING

A nasal insert including an antimicrobial agent is inserted into the nose to eliminate or reduce undesirable microbes in the area just inside the nose. Pads of the nasal insert can be formed from a blended polymer compound with a microbial agent. Processing of the pre-polymer results in the microbial agent being trapped in the polymer. A blowing agent or COgas can be introduced in the process after decompression, and before molding to improve attraction of liquid born microbes to the nasal insert. 1. (canceled)2. The nasal insert of wherein each of said first pads have a length which is longer than the width to form an elongated pad.3. The nasal insert of wherein said nylon is synthetic polyamide polymer.4. The nasal insert of wherein said antimicrobial agent is a silver cation.5. The nasal insert of wherein said joiner is formed of a flexible plastic material to bias said pair of rings.6. The nasal insert of wherein texture is formed on a surface of the pads.7. The nasal insert of wherein a surface wave is formed on an inner and/or an outer surface of the pads claim 16 , the surface wave comprising a plurality of ridges.8. The nasal insert of wherein the nasal insert is formed in an injection molding process and a blowing agent or gas is introduced to the blend before the injection molding process.9. The nasal insert of further comprising:an insertion tab removably coupled to the joiner, said insertion tab including a frangible detail having a width smaller than the width of the insertion tab.10. The nasal insert of wherein said detail is attached within a recess in a top of said joiner.11. The nasal insert of wherein said joiner has a curved shape.12. The nasal insert of further comprising a colorant.13. (canceled)14. (canceled)15. The nasal insert of wherein said pads are formed of a plastic material co-molded claim 16 , over molded or insert molded with a thermoplastic material forming said joiner and said micro-joiners.16. A nasal insert comprising;a plurality ...

ANTIMICROBIAL COATING COMPOSITION AND ANTIMICROBIAL COATING METHOD USING SAME

Disclosed is an antimicrobial composition and a coating method using the same. The composition is highly hydrophilic and biocompatible, thereby enabling a thin and flexible coating layer and exhibiting antimicrobial activity. The coating composition of the present invention is suitably used for coating vascular catheters, stents, guide wires, and other invasive medical devices. 1. An antimicrobial coating composition comprising:a first coating solution comprising at least one selected from the group consisting of an acrylic compound and a polyurethane compound;a second coating solution comprising a polysaccharide and silver nitrate; anda cross-linking agent.2. The antimicrobial coating composition of claim 1 , wherein the first coating solution is to be bound to a substrate and the second coating solution is to be bound claim 1 , by the cross-linking agent claim 1 , to the first coating solution bound to the substrate.3. The antimicrobial coating composition of claim 1 , wherein the acrylic compound is an acrylate polymer.4. The antimicrobial coating composition of claim 1 , wherein the polyurethane compound is polyether polyurethane.5. The antimicrobial coating composition of claim 1 , wherein the polysaccharide is hyaluronic acid.6. The antimicrobial coating composition of claim 1 , wherein the cross-linking agent is a polyaziridine-based or polyisocyanate-based cross-linking agent.7. The antimicrobial coating composition of claim 1 , wherein the second coating solution further comprises polyether polyurethane.8. The antimicrobial coating composition of claim 7 , wherein the polysaccharide and the polyether polyurethane are present in a weight ratio of 10:0.5 to 2.9. The antimicrobial coating composition of claim 1 , wherein the second coating solution further comprises chitosan.10Reynoutria japonica. The antimicrobial coating composition of claim 1 , wherein the second coating solution further comprises at least one natural extract selected from the group ...

MODIFIED METAL NANOPARTICLE AND PHARMACEUTICAL COMPOSITION

A modified metal nanoparticle comprising a metal nanoparticle and a cyclic polyether modifying the metal nanoparticle. 1. A modified metal nanoparticle , comprising:a metal nanoparticle; anda cyclic polyether modifying the metal nanoparticle.2. The modified metal nanoparticle according to claim 1 , wherein the metal nanoparticle is a gold nanoparticle or a silver nanoparticle.3. The modified metal nanoparticle according to claim 1 , wherein an average particle size of the metal nanoparticle is 1 to 1000 nm.4. The modified metal nanoparticle according to claim 1 , wherein the cyclic polyether is a cyclic polyethylene oxide.5. The modified metal nanoparticle according to claim 1 , wherein a number average molecular weight of the cyclic polyether is 500 to 20000.6. The modified metal nanoparticle according to claim 1 , whereinthe metal nanoparticle is a gold nanoparticle, anda mass ratio of the cyclic polyether to the gold nanoparticle is 50 to 1500.7. The modified metal nanoparticle according to claim 1 , whereinthe metal nanoparticle is a silver nanoparticle, anda mass ratio of the cyclic polyether to the silver nanoparticle is 0.1 to 50.8. A pharmaceutical composition comprising the modified metal nanoparticle according to .9. The pharmaceutical composition according to claim 8 , wherein the pharmaceutical composition is a radiosensitizer claim 8 , a photothermal therapeutic agent claim 8 , or an MRI contrast agent. The present invention relates to a modified metal nanoparticle and a pharmaceutical composition comprising the modified metal nanoparticle.Conventionally, metal nanoparticles have been applied in applications such as biosensors, intracellular probes, drug delivery substances, and optical contrast substances. For example, Patent Literature 1 discloses the use of metal nanoparticles as a pharmaceutical composition used for radiotherapy.Patent Literature 1 Japanese Unexamined Patent Publication No. 2012-532847However, conventional metal nanoparticles are ...

SILVER OXIDE FORMULATIONS

Topical formulations for application to exposed body tissue. 2. A method comprising:(a) providing a silver oxide raw material, said silver oxide raw material predominantly including a silver(II) oxide;(b) milling said silver oxide raw material in a vortex mill, to produce a silver oxide powder in which an average particle size is smaller by at least one micrometer an average particle size of silver oxide raw material;wherein said silver oxide powder contains a silver(I) oxide and said silver(II) oxide, and wherein a concentration of said silver(I) oxide in said silver oxide powder exceeds a concentration of said silver(I) oxide in said silver oxide raw material.3. The method of claim 2 , wherein said silver oxide powder has an average particle size (D) within a range of from above 0.8 micrometers to below 8 micrometers.4. The method of claim 3 , wherein said silver(II) oxide in said silver oxide powder has an irregular macrocrystal structure claim 3 , (i) a measured full width half maximum (FWHM) of at least 0.30 degrees of 2θ and not more than 0.466 degrees of 2θ; and', '(ii) a net full width half maximum (net FWHM) of at least 0.20 degrees of 2θ and not more than 0.366 degrees of 2θ., 'said irregular macrocrystal structure characterized by a diffraction peak in a {111} diffraction plane, said diffraction peak having at least one of the following structural properties5. The method of claim 3 , wherein said silver(II) oxide in said silver oxide powder has an irregular macrocrystal structure claim 3 ,wherein said irregular macrocrystal structure is structurally characterized by a lability pattern of a thermogravimetric analysis (TGA) performed on said solid phase in a chamber, under a pure nitrogen environment and a temperature ramp rate of 10° C./minute, said lability pattern characteristic of structural properties within said irregular macrocrystal structure,said lability pattern having both of the following properties:(i) a derivative of weight loss of said solid ...

DERMAL SKIN PROTECTANT AND CARRIER

A dermal skin protectant and carrier comprising a combination of two different viscosity dimethicone components, wherein the difference between the two different viscosity dimethicone components is about 2.0 million cP or greater; and comprising at least one active ingredient. 1. A dimethicone-based dermal skin protectant and carrier comprising a first dimethicone material having a viscosity of between about 1 ,000 cP and 25 ,000 cP , and a second dimethicone material having a viscosity of between about 2.0 million and 3.0 million cP; and at least one active agent.2. The dermal skin protectant and carrier of wherein the at least one active agent is selected from the group consisting of: an antimicrobial agent claim 1 , an anesthetic agent claim 1 , a hemostatic agent claim 1 , an anti-inflammatory agent claim 1 , a hemp-based extract claim 1 , a deodorant claim 1 , a pain relief agent claim 1 , a UV protection agent claim 1 , and combinations thereof.3. The dermal skin protectant and carrier of wherein two or more active agents are combined together in the dermal skin protectant and carrier.4. The dermal skin protectant and carrier of wherein the ratio between the first dimethicone to the second dimethicone is between 100:1 and 1:10.5. The dermal skin protectant and carrier of wherein the concentration of the at least one active agent is between 0.1 and 10%.6. The dermal skin protectant and carrier of wherein said antimicrobial agent is an antifungal claim 2 , antiviral claim 2 , or antibacterial agent.7. The dermal skin protectant and carrier of further comprising at least one essential oil.8. The dermal skin protectant and carrier of wherein the antimicrobial agent is selected from the group consisting of: benzalkonium chloride claim 2 , cetylpyridinium chloride claim 2 , and combinations thereof.9. A method of manufacturing a dermal skin protectant and carrier comprising: a first dimethicone material having a viscosity of between about 1 claim 2 ,000 cP and 25 ...